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Chronic kidney disease 
Chronic kidney disease as a global problem 
Chronic kidney disease (CKD) is a significant and increasing global challenge for public 
health. It affects approximately 10% of the general population in industrialized nations, 
incurring high morbidity and mortality and posing a substantial financial burden to the 
health care systems. The worldwide rise in the number of patients with CKD and 
consequent end-stage renal disease (ESRD) necessitating renal replacement therapy 
(hemodialysis or kidney transplantation) is threatening to reach epidemic proportions.1-3 
As there is a direct relation between the gross national product and the availability of 
renal replacement therapy,1,3 the increase in ESRD burden paralleled by the increasing 
demand for dialysis and kidney transplantation will be most notable in developing 
countries, since only few countries have robust economies able to meet the challenges 
posed in terms of health care costs. Therefore, a global and concerted approach to 
CKD, aimed at finding novel strategies of treatment and prevention, must be urgently 
adopted in both more and less developed countries to avoid a major catastrophe and 
reverse the worsening situation. 
 
Potential of genetics in resolving the big issues in chronic kidney disease 
CKD is a complex, multifactorial disease with an important genetic component. Together 
with environmental factors, the genetic predisposition of an individual is crucial for renal 
disease onset, manifestation and rate of progression. Therefore, identification of the 
genetic variants involved in susceptibility and progression of CKD, and identification of 
the mechanism involved in genetically conferred renal risk is critically important. First, it 
will potentially improve risk prediction and hence allocation of care. Using genetic 
information, along with classical predictors, will improve identification of individuals at 
risk for progressive CKD, which will enable targeting interventions and more aggressive 
primary and secondary prevention to the identified high-risk groups, while preventing the 
burden of treatment in low risk subjects. Second, it can improve our understanding of 
biological mechanisms underlying renal function loss by enriching our current knowledge 
base with novel insights and redefining our prior concepts of kidney pathophysiology. 
Accordingly, it can identify novel targets for intervention, and hence guide the 
development of novel tools for diagnosis, prevention and treatment of CKD. Thus, it may 
also support a basis for improving outcome by personalized therapy in the future.  
 
Kidney function and disease as heritable traits  
It had long been noted that there are racial differences in occurrence of kidney disease, 
with disproportionately higher risk of ESRD in African Americans compared to individuals 
of European ancestry4-6. Further, a population-based analysis revealed that a substantial  
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proportion of ESRD patients had close relatives with kidney disease. Consistently, 
familial aggregation studies demonstrated that CKD and ESRD cluster in families.7-12 All 
these facts collectively were suggestive of potential genetic background and led to the 
concept that CKD, probably, involves an inherited, genetic component.  
Indeed, heritability studies of kidney function measures have shown a relatively high 
contribution of genetic factors to the variability of these traits. For instance, heritability of 
glomerular filtration rate (GFR) was estimated to range from 33 to 75%,13,14 indicating 
that between approximately 33 and 75% of the inter-individual variation in GFR could be 
explained by additive genetic effects. The heritabilities for serum creatinine and 
calculated creatinine clearance were reported to be 37 and 33-63%, respectively.15,16 
Further, heritability estimates of albuminuria, considered a key sign of kidney damage, 
range from 16 to 49%.13,14  
Identifying heritability provided evidence for the importance of genetic factors in 
determining kidney phenotypes and thus also provided a rationale for searching for 
common variants associated with renal function and kidney disease. 
Large progress has been made over the last decades in the elucidation of the genetic 
basis of monogenic, Mendelian renal disorders, such as, for instance, autosomal-
dominant polycystic kidney disease and the Alport syndrome. More recently, gradual 
progress is being made regarding CKD in non-diabetic and diabetic patients, as a 
common, complex disorder.18-26 In this thesis, emphasis will be on the genetics of CKD 
as a complex disorder. 
 
Complex trait genetics and methodology 
Complex diseases, in contrast to monogenic (Mendelian) disorders, are polygenic and 
multifactorial, i.e. arise from a combination of multiple genetic and environmental factors, 
with various environmental exposures acting on genetically susceptible individuals.  
It is assumed that complex diseases are caused by common genetic variants, i.e. 
relatively frequent (>1%) in a given population − a concept known as the “common 
disease, common variant” hypothesis. These common variants, in contrast to rare 
Mendelian mutations, have small individual effects with a cumulative biological effect 
(Table 1, Figure 1). That is, each common genetic variant individually makes a limited 
contribution to the phenotypic outcome, and the combined effects of multiple variants in 
multiple genes, affecting different parts (or pathways) relevant to the complex disorder 
determine the biological effect that can be either deleterious or protective. Accordingly, 
the mechanisms involved in the genotype-phenotype relationships are usually complex, 
and involve multiple interactions, which renders their elucidation quite a challenge.  
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Table 1. Characteristics of monogenic and complex diseases 
(adapted from Köttgen et al Am J Kidney Dis 2010) 
 Monogenic diseases Complex diseases 
Prevalence Rare Common 
Public health impact Small to moderate Large 
Magnitude of associated disease 
risk 
High (often relative risk 
>5) 
Moderate (often relative risk 
<1.5) 
Frequency of genetic risk variants Rare Common 
Mendelian inheritance pattern Yes No 
Cause of disease Single gene mutations, 
highly penetrant 
Multifactorial, multiple genetic 
and environmental risk 






Figure 1. Relationship between 
effect size and risk allele 
frequency (adapted from Böger et 
al Kidney Blood Press Res 2011) 
 
Classical genetic approaches: linkage analysis and candidate gene studies  
Classical genetic mapping approaches, e.g., linkage analyses, in families with index 
patients affected by a rare disease proven to be successful in discovering mutations 
causing rare single-gene diseases with a clear Mendelian mode of inheritance and a 
clear-cut clinical phenotype. However, the use of these hypothesis-free methods had 
limited success with complex diseases, reflecting the differences in genetic architecture 
underlying monogenic and polygenic diseases. 
Hypothesis-driven studies, aimed at investigation the association of common genetic 
variants in biologically plausible candidate genes with phenotypes, represent an 
additional approach, based on prior biological knowledge implicating target genes with a 
known or presumed functional role in pathways or diseases. However, since this 
approach depends on prior knowledge it does not lead to discovery of novel genes. 
Therefore, in discovery strategies, often a combination of hypothesis-free and 
hypothesis-testing strategies is applied.   
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Genome-wide association studies 
Recent technological advances led to the availability of affordable microarray-based 
genotyping platforms, as a methodological basis for whole genome analysis. This 
resulted in evolvement of a novel powerful instrument in the toolbox of genetic research 
of complex diseases − genome-wide association studies (GWASs).  
GWAS is aimed at determining the statistical relationship between common DNA 
variants and an observable disease-related characteristics or trait. The most commonly 
studied variants are single-nucleotide polymorphisms (SNPs), where a single base at a 
particular genomic location differs among individuals. Contemporary platforms allow 
parallel genotyping of more than 1 million SNPs. Since 2005, when the first successful 
GWAS was published, a rapidly expanding number of traits and complex diseases has 
been studied using this powerful method. By September 2011, a total of 1,596 GWASs 
for 249 traits was published.17 
GWAS represent a hypothesis-free type of study design, and is thus unbiased by prior 
knowledge. The main strength of GWAS is in its potential for discovery of hitherto 
unsuspected, truly novel genes. Thus, it can guide the discovery of novel pathways of 
disease, by providing the foundation for novel hypotheses to be tested. Of note, 
association does not necessarily implicate causality, and functional studies are required 
to substantiate a pathophysiological role of an associated locus. Moreover, SNPs 
identified by GWAS are often not involved themselves, but rather implicate 
corresponding genetic loci. So, GWAS has great discovery potential but requires 
substantial additional study to translate the impact of discovered loci to disease 
pathophysiology. 
 
Genetics of chronic kidney disease as a complex disorder 
 
GWASs of renal phenotypes: measures of kidney function and CKD  
Renal phenotypes 
Proper phenotype definition is critically important for genetic analyses. In nephrogenetic 
research, a number of different renal traits and diseases have been studied for genome-
wide association: serum creatinine, eGFR, albuminuria, CKD, ESRD, etc. Among these, 
serum creatinine, eGFR and albuminuria are quantitative traits, whereas presence of 
CKD or ESRD are dichotomous traits. These phenotypes all are assumed to represent 
CKD one way or another, with ESRD as its most advanced form, and higher creatinine 
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or albuminuria and lower eGFR allegedly representing earlier forms of renal damage, 
that may or may not progress to overt CKD.  
• The main index of the functional state of the kidney is glomerular filtration rate 
(GFR) which describes the flow rate of filtered fluid through the kidney. Its direct 
measurement (e.g. by 125I-iothalamate clearance), although considered the 
“gold standard”, is an invasive and expensive procedure. Owing to the large 
target sample size dictated by statistical power considerations for a GWAS, it is 
unfeasible to measure GFR in a population-based study. Therefore, GFR is 
estimated (eGFR) from serum filtration markers, usually creatinine, and 
sometimes also cystatin C (eGFRcreat or eGFRcys, respectively), combined with 
empirical algorithms that link the serum value of creatinine and/or cystatin to 
glomerular filtration rate.  
• Albuminuria, i.e. elevated urinary albumin, expressed as either as urinary 
albumin-to-creatinine ratio or as concentration of albumin in urine, is considered 
to indicate renal damage, irrespective of GFR.  
• CKD is conventionally defined in epidemiological studies as eGFR < 60 
ml/min/1.73 m2.  
• ESRD is the most severe renal phenotype. As a clinical endpoint of progressive 
CKD, it is defined as initiation of renal replacement treatment − dialysis or 
kidney transplantation. 
 
Associated genetic loci 
To date, more than 15 GWASs have been performed on various forms of renal 
phenotype, resulting in discovery of a number of genes18-26 (Figure 2, Table 2). A meta-
analysis of GWASs of renal function indices in population-based cohorts of 
approximately 70,000 individuals yielded a total of 28 loci at the genome-wide significant 
level (p<5×10-8).19 Collectively, these renal function loci accounted for 1.4% of the 
variation in eGFRcreat. 
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Figure 2. Graphical presentation of the results from a GWAS of eGFR: a Manhattan plot 
(Köttgen et al. Nat Genet 2010). 
Chromosomal location is plotted on the x-axis, statistical significance (-log10 p values) for association with 
eGFR − on the y-axis. The horizontal grey dotted line denotes the threshold of genome-wide statistical 
significance (5×10-8). The plot displays 25 significant hits. 
 
 
The majority of the loci associated with lower eGFR showed nominal associations with 
prevalent CKD.18,19 In a follow-up study, several of these renal function loci were 
associated with incident CKD and prevalent ESRD.22 Other loci for eGFR, however, 
were not associated with CKD or ESRD: this could implicate that low eGFR is not always 
an early stage of CKD. Alternatively, there could be selection bias in studies in CKD and 
ESRD populations, as CKD is associated with increased mortality.  
A GWAS of albuminuria traits (urinary albumin-to-creatinine ratio and microalbuminuria) 
identified one non-synonymous SNP in the CUBN gene, explaining 0.2% of total 
variance of this phenotype.21 No other loci previously found to be associated with eGFR 
and CKD showed genome-wide significance for association with albuminuria or vice 
versa, supporting the proposed concept of distinct, disparate genes responsible for 
these renal phenotypes.14,27 Yet, considering the consistent predictive effect of 
albuminuria for progressive renal function loss, the lack of data on association of CUBN 
variants is somewhat surprising, and warrants better study.  
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Limitations of GWAS specifically in nephrology research 
Despite the large utility of the GWAS approach, there are also some limitations. The 
requirement for a high degree of statistical significance, along with the fact that risk 
variants for complex traits usually confer small-to-modest effects, makes a very large 
sample size essential for adequate statistical power. As a consequence, GWAS has to 
rely on rather crude phenotypes, as for very large cohorts detailed phenotyping is 
usually not affordable. The best-studied, crude phenotypes for renal disease, eGFR and 
albuminuria, are widely available because they are cheap and simple to obtain, but both 
are only an indirect reflection of the degree of renal damage in an individual, and of the 
propensity to future progressive renal function loss.  
Another important limitation is that most GWASs in nephrology were based on cross-
sectional renal data-sets. A main drawback of such designs is that the clinically most 
relevant phenotypes, namely onset and progression of renal function loss, are not 
studied. In fact, onset and progression of CKD towards ESRD is a long-term process 
which typically takes decades, while the rate of renal function loss varies between 
patients. Accordingly, due to practical and methodological issues, case-control studies 
are so far the mainstay of GWAS for CKD, but longitudinal studies are definitely 
warranted to investigate the role of genetic factors in the dynamics of CKD progression. 
Finally, as noted above, statistical association does not necessarily implicate causality. 
Functional studies are needed to investigate whether associated loci are indeed 
pathophysiologically involved.  
It should be mentioned also, that functional studies are generally time-consuming and 
costly. Considering the substantial number of candidate loci generated by GWASs, this 
poses the enormous challenge of prioritizing the loci most likely to be involved in the 
pathophysiology of renal damage as topics for further study.  
 
From genotype to phenotype in CKD  
Prioritization of loci for follow-up 
Prioritization of loci from GWAS can be guided by both bio-informatics and by 
pathophysiological considerations (Figure 3), and by their combination. The obvious 
first-priority candidates for hypothesis-driven post-GWAS follow-up studies are renal loci 
which are biologically plausible, i.e. those that can be linked to kidney function and/or 
disease based on existing knowledge on gene expression and its involvement in specific 
pathways and physiological processes. With regard to the pathophysiological 
considerations, refining the phenotype can also be useful.  
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Loci studied in this thesis 
In this thesis, in a series of clinical post-GWAS studies, we used several strategies to 
translate GWAS findings to renal pathophysiology. First, we selected loci with biological 
plausibility based on prior knowledge of the function of gene in renal (patho-) physiology, 
namely SLC22A2, coding for OCT2, a tubular transporter involved in creatinine 
secretion; CUBN, coding for cubilin, which plays a role in protein reabsorption in 
proximal tubule, and UMOD, coding for uromodulin, the most abundant protein in urine. 
Second, we studied refined renal phenotypes, allowed by the smaller scale of our 
studies in a dedicated nephrology setting. Third, we used the unique setting of renal 
transplantation in a study design allowing both case-control analysis for association of 
loci with ESRD in native and transplanted kidneys, and dissection of intra- and extra-
renal pathways of disease.  
 
SLC22A2 
GWASs on renal function so far rely heavily on creatinine-based renal function 
estimates, i.e. eGFR. Serum creatinine, however, is a complex and composite 
phenotype and its levels are not only based on the renal phenotype it is assumed to 
reflect, namely GFR. Creatinine concentration in blood is determined by the interplay of 
many factors such as its metabolic generation, renal excretion which includes glomerular 
filtration, tubular secretion and reabsorption, and extra-renal elimination28-32 (Figure 4).  




Figure 4. Schematic overview of determinants of serum creatinine levels and the presumed 
functional involvement of three examples of creatinine-associated genetic loci.  
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Therefore, assuming that serum creatinine phenotype specifically reflects GFR might 
lead to erroneous conclusions. Dissecting the exact biological mechanism underlying the 
genetic association with serum creatinine can guide the interpretation of GWAS findings 
and help to translate them into a clinically meaningful message. It is, thus, important to 
separate genetic loci that affect concentrations of creatinine independently of underlying 
renal disease from those that truly reflect disease-association (i.e. decline of renal 
function in terms of GFR). Indeed, among the loci associated with creatinine and/or 
eGFR was GATM, a gene involved in creatinine metabolism, and SLC22A2, that may 
affect tubular creatinine handling.  
Using a second measure of renal function, e.g. cystatin C-based eGFR, helps to 
distinguish between true renal function loci and creatinine production/secretion loci. 
Applying this approach, the previously reported renal loci were classified into two 
groups: the loci that were associated with both eGFRcreat and eGFRcys, and, thus, are 
likely to be involved in renal function and susceptibility to CKD, and the loci that were 
associated with eGFRcreat only and, therefore, were suspected to affect creatinine 
production and secretion.13,19,33 
SLC22A2 was considered as a likely creatinine secretion locus, which makes it stand 
apart from the other, supposedly GFR- or creatinine biosynthesis-associated, genes 
identified by GWAS of renal function traits. In the abovementioned GWA studies the 
SLC22A2 SNPs were associated with GFR estimated from serum creatinine but not from 
cystatin C.19,33 The SLC22A2 gene encodes the organic cation transporter 2, OCT2. 
From its general biology it is known to be a predominant transporter involved in the renal 
secretion of creatinine. In the kidney it is expressed in the basolateral membrane of 
proximal tubule cells, where it mediates tubular uptake of creatinine from the peritubular 
capillaries, as an initial step in its vectorial transport to the apical cell membrane followed 
by secretion into the lumen. The active tubular secretion of creatinine is assumed to be 
relatively insignificant (it accounts for an additional 10-20% of urinary creatinine 
excretion), and therefore is neglected in the routine estimation of renal function in clinical 
practice. However, existence of tubular secretion of creatinine as an additional 
mechanism of its clearance translates into systematic error (bias) in creatinine-based 
GFR estimation equations. 
The significance of the abovementioned facts is two-fold. First, it points to the complexity 
of creatinine metabolism and importance of proper interpretation of the results of GWAS 
of creatinine-related phenotypes. Second, it suggests that the genetic variation in the 
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CUBN 
Cubilin has long since been studied in renal disease. In the kidney, cubilin is expressed 
predominantly in the apical brush border of proximal tubular cells, where it plays a key 
role in the receptor-mediated endocytotic reabsorption of albumin and other low-
molecular-weight proteins. The essential role of the cubilin-megalin complex in the 
reuptake of albumin by the proximal tubule has been demonstrated in animal 
experimental studies.34-36 Consistently, a rare autosomal-recessive disorder caused by 
mutations in the CUBN gene which encodes cubilin, Imerslund-Gräsbeck disease, 
(OMIM #261100, Finnish type) typically manifests with varying degrees of proteinuria as 
a result of a molecular defect leading to inefficient proximal tubular protein reabsorption37 
(Figure 5).  
Renewed interest in cubilin was fueled by a recent GWAS of albuminuria21 that found an 
association with the CUBN locus. As albuminuria is a main predictor of progressive renal 
damage, it would be plausible to investigate whether common genetic variation in CUBN 
associates with CKD. Alternatively, the association between albuminuria and the CUBN 
locus might reflect urinary albumin loss due to selective alteration of albumin uptake in 
the proximal tubulus.  
 
UMOD 
Among renal loci, a prominent place is taken by UMOD, which has been reproducibly 
identified in multiple cohorts as one of the top loci associated with renal function 
parameters. Also, Mendelian mutations in UMOD have been described, such as 
glomerulocystic kidney disease, familial juvenile hyperuricemic nephropathy and 
medullary cystic kidney disease 2.  
The UMOD gene encodes uromodulin (or Tamm-Horsfall protein), which is expressed 
exclusively in the kidney in a peculiar pattern − it localizes in the thick ascending limb of 
the loop of Henle specifically omitting the macula densa38-40 (Figure 6). Uromodulin 
functions, among other, as a protective molecule against urinary tract infections and 
stone formation. Nevertheless, its exact physiological role, despite more than 60-years 
of investigation,41 remains obscure.38-40 
Uromodulin is excreted into urine and is in fact long since known as the most abundant 
tubular urinary protein in healthy subjects. Its constitutive physiological excretion occurs 
from the 15th week of gestation on,42 and it is such an inherent urinary constituent that it 
is used for forensic identification of urine.43,44 This feature is unique among the currently 
identified loci for renal function, as it constitutes a non-invasive intermediate phenotype 
that could be highly useful to unravel genotype-phenotype relationships. 
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Figure 5. Cubilin structure and function. 
Cubilin is a multiligand endocytic receptor. ① Low-molecular-weight proteins, e.g. albumin, are 
filtered into the primary urine and, under normal conditions, virtually completely reabsorbed by 
proximal tubule cells via the cubilin-mediated endocytosis pathway. ② Functional cubilin deficiency 
results in defective tubular re-uptake of filtered proteins clinically manifesting as low-grade tubular 
proteinuria.  




Figure 6. Uromodulin structure and function.  
*Own data: Uromodulin immunofluorescence (green) on acetone-fixed rat renal cryosections using 
sheep polyclonal anti-uromucoid antibody and rabbit-anti-sheep/FITC conjugated secondary 
antibody (Abcam Inc., Cambridge, MA); nuclei (blue) stained with DAPI. Glomeruli cross-sections 
are encircled with white dashed lines. The macula densa areas are indicated with arrows and are 
negatively stained demonstrating absence of uromodulin protein expression.  
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Recent data suggest a role of genetic variation in the UMOD gene, uromodulin excretion 
and the susceptibility to renal damage. Several studies highlighted a region upstream 
from the UMOD gene containing a linkage disequilibrium block of several SNPs (e.g., 
rs12917707, rs4293393 and rs13333226) which were repeatedly shown to be 
associated with uromodulin urinary concentration.45-47 Furthermore, genetic variation in 
the UMOD gene was associated with hypertension,47 and, moreover, genetically 
determined elevated urinary uromodulin levels were associated with increased risk of 
incident CKD.45 This is of particular interest, as it might implicate that urinary uromodulin 
could be an intermediate phenotype for the genetic susceptibility to renal damage.  
However, physiological regulation of urinary uromodulin excretion is rather complex and, 
probably, goes beyond the straightforward single locus genetic effect. Besides, 
uromodulin is subject to diverse environmental influences. Therefore, the genotype-
phenotype associations between variation in the UMOD gene, urinary uromodulin 
excretion and the susceptibility to renal damage warrants better in-depth investigation. 
 
Kidney transplantation as a dissecting tool for nephrogenetic research 
GWAS data on renal traits so far are limited to subjects with their native kidneys, in the 
general population and in renal disease populations. Studies in renal transplant 
recipients would be of great interest as well, for several reasons. First, renal 
transplantation recipients represent a population with a high burden of disease. 
Identification of genes associated with loss or preservation of the transplanted kidney 
might be highly useful for risk stratification as well as contribute to identification of new 
treatment targets. Second, the renal transplantation setting has particular characteristics 
that might be relevant to obtain insights in the genetic basis of renal damage in native 
kidneys as well:  
• Genotypes of recipients and donors can be contrasted in a case-control design, 
with recipients being cases (patients with ESRD requiring kidney 
transplantation) and donors serving as controls (individuals either without 
kidney disease (deceased donors) or specifically selected for superior kidney 
function to be eligible for donation (living donors)). Using kidney donors, instead 
of the general population, as controls may augment statistical power to reveal 
the subtle genetic effects expected from common variants, thus representing an 
“extreme” case-control design.  
• A transplant population provides the opportunity to study renal function loss in 
both native and transplanted kidneys through investigation of ESRD before and 
graft failure (GF) after transplantation. Availability of long-term post-transplant 
follow-up for GF in the recipients enables implementation of a longitudinal study 
design, in a dedicated setting, without loss to follow-up. Importantly, 
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reproducing case-control genotype-phenotype associations in the longitudinal 
study serves as a (proof-of-principle) independent replication of the results 
between the native and transplanted kidney, within the same individual.  
• Finally, transplantation represents a peculiar and unique setting from a genetic 
point of view: an organ with its own genotype functions in an organism with 
another genotype. The elegant study design involving testing of both donor and 
recipient genotype for association with phenotypes allows to discriminate 
between local (intra-renal) and systemic (extra-renal) processes influencing 
renal traits. 
 
Outline of this thesis 
The general aim of this thesis is to extend data from recent GWAS on renal traits 
towards the clinically relevant renal phenotypes. 
We aimed to fill the gap between associated genetic loci and disease phenotypes by 
studying relevant intermediate phenotypes, and exploring additional, previously 
uninvestigated kidney phenotypes. 
We followed up the previous GWASs focusing on the most prominent, biologically 
plausible renal loci, namely: UMOD, CUBN and SLC22A2 (Figure 7). 
Chapters 2 to 4 of this thesis are devoted to UMOD. In chapter 2 we evaluate the 
predictive performance of urinary uromodulin excretion for incidence of graft failure in 
renal transplant recipients. In chapter 3 we investigate non-genetic determinants of 
urinary uromodulin in healthy subjects as well as in renal patients. Questions of intra-day 
and day-to-day variability of uromodulin excretion are addressed in part 1 of chapter 3. 
In part 2 we study the effects of dietary sodium intake and renoprotective 
pharmacological interventions on urinary uromodulin levels in CKD patients. Chapter 4 
investigates the association of the UMOD gene polymorphism with end-stage renal 
disease in native kidneys and graft failure in transplanted kidneys, as well as with urinary 
uromodulin in transplanted kidneys. 
In chapter 5 we investigate the CUBN genetic variants for association with phenotypes 
of renal damage (proteinuria) and progressive function loss (end-stage renal disease 
and graft failure, respectively) in a kidney transplant cohort.  
In chapter 6 we attempt to dissect the previously reported association of genetic 
variation in SLC22A2 with estimated GFR in the glomerular and the tubular component 
of creatinine clearance. We hypothesize that the association is mediated by tubular 
creatinine handling rather than by glomerular filtration. Accordingly, we test whether the 
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genetic variation in SLC22A2 affects the accuracy of estimating true GFR from serum 
creatinine, by modulating the tubular component of renal creatinine excretion.  
Finally (chapter 7), blood urea level is often used as a generic measure for the 
metabolic impact of renal function impairment. As a first step to elucidate the genetic 
basis of blood urea level as an additional and potentially relevant renal trait, we 
performed a GWAS for blood urea, a novel renal phenotype for which associated genetic 
loci have not been identified in Caucasians thus far. 
 
 
Figure 7. The genetic loci studied in this thesis: relative spatial localization of 
expression in the kidney coupled with a relevant physiological process. 
  
Chapter 1  
28 
References: 
1. Meguid El Nahas A, Bello AK. Chronic kidney disease: the global challenge. Lancet 2005;365:331-40.  
2. Levey AS, Atkins R, Coresh J, et al. Chronic kidney disease as a global public health problem: 
approaches and initiatives - a position statement from Kidney Disease Improving Global Outcomes. 
Kidney Int 2007;72:247-59.  
3. Baumeister SE, Boger CA, Kramer BK, et al. Effect of chronic kidney disease and comorbid conditions 
on health care costs: A 10-year observational study in a general population. Am J Nephrol 2010;31:222-9.  
4. Martins D, Tareen N, Norris KC. The epidemiology of end-stage renal disease among African 
Americans. Am J Med Sci 2002;323:65-71.  
5. Lopes AA. Relationships of race and ethnicity to progression of kidney dysfunction and clinical 
outcomes in patients with chronic kidney failure. Adv Ren Replace Ther 2004;11:14-23.  
6. Collins AJ, Foley R, Herzog C, et al. Excerpts from the United States Renal Data System 2007 annual 
data report. Am J Kidney Dis 2008;51:S1-320.  
7. Freedman BI, Spray BJ, Tuttle AB, Buckalew VM,Jr. The familial risk of end-stage renal disease in 
African Americans. Am J Kidney Dis 1993;21:387-93.  
8. Bergman S, Key BO, Kirk KA, Warnock DG, Rostant SG. Kidney disease in the first-degree relatives of 
African-Americans with hypertensive end-stage renal disease. Am J Kidney Dis 1996;27:341-6.  
9. O'Dea DF, Murphy SW, Hefferton D, Parfrey PS. Higher risk for renal failure in first-degree relatives of 
white patients with end-stage renal disease: a population-based study. Am J Kidney Dis 1998;32:794-801.  
10. Spray BJ, Atassi NG, Tuttle AB, Freedman BI. Familial risk, age at onset, and cause of end-stage 
renal disease in white Americans. J Am Soc Nephrol 1995;5:1806-10.  
11. Lei HH, Perneger TV, Klag MJ, Whelton PK, Coresh J. Familial aggregation of renal disease in a 
population-based case-control study. J Am Soc Nephrol 1998;9:1270-6.  
12. Freedman BI, Volkova NV, Satko SG, et al. Population-based screening for family history of end-stage 
renal disease among incident dialysis patients. Am J Nephrol 2005;25:529-35.  
13. Kottgen A. Genome-wide association studies in nephrology research. Am J Kidney Dis 2010;56:743-
58.  
14. Boger CA, Heid IM. Chronic kidney disease: novel insights from genome-wide association studies. 
Kidney Blood Press Res 2011;34:225-34.  
15. Hunter DJ, Lange M, Snieder H, et al. Genetic contribution to renal function and electrolyte balance: a 
twin study. Clin Sci (Lond) 2002;103:259-65.  
16. Hunt SC, Hasstedt SJ, Coon H, et al. Linkage of creatinine clearance to chromosome 10 in Utah 
pedigrees replicates a locus for end-stage renal disease in humans and renal failure in the fawn-hooded 
rat. Kidney Int 2002;62:1143-8.  
17. Hindorff LA, MacArthur J(BI, Wise A, et al. A Catalog of Published Genome-Wide Association Studies. 
Available at: www genome gov/gwastudies Accessed June 29, 2012;.  
18. Kottgen A, Glazer NL, Dehghan A, et al. Multiple loci associated with indices of renal function and 
chronic kidney disease. Nat Genet 2009;41:712-7.  
19. Kottgen A, Pattaro C, Boger CA, et al. New loci associated with kidney function and chronic kidney 
disease. Nat Genet 2010;42:376-84.  
20. Chambers JC, Zhang W, Lord GM, et al. Genetic loci influencing kidney function and chronic kidney 
disease. Nat Genet 2010;42:373-5.  
21. Boger CA, Chen MH, Tin A, et al. CUBN Is a Gene Locus for Albuminuria. J Am Soc Nephrol 2011;.  
22. Boger CA, Gorski M, Li M, et al. Association of eGFR-Related Loci Identified by GWAS with Incident 
CKD and ESRD. PLoS Genet 2011;7:e1002292.  
23. Liu CT, Garnaas MK, Tin A, et al. Genetic association for renal traits among participants of African 
ancestry reveals new loci for renal function. PLoS Genet 2011;7:e1002264.  
 General Introduction 
29 
24. Meyer TE, Verwoert GC, Hwang SJ, et al. Genome-wide association studies of serum magnesium, 
potassium, and sodium concentrations identify six Loci influencing serum magnesium levels. PLoS Genet 
2010;6:e1001045.  
25. Pattaro C, De Grandi A, Vitart V, et al. A meta-analysis of genome-wide data from five European 
isolates reveals an association of COL22A1, SYT1, and GABRR2 with serum creatinine level. BMC Med 
Genet 2010;11:41.  
26. Pattaro C, Kottgen A, Teumer A, et al. Genome-wide association and functional follow-up reveals new 
loci for kidney function. PLoS Genet 2012;8:e1002584.  
27. Placha G, Canani LH, Warram JH, Krolewski AS. Evidence for different susceptibility genes for 
proteinuria and ESRD in type 2 diabetes. Adv Chronic Kidney Dis 2005;12:155-69.  
28. Perrone RD, Madias NE, Levey AS. Serum creatinine as an index of renal function: new insights into 
old concepts. Clin Chem 1992;38:1933-53.  
29. Sinkeler SJ, Visser FW, Krikken JA, Stegeman CA, Homan van der Heide JJ, Navis G. Higher body 
mass index is associated with higher fractional creatinine excretion in healthy subjects. Nephrol Dial 
Transplant 2011;26:3181-8.  
30. Stevens LA, Levey AS. Measured GFR as a confirmatory test for estimated GFR. J Am Soc Nephrol 
2009;20:2305-13.  
31. Musso CG, Michelangelo H, Vilas M, et al. Creatinine reabsorption by the aged kidney. Int Urol 
Nephrol 2009;41:727-31.  
32. Breyer MD, Qi Z. Better nephrology for mice--and man. Kidney Int 2010;77:487-9.  
33. O'Seaghdha CM, Fox CS. Genome-wide association studies of chronic kidney disease: what have we 
learned? Nat Rev Nephrol 2011;8:89-99.  
34. Christensen EI, Birn H. Megalin and cubilin: multifunctional endocytic receptors. Nat Rev Mol Cell Biol 
2002;3:256-66.  
35. Christensen EI, Nielsen R. Role of megalin and cubilin in renal physiology and pathophysiology. Rev 
Physiol Biochem Pharmacol 2007;158:1-22.  
36. Birn H. The kidney in vitamin B12 and folate homeostasis: characterization of receptors for tubular 
uptake of vitamins and carrier proteins. Am J Physiol Renal Physiol 2006;291:F22-36.  
37. Grasbeck R. Imerslund-Grasbeck syndrome (selective vitamin B(12) malabsorption with proteinuria). 
Orphanet J Rare Dis 2006;1:17.  
38. Serafini-Cessi F, Malagolini N, Cavallone D. Tamm-Horsfall glycoprotein: biology and clinical 
relevance. Am J Kidney Dis 2003;42:658-76.  
39. Vyletal P, Bleyer AJ, Kmoch S. Uromodulin Biology and Pathophysiology - An Update. Kidney Blood 
Press Res 2010;33:456-75.  
40. Devuyst O, Dahan K, Pirson Y. Tamm-Horsfall protein or uromodulin: new ideas about an old 
molecule. Nephrol Dial Transplant 2005;20:1290-4.  
41. Tamm I, Horsfall FL,Jr. Characterization and separation of an inhibitor of viral hemagglutination 
present in urine. Proc Soc Exp Biol Med 1950;74:106-8.  
42. Phimister GM, Marshall RD. Tamm-Horsfall glycoprotein in human amniotic fluid. Clin Chim Acta 
1983;128:261-9.  
43. Taylor MC, Hunt JS. Forensic identification of human urine by radioimmunoassay for Tamm-Horsfall 
urinary glycoprotein. J Forensic Sci Soc 1983;23:67-72.  
44. Akutsu T, Ikegaya H, Watanabe K, et al. Evaluation of Tamm-Horsfall protein and uroplakin III for 
forensic identification of urine. J Forensic Sci 2010;55:742-6.  
45. Kottgen A, Hwang SJ, Larson MG, et al. Uromodulin levels associate with a common UMOD variant 
and risk for incident CKD. J Am Soc Nephrol 2010;21:337-44.  
46. Shlipak MG, Li Y, Fox C, Coresh J, Grunfeld C, Whooley M. Uromodulin concentrations are not 
associated with incident CKD among persons with coronary artery disease. BMC Nephrol 2011;12:2.  
47. Padmanabhan S, Melander O, Johnson T, et al. Genome-wide association study of blood pressure 









Urinary uromodulin is elevated in renal 
transplant recipients and associated with 
graft failure in a bimodal fashion 
 
Anna Reznichenko1, Marcory C.R.F. van Dijk2, Jaap Homan van 
der Heide1, Stephan J.L. Bakker1, Marc Seelen1, Gerjan Navis1 
1Department of Internal Medicine, Division of Nephrology,  
2Department of Pathology and Medical Biology,  




American Journal of Nephrology 2011;34:445-51. 
Chapter 2  
32 
Abstract 
Urinary uromodulin predicts renal prognosis in native kidneys, but data are conflicting. 
We investigated its prognostic impact for graft failure (GF) in renal transplant recipients 
(RTR, n=600).  
Uromodulin concentration was measured cross-sectionally in RTR at 6.0 [2.6-11.4] years 
post-transplant, in matched patients with native chronic kidney disease (CKD) and 
healthy subjects.  
During a follow-up of 5.3 [4.5-5.7] years GF had occurred in 7% of RTR. Median 
uromodulin excretion (mg/24h) was 20.4 in RTR, 11.6 in CKD and 5.7 in controls 
(p<0.001). There was a curvilinear association between uromodulin excretion and 
baseline renal function (p<0.003) and death-censored GF, with 5.5%, 11.5% and 4.0% 
cases in subsequent uromodulin excretion tertiles, respectively (p=0.002). On 
multivariate Cox regression analysis hazard ratios for GF for the 1st and 3rd tertiles were 
0.37 (p=0.01) and 0.21 (p=0.001) respectively. In 59 RTR allograft biopsies were 
reviewed. Interstitial fibrosis and tubular atrophy were more severe in the middle tertile 
(p=0.007).  
We conclude that urinary uromodulin is elevated in RTR and associated with graft 
function, morphology and outcome in a bimodal fashion. Dissection of the disparate 
mechanisms of GF prediction by urinary uromodulin might provide new clues for its 




CKD, Chronic Kidney Disease; ELISA, Enzyme-linked Immunosorbent Assay; GF, Graft 
Failure; IFTA, Interstitial Fibrosis and Tubular Atrophy; RTR, Renal Transplant 
Recipients. 
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Introduction 
Uromodulin, or Tamm-Horsfall glycoprotein, is the most abundant protein in the urine of 
healthy subjects. It is exclusively expressed in the cells of the thick ascending limb of 
Henle’s loop and the early distal convoluted tubule and excreted in the urine by 
shedding. Uromodulin functions, among other, as a protective molecule against urinary 
tract infections and stone formation, and a number of other roles and mechanisms has 
been proposed.1-3  
Urinary uromodulin has been widely studied for its potential as a renal biomarker. It was 
found to be reduced in several renal conditions, i.e diabetic nephropathy, polycystic 
kidney disease, tubulointerstitial nephropathy,4 acute tubular necrosis,5 nephrolithiasis,6 
medullary cystic kidney disease-2 and familial juvenile hyperuricemic nephropathy,7 and 
in miscellaneous conditions, such as preeclampsia,8 hyperprostaglandin E-syndrome9 
and hypothyroidism.10 Elevated uromodulin was reported in the hyperfiltration stage of 
diabetes mellitus type 1,11 Balkan endemic nephropathy,12 after uninephrectomy due to 
kidney donation13 and in pregnancy.8  
Interestingly, urinary uromodulin was reported to have prognostic value for the 
subsequent course of renal function, albeit not uniformly. Decreased uromodulin 
concentrations predict development of renal failure within 20 years in diabetes mellitus 
type I14 and onset of renal insufficiency immediately after liver transplantation.15 In 
contrast, recent data showed elevated urinary uromodulin levels to associate with 
progressive renal function decline and increased risk for CKD in the general 
population.16 Few data are available on uromodulin excretion in renal 
transplantation,5,13,17-19 and data on its prognostic value in renal transplantation are 
lacking altogether. In the present study, therefore, we investigated urinary uromodulin 
levels in a large single center cohort of renal transplant recipients (RTR) and assessed 
its predictive value for development of late graft failure (GF). 
 
Methods & Materials 
Study design and patients 
The details of the current RTR cohort have been published previously.20 Briefly, a total of 
606 outpatient RTR (age 51.5±12.1 years; 55% male; at 6.0 [2.6-11.4] years post-
transplant) with a functioning graft >1 year were enrolled and followed up during 5.3 [4.5-
5.7] years for graft failure, which was censored for death and defined as return to 
dialysis or re-transplantation. At the study enrollment 24h urine samples were collected, 
processed by centrifugation (1000×g for 10 min), aliquoted and stored at -80°C until 
uromodulin measurement. The Institutional Review Board approved the study protocol 
(METc 01/039).  
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Uromodulin measurement 
All urine samples were pretreated by low-speed centrifugation to pellet large particulate 
matter (cellular debris, etc.) and, in the same time, avoid loss of large uromodulin 
aggregates, if any.21 Uromodulin urinary concentration was measured by commercially 
available enzyme-linked immunosorbent assay (ELISA) kit (MD Bioproducts, St. Paul, 
MN, Tamm-Horsfall Glycoprotein ELISA, catalog number M036020) according to the 
manufacturer’s instructions. The principle of the assay is based on a colorimetric 
sandwich immunoassay utilizing a polyclonal antibody against human uromodulin as the 
capture antibody and a biotinylated polyclonal antibody against human uromodulin as 
the detection antibody. For this assay, the interassay coefficient of variation (CV) is 
10.5% at a mean concentration of 21.8 ng/mL and 12.2% at 95.1 ng/mL; the sensitivity is 
less than 0.75 ng/mL.  
Prior to measurements of the RTR samples we run pilot experiments to determine 
optimal assay conditions. Performance of the ELISA has been tested and optimal urine 
samples dilution has been defined (>1:200). Results obtained after samples 
pretreatments with previously published TEA buffer22 or 7M urea were not different from 
using supplied with the kit buffer only (pH=7.33). Also, we obtained reference values for 
uromodulin levels in healthy subjects. In these subjects (n=18; 9 men, 9 women, median 
age 25 yrs, range 19-42 yrs) uromodulin concentration was 3.8 [2.7-5.1] µg/ml with a 
day-to-day CV of 35% during 5 consecutive days and its excretion was 5.7 [2.8-10.3] 
mg/24h. 
Immediately after the ELISA procedure absorbance reading was performed at 450 nm. A 
standard curve was generated with each set of samples by reducing the data using 4-
parameter logistic curve fit. Uromodulin concentration was calculated from the standard 
curve. Uromodulin concentration values which were below the detection limit (in n=10 
samples) were set to the lowest value in the dataset. The data are presented as 
uromodulin 24h excretion (mg/24h) as well as uromodulin concentration – absolute 
(µg/ml) and indexed to urinary creatinine (ng/mmol), to allow for comparisons with 
different data formats in other publications. Uromodulin levels were also measured in 




In the transplant cohort, we selected a subset of patients (n=59) for whom episode renal 
allograft biopsies were available within a time-window of 22 months before till 14 months 
after urine sampling at the study enrollment (=uromodulin measurement) and reviewed 
the archival slides of biopsies sections stained by standard methods for routine 
microscopy (hematoxyline and eosin-, Jones- and PAS-staining). Selection criteria were 
minimal possible time interval between biopsy taking and uromodulin measurement and 
sufficient amount of allograft tissue material for histological diagnosis assessed by 
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glomeruli number and section area. Histological changes were scored according to the 
Banff ’97 classification revised in 2007.23 In addition, interstitial fibrosis and tubular 
atrophy (IFTA) and hyaline casts were assessed semi-quantitatively. The biopsies 




Analyses were performed with SPSS 16.0 (SPSS Inc., Chicago, IL). Normally distributed 
variables are presented as means±SD, non-normally distributed ones – as medians 
[25th-75th percentile] unless other is indicated. Urinary uromodulin concentrations were 
measured in a total of 606 transplant recipients; after exclusion of cases with missing 
data as a result of dataset quality control, statistical analyses were performed on a final 
sample of n=600. The subjects were divided in tertiles based on uromodulin excretion 
level. Differences between tertiles were tested by one-way ANOVA in case of a 
parametric variable or the Kruskal-Wallis test in case of a non-parametric variable; the 
chi-square test was used in case of a categorical variable. Kaplan-Meier survival 
analysis was performed for analysis of graft loss. A Cox regression analysis was used to 
test predictive performance of uromodulin excretion.  
 
Results 
Uromodulin levels are elevated in renal transplant recipients and associated with graft 
failure in a bimodal fashion 
In baseline 24-h urine, uromodulin concentration ranged from 0.3 µg/ml to 96.9 µg/ml 
with a median of 8.9 µg/ml; urinary uromodulin/creatinine ratio was 1.8 [1.1-3.0] 
ng/mmol. Uromodulin 24h excretion was 20.5 [13.2-35.3] mg/24h, which was 
substantially elevated comparing to CKD patients and healthy controls (Figure 1). 
The most important transplantation-related and outcome parameters are presented as 
break-up by tertiles of uromodulin excretion (Table 1). Duration of pre-transplant 
dialysis, cold and warm ischemia times, proteinuria, study enrollment time-point and 
duration of follow-up beyond the baseline did not differ between the tertiles. Also there 
were no differences between uromodulin excretion tertiles by sex, age (both recipients’ 
and donors’), smoking habits, body size parameters (BMI and BSA), blood pressure, 
diabetes and glucose homeostasis parameters, blood lipid profile, anti-hypertensive, 
immunosuppressive and diuretic medications, blood uric acid and history of gout, sodium 
excretion (data not shown). Renal function as estimated by creatinine clearance at the 
study enrollment was the lowest in the 2nd uromodulin tertile. Serum urea was elevated 
in the 2nd tertile. 
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Table 1. Baseline transplant-related and outcome parameters subdivided by tertiles of 
uromodulin excretion. 
 
Tertiles of uromodulin excretion, mg/24h p-
value 10.2 [5.7-13.2] 20.4 [17.6-24.1] 45.9 [35.3-62.0] 
N 200 200 200  
UMOD concentration, µg/ml 4.7 [3.0-6.6] 8.7 [7.2-10.7] 17.2 [12.3-23.8] <0.001 
UMOD/uCrea, ng/mmol 0.86 [0.48-1.18] 1.78 [1.49-2.25] 3.78 [2.87-5.83] <0.001 
Recipient age, yr 51±13 50±12 52±11 NS 
Recipient sex: male, n (%) 117 (58,5) 106 (53,0) 107 (53,5) NS 
Donor age, yr 37±15 37±16 37±16 NS 
Cold ischemia time, h 22 [14-26] 21 [13-28] 22 [15-27] NS 
Total warm ischemia time, min 35 [30-43] 35 [30-46] 37 [30-45] NS 
Time post-transplant at enrollment, yr 5.6 [2.5-11.4] 6.1 [2.7-11.1] 6.1 [2.7-12.0] NS 
Follow-up beyond enrollment, yr 5.2 [4.5-5.7] 5.2 [4.5-5.7] 5.3 [4.5-5.7] NS 
Baseline proteinuria, g/24h 0.2 [0.1-0.5] 0.2 [0.0-0.5] 0.2 [0.0-0.5] NS 
Baseline serum creatinine, µmol/l 147±56 154±60 142±61 0.005 
Baseline creatinine clearance, ml/min 61±23 59±22 64±22 0.003 
Baseline serum urea, mmol/l 9.4 [7.0-13.5] 10.3 [7.9-13.7] 8.9 [6.8-11.9] 0.007 
Death-censored GF, n (%) 11 (5.5%) 23 (11.5%) 8 (4.0%) 0.008 
UMOD, uromodulin; uCrea, urinary creatinine; GF, graft failure 
 
Figure 1. Uromodulin urinary concentration and 24h excretion in renal transplant recipients 
(n=600) versus healthy controls (n=18) and chronic kidney disease (CKD) patients (n=20). 
Columns represent respective medians of values, error bars – interquartile range. P-values are given to indicate 
statistical significance of observed differences between the groups.  
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During the follow-up of 5.3 [4.5-5.7] yrs, 42 (7.0%) RTR developed GF. According to the 
tertiles statistics, occurrence of GF was significantly increased in the middle tertile of 
uromodulin excretion: 5.5%, 11.5% and 4.0% of cases were observed in the 1st, 2nd and 
3rd tertiles respectively (p=0.008). Consistently, Kaplan-Meier survival analysis revealed 
worse graft survival for the middle tertile of uromodulin excretion as compared to the 1st 
and 3rd tertiles (Figure 2). 
 
 
Figure 2. Curves 
of renal graft 
survival by tertiles 
of uromodulin 
excretion. The 
logrank test showed 
significance of the 
differences between 




Since both 1st and 3rd tertiles displayed unidirectional trends, for subsequent regression 
analyses the middle tertile was used as a reference category. In a multivariate Cox 
regression analysis hazard ratios for graft failure for the 1st and 3rd tertiles of uromodulin 
excretion were 0.37 [95% CI 0.17-0.79] (p=0.01) and 0.21 [0.08-0.50] (p=0.001) 
respectively in the model adjusted for baseline serum creatinine and proteinuria (Table 
2). Adjustment for donor age did not substantially influence regression coefficients and 
p-values (data not shown).  
 






Model, adjusted for 
serum creatinine 
Model, adjusted for 
serum creatinine and 
proteinuria 
HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value 
1st 0.48 (0.24-0.99) 0.047 0.32 (0.15-0.68) 0.003 0.37 (0.17-0.80) 0.011 
2nd 1.00 - 1.00 - 1.00 - 
3rd 0.35 (0.15-0.77) 0.009 0.21 (0.09-0.50) <0.001 0.21 (0.08-0.50) 0.001 
HR, hazard ratio; 95% CI, 95% confidence interval
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Uromodulin excretion is associated with allograft interstitial fibrosis and tubular atrophy 
Allograft biopsies were analyzed in 59 patients out of the RTR cohort. In this sample, 
mean age was 48.79±12.11 yrs (63% males), follow-up beyond baseline was 4.7 [2.5-
5.4] yrs, during which 15 patients (25.4%) developed graft loss. Uromodulin excretion 
was 20.9 [14.0-30.1] mg/24h, its urinary concentration – 8.4 [6.0-12.4] µg/ml. Likewise in 
the total cohort, subjects were divided into tertiles of uromodulin excretion (Table 3). 
 
Table 3. Allograft histology parameters subdivided by uromodulin tertiles. 
 
Tertiles of uromodulin excretion p-
value 
13.6 [8.8-14.7] 20.7 [18.7-22.3] 43.1 [28.5-57.3] 
N 19 20 20  
Uromodulin concentration, 
µg/ml 5.7 [4.1-6.9] 8.2 [7.2-9.4] 17.8 [10.9-22.2] <0.001
Interval biopsy-urine 
collection, months -10.6±1.7 -7.9±2.1 -9.0±2.1 NS 
Interstitial fibrosis score 
(Banff, ci) 0.28±0.14 0.95±0.26 0.32±0.15 0.015 
Tubular atrophy score 
(Banff, ct) 0.28±0.14 1.11±0.23 0.32±0.15 0.001 
IFTA semi-quantitatively, 
mean score 
0.31±0.09 0.96±0.24 0.33±0.12 0.007 
Tubular atrophy: yes, n (%) 4 (21.1%) 13 (65.0%) 6 (30.0%) 0.012 
Tubular atrophy: moderate-to-
severe, n (%) 1 (5.3%) 9 (45.0%) 3 (15.0%) 0.008 
Baseline creatinine clearance, 
ml/min 63 [43-80] 49 [39-68] 51 [36-64] NS 
Death-censored graft failure, 
n (%) 4 (21%) 7 (35%) 4 (20%) NS 
 
Most of the biopsies preceded baseline urine collection; duration of the interval was not 
different between the tertiles. uromodulin excretion was associated with Banff scores of 
tubular atrophy and interstitial fibrosis (IFTA): these lesions were significantly more 
prevalent in the middle tertile of uromodulin excretion. Semi-quantitative assessment of 
IFTA confirmed these findings (p=0.007) contributing more precision and higher 
resolution. If analyzed as a categorical variable, tubular atrophy, especially severe, was 
mostly observed in the middle uromodulin tertile, whereas normal, non-atrophic tubuli 
were present at both lower and higher uromodulin levels (1st and 3rd tertiles, 
respectively) [Table 3]. Hyaline casts quantity was not associated with uromodulin level 
(data not shown).  
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Discussion 
Urinary uromodulin was substantially elevated in RTR as compared to native CKD 
patients and healthy controls. Uromodulin excretion was associated with subsequent late 
graft failure in a non-linear, bimodal fashion with a lower risk in subjects with the lowest 
and highest uromodulin excretion. This bimodal association was also found between 
uromodulin excretion and baseline renal function, and, in a subgroup, allograft histology 
with less IFTA in subjects with low and high uromodulin levels.  
To our knowledge this is the first report of elevated urinary uromodulin in RTR. The 
differences between RTR, CKD patients and healthy subjects were similar for 
uromodulin concentration and total 24-hour excretion, thus excluding bias by differences 
in urinary volume and supporting the robustness of the finding. The elevated uromodulin 
excretion in RTR is remarkable, considering that RTR have only one functioning kidney. 
Increased excretion of uromodulin could be due to its increased synthesis in the kidney, 
increased shedding into urine, or both.2,3 Unfortunately, our data do not allow to 
distinguish between these possibilities. Factors known to affect uromodulin excretion are 
sodium status,24,25 genetic factors16,26,27 and renal damage.28,29 In our study sodium 
status did not explain the differences between RTR and CKD (data not shown). In our 
population genetic data were not available, and an association with the severity of renal 
damage was indeed present – albeit bimodal. However, it is remarkable that average 
uromodulin excretion was elevated as compared to native CKD with an approximately 
similar renal function. Assay factors should be considered, as urinary uromodulin from 
RTR has a different glycosylation pattern than urinary uromodulin in native CKD.18 We 
assume that our ELISA was robust against this since the antibodies recognize peptide 
epitopes of uromodulin and not its carbohydrate part. Uromodulin is known for its potent 
aggregation and polymerization capacity, which can be an obstacle for its precise 
measurement.2,21,22,30 In our study, we used commercial ELISA, which we extensively 
tested in pilot experiments prior to main measurements, and ensured adequate handling 
of the samples which were assayed at high dilution in a buffer with alkaline pH. All these 
methodological measures were directed to provide the highest solubilization of 
uromodulin to ensure its most accurate quantification.21,22  
We tested the predictive performance of uromodulin excretion for subsequent GF and 
found a bimodal association, which is relatively unusual for biomarkers. The bimodal 
association was also present for baseline renal function, with a slightly, but significantly 
lower renal function in the middle tertile. Adjusting for the difference in renal function on 
a Cox regression analyses, however, did not annihilate the predictive value of urinary 
uromodulin for GF. Data in the literature on the prognostic impact of uromodulin are 
contradictory so far. Decreased uromodulin concentrations predicted development of 
renal failure in diabetes mellitus type 114 and onset of renal insufficiency after liver 
transplantation,15 whereas other studies showed that elevated uromodulin levels 
associate with development of CKD in the general population.16 The discrepancies 
between the above studies and our current data might well be due to differences in the 
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nature extent of renal damage in the different populations and in differences in modifying 
factors. Our data, however, suggest the possibility of a different explanation for the 
discrepancies, namely a bimodal association, that can mimic a positive or a negative 
association, as well as the lack of an association when the study population is relatively 
small or contains only a limited range of renal function or uromodulin excretion. Our 
study provides the largest population so far with data on the prognostic impact of 
uromodulin, the number of subjects in other studies ranging between 3415 and 200,16,23 
usually in case-control design. Thus, it may have been the larger power and the 
prospective cohort design that allowed to identify the bimodal association pattern.  
In our study we confirmed the bimodal pattern also for the association between 
uromodulin and renal morphology. In a subset of patients in whom a renal biopsy was 
available within a reasonable time frame from the uromodulin measurement, we found 
more severe IFTA in the middle tertile of uromodulin excretion. This further enhances the 
robustness of our findings, but of course the interpretation of the morphological data is 
limited as the biopsies represent a distinct selection, with biopsies being taken on clinical 
indication, at points in time that were many months apart from the urine sampling for 
uromodulin measurement. 
Literature data reports an association between uromodulin and renal function (serum 
creatinine and urea, creatinine clearance, GFR)4,16,27,29 and morphological damage.28,29 
In our study, we also found these parameters to be associated with uromodulin levels, 
although in a bimodal fashion. 
Our interpretation of the findings is based on assumption of uromodulin inductional 
changes. Uromodulin is a pleiotropic and overall “protective” protein, therefore, it seems 
plausible to expect its compensatory up-regulation upon renal damage to execute its 
protective role. Thus, we hypothesize that in case of renal damage it is up-regulated and 
contributes to reparation processes. However, in diseased condition with persistent renal 
injury, initial compensatory up-regulation is followed by a state when uromodulin 
excretion is fixed to some intermediate level due to failure of further up-regulation (for 
instance, because of tubular cells atrophy). If that is the case, group of lower values of 
uromodulin excretion (1st tertile) would represent cases without renal damage and 
favourable outcome; higher values (3rd tertile) – cases of successful uromodulin up-
regulation and, consequently, also favorable outcome; average values (2nd tertile) – 
failure to up-regulate uromodulin (or exhaustion of up-regulation mechanism due to long-
lasting damage triggers) and progressive decline in renal function up to graft loss. 
In agreement with this hypothesis, we observed low values of uromodulin excretion, 
comparable with the 1st tertile, in healthy subjects (p=0.1), while biopsies analyses 
revealed morphologically preserved, non-atrophic tubuli in case of both low and high 
uromodulin excretion values. Thus, it seems tempting to conclude that low UMOD levels 
are physiological norm and intact tubuli morphology is a prerequisite of ability to increase 
uromodulin production, as we speculate, in response to damage triggers.  
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Longitudinal data on uromodulin excretion over time, in association with development of 
renal damage, would be useful to substantiate this hypothesis.  
A limitation to our study is the lack of certainty on uromodulin origin. We assume that 
urinary uromodulin originated from the allograft, but a contribution of native kidneys is 
not completely ruled out for all patients. However, native urine production seems rather 
unlikely at a median of 6 years post-transplant. 
Conclusion 
We found an excretion of uromodulin to be associated with renal allograft function, 
morphology and outcome in a bimodal fashion. In our RTR population, both lower and 
higher uromodulin levels consistently associate with higher creatinine clearance, lower 
IFTA and reduced risk of graft failure. We believe that these intriguing findings will 
encourage further research and finally dissection of disparate mechanisms of graft loss 












Figure S1. Histogram of uromodulin excretion values 
distribution (n=600).  
X axis is log10-transformed. The distribution approximates 
normality. 
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Introduction 
Uromodulin, or Tamm-Horsfall glycoprotein, is long known as the most abundant urinary 
protein in healthy subjects. It is encoded by the UMOD gene which in humans is 
expressed in the cells of the thick ascending limb of Henle’s loop. Uromodulin is thus 
produced exclusively in the kidney, is excreted into urine from the 15th week of gestation 
on,1 and is such an inherent urinary constituent that it is used for forensic identification of 
urine.2,3 
Uromodulin functions, among other, as a protective molecule against urinary tract 
infections and stone formation, although its exact physiological role, despite more than 
60-year-history of investigation, remains obscure.4-7  
Due to potential biomarker properties, uromodulin has been extensively studied in a 
wide range of renal and extra-renal diseases and in a number of pathological conditions 
its urinary excretion was found to be changed: either reduced (in diabetic nephropathy, 
polycystic kidney disease, tubulointerstitial nephropathy8, acute tubular necrosis,9 
nephrolithiasis,10 UMOD mutations,11 preeclampsia,12 hyperprostaglandin E-syndrome,13 
hypothyroidism14) or elevated (in hyperfiltration stage of diabetes mellitus type I15, 
Balkan endemic nephropathy,16 post-nephrectomy due to kidney donation17 and in 
pregnancy12).  
Moreover, uromodulin have been tested for prognostic utility. A number of studies 
attempted to predict prospective disease outcomes by preceding level of uromodulin 
urinary concentration. For instance, it has been shown that decreased uromodulin 
concentrations predict development of renal failure in diabetes mellitus type 118 and 
onset of renal insufficiency after liver transplantation.19 Another study showed elevated 
urinary uromodulin levels to associate with progressive renal function decline and 
increased risk for CKD,20 and we have previously observed a bimodal association 
between uromodulin excretion and incidence of renal graft failure.21  
The abovementioned prognostic studies employed a prospective longitudinal design with 
a single baseline uromodulin measurement and subsequent follow-up of the patients. 
Importantly, literature data contain warnings about allegedly high day-to-day variability in 
uromodulin excretion, up to radical statements of inappropriateness of studies based on 
a single uromodulin measurement.22,23 However, data on uromodulin variability 
grounded on sufficient number of observations over substantial period of time are 
lacking.  
Furthermore, a diurnal rhythm is present for urinary volume as well as for many urinary 
compounds (e.g., albumin, β2-microglobulin, IgG, transferrin, sodium).24-27 Whether 
excretion of uromodulin is subject to diurnal fluctuations is unknown. 
To address these issues, we studied uromodulin urinary levels over 5 consecutive 24h 
periods (“days”), each consisting of 4 sub-periods (“portions”), in 20 young healthy 
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volunteers. Our research question was whether uromodulin levels in the urine indeed 
undergo significant changes from day to day (infradian variability) or in the course of the 
day (diurnal variability). To test that, we studied a time-course of three outcomes of 
interest: uromodulin urinary concentration, uromodulin excretion and urine volume, in 
relation to time-related predictors: “day” and “portion”. Since the inter-individual 
variability might be attributable to between-subject factors, we took into account such 
parameters as age, sex and body mass index. 
 
Methods & Materials 
Study design 
Definition of health in our study included: no history of renal disease, no medication 
intake, normal dipstick test, normal renal function by 24-h creatinine clearance. As 
uromodulin is produced by renal tubules, we also checked urinary levels of kidney 
tubular markers (NGAL, L-FABP and H-FABP) to confirm intact tubular morphology in 
the participants.  
Thus, 20 healthy subjects (11 men and 9 women, age range 19-42) were recruited from 
the hospital personnel and asked to collect 24-h urine during 5 consecutive days, with 4 
timed collections (portions) per day: 1 − first morning void; 2 − all the subsequent voids 
until 17:00 hr; 3 − all the subsequent voids after 17:00 hr on until the following portion; 4 
− last void before night sleep and voids during night if any. We did not aim to investigate 
equal times periods but representative parts of the day. Layout of our study design in 
shown in Figure 1. 
Each portion was collected separately into an individual sterile graduated 500 mL plastic 
container without additives. Participants were instructed to keep the containers in the 
refrigerator and return them the next day after collection. Volumes of the portions were 
recorded. Subsequently, specimens of the individual portions were centrifuged at low 
speed to remove large particulate matter (1000×g at 4 °C for 10 min), aliquoted in fresh 
polypropylene tubes and stored at -80°C until assayed. 
Although in a well-motivated and properly instructed population, composed of health 
care and research professionals, a proportion of incomplete urine collections is 
presumed to be small, we assessed completeness of the 24-h urine collections by 
comparing measured urinary creatinine and the one estimated from the equation: (22 - 
(age / 9)) × kg in women and (28 - (age / 6)) × kg in men.  
Once during the study (on day 3 to 5 of collection) a non-fasting venous blood sample 
was obtained by venipuncture and used for creatinine measurement. Creatinine 
concentration was also assessed in the corresponding 24-h urine collection, and 
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creatinine clearance was calculated as U×V/P, where U - creatinine concentration in 24-
h urine, V - 24-h urinary volume, and P - creatinine concentration in plasma.  
Participants were allowed to maintain their usual occupational and leisure activities and 
liberal diet during the study, avoiding heavy physical exercise and alcohol consumption. 
Data on age, weight, height, medication/food supplement intake were obtained by a self-
reporting uniform questionnaire. Body mass index (BMI, kg/m2) was calculated as 
weight, kg / (height, m)2. 
 
Figure 1. Hierarchy of the multilevel data for our study design. D1-5 designate 
corresponding days, P1-4 − urine portions. 
 
Uromodulin measurement 
Uromodulin urinary concentration was measured by a commercially available enzyme-
linked immunosorbent assay (ELISA) kit (MD Bioproducts, St. Paul, MN) according to 
the manufacturer’s instructions. Briefly, the principle of the assay is based on a 
colorimetric sandwich immunoassay utilizing a polyclonal antibody against uromodulin 
bound on the surface of microwells as the capture antibody and a biotinylated polyclonal 
antibody against uromodulin as the detection antibody. According to the manufacturer, 
the interassay coefficient of variation (CV) is 10.5% at a mean concentration of 21.8 
ng/mL and the intra-assay CV is 9.2% at a mean concentration of 22.9 ng/mL; the 
sensitivity is less than 0.75 ng/mL. 
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Prior to performing the assay, urine samples were thawed, brought to room temperature, 
mixed by vortexing avoiding foaming and diluted 1:200 (as determined to be optimal in 
pilot experiments) with the dilution buffer (pH=7.33) supplied with the assay kit. 
Immediately after the ELISA procedure absorbance reading was performed at 450 nm. 
With each set of samples a standard curve, which included seven two-fold dilutions of 
the supplied with the assay standard protein (150 ng/mL), was generated. Uromodulin 
concentration was calculated from the standard curve by reducing the data using a 4-
parameter logistic curve fit regression function. 
The data are presented as absolute uromodulin concentration (ng/mL) and uromodulin 
excretion − mg/portion, calculated as uromodulin concentration in a urinary portion × 
portion volume, and mg/24h, calculated as a sum of portions during the corresponding 
day. In case of absence of a timed urine collection (portion) due to reported absence of 
urination over the respective time period, urine volume and uromodulin concentration 
were set to zero for the corresponding portion (15 out of maximally possible 400 
collections, 3.75%). Uromodulin concentration values which were below the detection 
limit (in 17 out of 385 analyzed urine collections, 4.4%) were set to the lowest value in 
the corresponding assay. 
 
Urinary biomarkers measurements 
NGAL (neutrophil gelatinase-associated lipocalin), H-FABP (fatty acid binding protein, 
heart type) and L-FABP (fatty acid binding protein, liver type) urinary concentrations 
were measured with commercial ELISA kits (HycultBiotech, Uden, the Netherlands, 
catalog numbers HK330, HK402 and HK404 for NGAL, H-FABP and L-FABP, 
respectively), according to the manufacturer’s instructions. 
 
Statistical analysis 
An analysis of covariance model was fitted to the different uromodulin responses − its 
urinary concentration (ng/mL) and excretion (mg/portion or mg/24h, calculated as 
uromodulin concentration × urine volume). The factors subject, day, and portion and all 
two-way interaction terms were included in this model and considered random. The 








SPσ , and 
2
DPσ , respectively. The residual variance component, which is confounded with the 
three-way interaction term is denoted by 2Eσ . The random effects are corrected for the 
covariates sex, age, and BMI. The model parameters are estimated with restricted 
maximum likelihood.  
Chapter 3 - Part 1  
52 
The diurnal and infradian variability of the uromodulin responses for an individual urine 
sample are defined by the intra-day variability ( 22222Diurnal EDPSPP σσσσγ +++= ) and 
the inter-day variability ( 2222222Infradian EDPSPPSDD σσσσσσγ +++++= ), 
respectively. From these measures of variability intraclass correlation coefficients (ICCs) 
can be determined for an average response of different numbers of samples taken within 
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with P the number of portions taken on one day and D the number of days for collecting 
samples. It should be noted that the ICCDiurnal is always equal or larger than the 
ICCInfradian. The ICCs can be interpreted as the amount of information that is provided by 
the number of urine samples. The higher the ICC’s the more precise the uromodulin 
responses have been determined for a subject. The consequences of a low or high ICC 






Multiple samples on one day 
(P>1, 24-h collection would 
be advisable) from different 
days are needed (D>1) 
Multiple samples from 
different days are needed 
(D>1) 
High NA One sample is satisfactory (P=D=1) 
 
The measures of variability and the ICCs will be estimated to quantify the amount of 
changes uromodulin measurements undergo. 
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Results 
In all included individuals urinary levels of NGAL, L-FABP and H-FABP were either 
undetectable or below the reference values, thus confirming healthy status of the kidney. 
The measured/expected ratios for urinary creatinine were between 0.7 and 1.1 
confirming accuracy of the collections. Renal function by 24-h creatinine clearance was 
within the normal range. Over the course of 5 days, median 24-h uromodulin 
concentration and uromodulin excretion were 3.47 µg/mL and 6.25 mg/24h, respectively 
(Table 1). In Figure 2 summarized data (averaged for 20 subjects) on uromodulin 
concentration, excretion and urinary volume, observed intra-day (A) and inter-day (B), 
are visualized. Dynamics of the individual values observed from day to day is presented 
in Figure 3. 
Table 1. Study participants characteristics 
Age, years  26.5 (24-30.5) 
Sex: males / females, n 11 / 9 
BMI, kg/m2  22 (21-24.8) 
Serum creatinine, µmol/L  82.0 (67.5-87.8) 
24-h creatinine clearance, mL/min 138 (122-165) 
Uromodulin concentration, µg/mL  3.47 (2.18-4.44) 
Uromodulin excretion, mg/24h  6.25 (2.32-11.87) 
Urine volume, L/24h  1.6 (1.2-2.2) 
Data are presented as medians (IQR)  
 
Figure 2. Intra-day (A) and day-to-day (B) values of, respectively, uromodulin 
concentration, uromodulin excretion and urine volume, observed in 20 healthy 
subjects. The data are presented as medians and IQR.  
A
B
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Figure 3. Dynamics of uromodulin concentration, uromodulin excretion and urine volume 
observed over five consecutive 24-h periods. Each individual line represents a study subject. 
 
Variance estimates of “day”, “portion” and of the corresponding interaction term 
approximated zero for uromodulin concentration (Table 2). This is indicative of the 
absence of systematic bias and suggests no physiological rhythmic fluctuations (diurnal 
or infradian) for uromodulin urinary concentration. However, for uromodulin excretion 
effect of “portion” was higher than zero (although non-significant), most probably, 
reflecting interference by urinary volume diurnal pattern. 
Both diurnal and infradian ICCs for uromodulin concentration and excretion, measured in 
random urine portion (one timed collection on one day) were low and similar in 
magnitude (Table 3). Expanding the number of observations by assessing uromodulin in 
urine portions taken on several days increased the ICCs proportionately. Using 24-h 
urine collection for uromodulin measurement already gave moderate-to-high ICCs, which 
reached high values when collection over several days was employed. 
 
Table 2. Results of a linear mixed model on the dependent variables: uromodulin 
concentration and uromodulin excretion. 
Outcomes 
Estimates of: 
Random effects of within-subject factors and interactions Fixed effects of between-
subject factors 












0 0 0 3.06×106 1.18×105 0.43×105 55.61 -635.39 -205.31 
Uromodulin 
excretion, mg 0 0.49 0 1.56 0.14 2.02 0.08 0.07 -0.16 
Statistical significance in shown in bold. 
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Table 3. Intraclass correlation coefficients (ICCs) for diurnal and infradian variability of 







ICCDiurnal ICCInfradian ICCDiurnal ICCInfradian 
1 
1 33.5% 32.3% 22.1% 20.3% 
2 49.8% 48.9% 35.2% 33.7% 
5 71.0% 70.5% 57.0% 56.0% 
4* 
1 66.9% 64.4% 53.1% 48.8% 
2 79.9% 78.4% 68.5% 65.6% 
5 90.7% 90.0% 84.1% 82.7% 
*sum of 4 portions of the day = 24-h urine collection 
 
Discussion 
Reference values for urinary uromodulin reported in the literature vary dramatically, 
which can be most probably explained by using different laboratory techniques for its 
assessment. However, our primary interest was not the absolute values but relative, 
temporal changes in uromodulin excretion occurring in a given individual from day to day 
and in the course of the day under normal conditions. 
A number of previous reports pointed to existence of a large variation in daily uromodulin 
excretion.5,6,22,23 Studies attempting evaluation of uromodulin excretion on consecutive 
days showed that values varied considerably both within and between subjects, which 
led to the conclusion that studies based on a single baseline uromodulin measurement 
may not detect any significant results due to the large variability. 
However, the above mentioned studies were based on rather low numbers of 
observations over a short period of time (e.g. two healthy male volunteers during four 
consecutive days23). Besides, the studies employed different designs and approaches 
(e.g. assessing uromodulin concentration in 24-h urine collections on consecutive days23 
vs 2-h interval collections over 24 h22).  
We studied uromodulin urinary levels over 5 consecutive 24h periods, each consisting of 
4 intervals (“portions”), in 20 healthy volunteers to address problems of both day-to-day 
and intra-day variability of uromodulin. We revealed no obvious diurnal or infradian 
rhythms for uromodulin concentration in the urine. However, uromodulin excretion, 
calculated as a product of uromodulin concentration and urinary volume, reflected the 
diurnal pattern of the latter. 
The potential practical implications of our study are as follows. We demonstrated that a 
random urine portion cannot be reliably used for uromodulin measurement. According to 
our findings, an optimal option for uromodulin concentration assessment would be 24-h 
urine collection as the corresponding ICCs appeared to be fairly high, and in cases when 
Chapter 3 - Part 1  
56 
superior accuracy of the measurement is desired evaluation over several days is 
warranted. Furthermore, while being largely a methodological study, it nevertheless 
provides some mechanistic insights. We observed that in the course of the day urinary 
excretion of uromodulin closely followed diurnal fluctuations in urine volume. There was 
no “dilution effect” − drop in concentration with increase in volume of urine − that is 
usually seen for a number of substances excreted with urine. This phenomenon is 
suggestive of a role of urine volume in uromodulin shedding which is probably 
driven/facilitated by tubular flow. Our results are thus in agreement with an experimental 
study showing that urinary excretion of uromodulin followed the increased diuresis and 
increased in rats with polyuria.28 
Here we studied healthy individuals; correspondingly, the results might not be 
generalizable to renal patients as under pathophysiological conditions dysregulation of 
uromodulin excretion may occur. Therefore, investigation of uromodulin day-to-day and 
intra-day variability in specifically subjects with compromised kidney function would be of 
interest. However, a study of patients with nephrolithiasis, which evaluated uromodulin in 
three 24-h urine collections, found its excretion to be remarkably constant29, which is in 
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Introduction 
Uromodulin (or Tamm-Horsfall protein) is the most abundant tubular protein in the urine 
of healthy subjects. It is expressed in the kidney, primarily in the thick ascending limb of 
the loop of Henle with negligible expression elsewhere, and released into urine by 
proteolytic cleavage.  
Uromodulin excretion has been previously associated with renal prognosis. It has been 
shown that elevated urinary uromodulin levels associate with progressive renal function 
decline and increased risk for development of chronic kidney disease (CKD)1. For better 
interpretation of urinary uromodulin levels it is important to understand its determinants, 
in both healthy subjects and renal patients. 
Association of genetic variation in the UMOD gene with blood pressure and fractional 
excretion of sodium2, and the peculiar localization of its expression, i.e. in the distal 
tubule specifically omitting macula densa3,4, are suggestive of potential involvement of 
uromodulin in renal sodium handling. In healthy subjects sodium intake affects 
uromodulin excretion, with urinary uromodulin being positively associated with urinary 
sodium excretion2,5. Whether dietary sodium influences uromodulin excretion also in 
subjects with renal disease is unknown. 
Combination of renin-angiotensin-aldosterone system (RAAS) inhibition by either 
angiotensin converting enzyme inhibition (ACEi) or angiotensin receptor blockade (ARB) 
(or both, dual RAAS blockade) and low sodium diet constitutes an efficient strategy for 
renoprotection in patients with proteinuric kidney disease.  
We studied uromodulin excretion in renal patients receiving renoprotective treatment. 
We aimed to evaluate the impact of renoprotective therapy by means of sodium 
intervention with sodium restricted diet and RAAS inhibition on uromodulin urinary levels 
in patients with proteinuric kidney disease. To this purpose, we performed a post-hoc 
analysis of a previously published multicenter randomized double-blind placebo 
controlled cross-over trial6. Our study question was whether uromodulin excretion is 
affected by intensification of renoprotective treatment in CKD patients. 
 
Methods 
Study population and design 
The protocol was described in detail elsewhere6. Briefly, 52 patients with non-diabetic 
nephropathy were enrolled and completed the study between April 2006 and October 
2009 in three medical centers in the Netherlands. All patients were treated during four 6-
week periods, in random order (cross-over design), with ARB at maximal recommended 
dose (valsartan 320 mg/day) or placebo, each combined with, consecutively, a low 
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sodium diet (target 50 mmol Na+/day) and a regular sodium diet (target 200 mmol 
Na+/day), on a background of ACE inhibition at a maximal recommended dose (lisinopril 
40 mg/day) during the entire study. The drug interventions were double-blind, the dietary 
interventions were open-label. At the end of each 6-week treatment period patients 
collected 24-h urine. A flowchart of the study design is presented in Figure 1. 
 
Uromodulin measurement 
We measured uromodulin concentration in aliquots of the 24-h urine collections available 
at storage, using a commercially available enzyme-linked immunosorbent assay kit, 




Figure 1. Study design flowchart.  
During a 6-week run-in period, patients received ACE inhibition at maximal dose (lisinopril 40 mg/day) and 
stopped all other renin-angiotensin-aldosterone system blockers. Additional antihypertensive drugs such 
as β blockers, α blockers, calcium channel blockers, and diuretics were allowed and kept stable during the 
study; no dietary intervention took place during the run-in period. Consequently, the patients were treated 
during four 6-week periods, in random order, with angiotensin receptor blockade at maximal recommended 
dose (valsartan 320 mg/day) or placebo, each combined with, consecutively, a low sodium diet (target 50 
mmol Na+/day, approximately 3 g NaCl/day) and a regular sodium diet (target 200 mmol Na+/day, 12 g 
NaCl/day), on a background of ACE inhibition at a maximal recommended dose (lisinopril 40 mg/day) 
during the entire study. At the end of each 6-week treatment period patients collected 24-h urine.  
Lis, lisinopril; Val, valsartan; dark gray background color indicates regular sodium diet, light gray - low 
sodium diet. 
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Statistical analysis 
Uromodulin 24-h excretion (mg/24h) was calculated as uromodulin concentration × 24-h 
urine volume. Before statistical testing, uromodulin excretion values were natural log 
transformed to approximate normality of distribution. We used paired t-test (which 
account for the same patients providing data for both treatment groups) to determine the 
effect of treatment regimen. Six comparisons were made:  
1) lisinopril versus lisinopril plus valsartan,  
2) lisinopril versus lisinopril plus low sodium diet,  
3) lisinopril versus lisinopril plus valsartan plus low sodium diet,  
4) lisinopril plus valsartan versus lisinopril plus low sodium diet,  
5) lisinopril plus valsartan versus lisinopril plus valsartan plus low sodium diet,  
6) lisinopril plus low sodium diet versus lisinopril plus valsartan plus low sodium 
diet.  
To adjust for multiple testing, we set the significance threshold to 0.0083 (0.05/6, 
Bonferroni correction). To verify the absence of carry-over effects, we performed a linear 
mixed model analysis with uromodulin excretion as a dependent variable, participants as 
a random factor, treatment, sequence and the interaction term treatment*sequence as 
fixed factors. 
 
Results and Discussion 
Uromodulin excretion was not significantly affected by either mono or dual RAAS 
blockade or dietary sodium, as there were no statistically significant differences in 
uromodulin 24-h excretion between the treatment regimens: lisinopril versus lisinopril 
plus valsartan (p=0.822); lisinopril versus lisinopril plus low sodium diet (p=0.219); 
lisinopril versus lisinopril plus valsartan plus low sodium diet (p=0.065); lisinopril plus 
valsartan versus lisinopril plus low sodium diet (p=0.265); lisinopril plus valsartan versus 
lisinopril plus valsartan plus low sodium diet (p=0.026); lisinopril plus low sodium diet 
versus lisinopril plus valsartan plus low sodium diet (p=0.189). 
However, we observed a trend for decreased uromodulin urinary excretion during low 
sodium as compared to high sodium diet (Table 1, Figure 2). Such a direction of the 
effect is in line with the previous studies. It had been previously shown that sodium 
intake affects uromodulin excretion in healthy subjects2,5. Also in a recent report urinary 
uromodulin excretion was positively correlated with urinary sodium excretion7. Our study 
thus demonstrated that also in CKD patients urinary uromodulin is influenced by dietary 
sodium.  
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Table 1. Uromodulin 24-h 
excretion per treatment period.  








Figure 2. Uromodulin 24-h 
excretion by treatment 
regimen.  
The interventions are designated as 
follows: lis, lisinopril; lis+val, dual 
RAAS blockade with lisinopril and 
valsartan. The columns represent 
medians of untransformed values, the 




The fact that uromodulin response to sodium load is preserved in individuals with 
impaired renal function is of interest and large importance, since it then constitutes a 
potential target for intervention. 
High urinary uromodulin content is assumed to be harmful. First, it is a prognostic factor, 
as elevated uromodulin levels have been shown to be associated with increased risk for 
development of CKD1. Second, uromodulin is thought to play a direct pathogenetic role 
in renal disease by promoting inflammation-mediated tubulointerstitial damage8-10. 
Therefore, dietary sodium restriction might represent a plausible intervention to slow 
down progression of CKD through lowering urinary uromodulin. 
Angiotensin converting enzyme inhibition has previously been reported to decrease 
uromodulin excretion11. In our study dual RAAS inhibition with angiotensin receptor 
blockade on top of ACEi did not affect urinary uromodulin levels. This might be attributed 
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to the fact that maximal decrease of uromodulin has already been reached by lisinopril, 
and addition of valsartan did not further reduce excretion of uromodulin. In this respect, it 
would have been of interest to measure a baseline (without ACEi) uromodulin excretion. 
However, it is not feasible since the protocols of treatment of patients with proteinuric 
kidney disease include ACE inhibitors. 
A certain limitation of our study that needs to be mentioned is that there were no wash-
out periods between the treatments. However, the half-life of the used interventions is 
rather short (lisinopril 12.6 hours, valsartan 9 hours, low sodium diet <1 week). In 
addition, the treatments were given in random order. This allowed to design the study 
without wash-out periods. The linear mixed model analysis confirmed that there was no 
effect of order of the treatment regimens. 
We studied changes of uromodulin content in urine, assuming that urinary uromodulin 
reflects renal uromodulin content. However, uromodulin urinary excretion might not 
equal its tissue expression. During high dietary salt intake, elevated excretion of 
uromodulin could potentially be due to its increased synthesis in the kidney, increased 
shedding into urine, or both. Our study design did not allow to discriminate between 
these mechanisms. However, an experimental study performed in rats showed 
increased expression of uromodulin in the kidney in response to increased dietary 
sodium intake12. Studies involving simultaneous assessment of kidney and urinary 
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Abstract 
In recent genetic association studies, common variants including rs12917707 in the 
UMOD locus have shown strong evidence of association with eGFR, prevalent and 
incident chronic kidney disease and uromodulin urinary concentration in general 
population cohorts. The association of rs12917707 with end-stage renal disease (ESRD) 
in a recent case-control study was only nominally significant.  
To investigate whether rs12917707 associates with ESRD, graft failure (GF) and urinary 
uromodulin levels in an independent cohort, we genotyped 1142 ESRD patients 
receiving a renal transplantation and 1184 kidney donors as controls. After 
transplantation, 1066 renal transplant recipients were followed up for GF. Urinary 
uromodulin concentration was measured at median [IQR] 4.2 [2.2-6.1] yrs after kidney 
transplantation. 
The rs12917707 minor allele showed association with lower risk of ESRD (OR 0.89 
[0.76-1.03], p=0.04) consistent in effect size and direction with the previous report 
(Böger et al, PLoS Genet 2011). Meta-analysis of these findings showed significant 
association of rs12917707 with ESRD (OR 0.91 [0.85-0.98], p=0.008). In contrast, 
rs12917707 was not associated with incidence of GF. Urinary uromodulin concentration 
was lower in recipients-carriers of the donor rs12917707 minor allele as compared to 
non-carriers, again consistent with previous observations in general population cohorts.  
Our study thus corroborates earlier evidence and independently confirms the association 
between UMOD and ESRD. 
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Introduction 
Chronic kidney disease (CKD) is a significant and increasing global challenge for public 
health. It affects ≈10% of the general population in industrialized nations, incurring high 
morbidity and mortality, and posing a substantial financial burden to the health care 
systems [1-3]. It is a complex, multifactorial disorder with an important genetic 
component. Identification of the genetic variants involved in its susceptibility and 
progression to end-stage renal disease (ESRD) will improve our understanding of 
biological mechanisms underlying renal function and will ultimately lead to development 
of novel tools for diagnosis, prevention, prediction and treatment [4-6].  
Recent advances in genome-wide association (GWA) studies of kidney disease resulted 
in discovery of several genes. Among them a prominent place is taken by UMOD which 
has been reproducibly identified in multiple cohorts as one of the top loci associated with 
renal function parameters [7-10]. Several GWA studies highlighted a region upstream 
from the UMOD gene containing rs12917707 and several other SNPs in high linkage 
disequilibrium (LD). The mentioned LD block was repeatedly shown to be associated 
with prevalent and incident CKD, and also uromodulin urinary concentration. All the 
studies showed a consistent trend of association of the rs12917707 minor allele with 
lower risk of CKD [7, 11-15], and the minor alleles of SNPs in perfect LD with 
rs12917707, rs4293393 and rs13333226, were associated with lower urinary uromodulin 
levels [11, 15].  
A recent study examined the role of rs12917707 genotype in risk for a more severe renal 
phenotype, ESRD, with the minor allele again showing a protective effect: OR [95% CI] 
0.92 [0.86-1.0] [14]. However, the level of statistical significance was only nominal 
(p=0.04), warranting further investigation to confirm the association of the UMOD 
variants with kidney damage phenotypes.  
We thus analyzed the association of rs12917707 with ESRD and with graft failure (GF) 
after kidney transplantation, and investigated the effect of rs12917707 genotype on 
urinary uromodulin levels. First, we performed a case-control study where cases were 
1142 ESRD patients receiving transplantation and controls were 1184 kidney donors (a 
flowchart of the participants selection is shown in Figure 1). Second, to analyze whether 
UMOD affects long-term kidney transplant function, we performed a survival association 
analysis of donor rs12917707 genotype impact on incidence of GF in 1066 renal 
transplant recipients. 
The UMOD gene expression product is uromodulin, also known as Tamm-Horsfall 
protein, which is excreted with urine, easily measurable [16-18] and thus presents a 
perfect intermediate phenotype for genetic association research. As the UMOD gene is 
expressed exclusively in the kidney, it was assumed that it was kidney genotype that 
was associated with urinary uromodulin in the previous reports [11-13, 15]. To prove it, 
we aimed to investigate whether this association holds after the kidney is transplanted. 
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Methods & Materials 
 
Study population 
This study was conducted in the REGaTTA cohort [19, 20]. Briefly, from all renal 
transplantations carried out in our center between 1993 and 2008 we included 1142 first 
graft recipients and 1186 donors (1066 matched donor-recipient pairs) for the present 
genetic study. The exclusion criteria were: re-transplantation, combined kidney/pancreas 
or kidney/liver transplantation, technical problems, absence of DNA and loss of follow-
up. A flowchart of the study participants selection is shown in Figure 1. After 
transplantation the recipients were followed up for median [IQR] 5.5 [2.9-8.8] years and 
immunosuppression regimen, clinical and laboratory parameters, and time to GF were 
documented. GF was defined as return to dialysis or re-transplantation and was 
censored for death with a functioning graft. Patients characteristics, transplantation-
related parameters, clinical and laboratory data were retrieved from medical records. 
The Institutional Review Board of the University Medical Center Groningen approved the 
study protocol. Informed consent was given by all transplant recipients and living donors. 
For deceased donors, with research carried out after the organ removal and 
implantation, no consent was required. According to Dutch law general consent for 
organ donation and transplantation includes consent for research projects. The study 
was conducted according to the principles of the Declaration of Helsinki. All the genetic 
and clinical data were anonymized prior to analyses. 
 
DNA isolation and genotyping 
DNA was extracted from peripheral whole blood (in recipients and living donors) or 
lymph nodes/spleen lymphocytes (in deceased donors) using a commercial kit following 
the manufacturer’s instructions, transferred into 2 ml Eppendorf tubes and stored at -
20°C. Absorbance at 260nm was measured with NanoDrop spectrophotometer (ND-
1000, NanoDrop Technologies) and DNA concentration was calculated by the NanoDrop 
nucleic acid application module. As a measure of DNA purity 260/280 and 260/230 
absorbance ratios were assessed. Where samples failed to meet the minimum DNA 
concentration and purity recommended for Illumina genotyping, repeated isolation 
attempts were made. Genotyping of the rs12917707 SNP in the UMOD locus was 
performed using the Illumina VeraCode GoldenGate assay kit (Illumina, San Diego, CA, 
USA), according to the manufacturer's instructions. Genotype clustering and calling were 
performed using BeadStudio Software (Illumina). Genotyping was unsuccessful in two 
individuals.  
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Uromodulin measurement 
For 282 outpatient renal transplant recipients at median [IQR] 4.2 [2.2-6.1] years post-
transplant, 24 h urine samples were available at storage. Uromodulin concentration was 
measured by a commercially available enzyme-linked immunosorbent assay kit (MD 
Bioproducts, St. Paul, MN, Tamm-Horsfall Glycoprotein ELISA, catalog number 
M036020) according to the manufacturer’s instructions. For this assay, the interassay 
coefficient of variation is 10.5% at a mean concentration of 21.8 ng/mL and 12.2% at 
95.1 ng/mL; the sensitivity is less than 0.75 ng/mL. The principle of the assay is based 
on a colorimetric sandwich immunoassay utilizing a polyclonal antibody against human 
uromodulin as the capture antibody and a biotinylated polyclonal antibody against 
human uromodulin as the detection antibody. Immediately after the ELISA procedure 
absorbance reading was performed at 450 nm. A standard curve was generated with 
each set of samples by reducing the data using 4-parameter logistic curve fit. 
Uromodulin concentration was calculated from the standard curve. 
 
 
Figure 1. A flowchart of the study participants selection  
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Statistical analysis 
Analyses were performed with PASW Statistics 18.0 (SPSS Inc., Chicago, IL) and 
PLINK v1.07 (S. Purcell, http://pngu.mgh.harvard.edu/purcell/plink/ [21]). QUANTO 
v1.2.4 (http://hydra.usc.edu/gxe/) and PASS v11 were used for power estimation. 
Deviation from Hardy-Weinberg equilibrium was tested in donors. Two individuals 
(donors), in which genotyping of rs12917707 was unsuccessful, were excluded and 
subsequent statistical analyses were performed on a final sample of 2326 subjects in a 
case-control design (1142 recipients vs 1184 donors) and 1066 matched donor- 
recipient pairs in a longitudinal design. Genotype-phenotype associations were tested 
under an additive genetic model and results (regression coefficients and p-values) are 
reported per copy of the minor allele. 
Since we tested the hypothesis that the minor rs12917707 allele is associated with 
reduced risk, such a priori directional prediction allowed us to assume statistical 
significance at a one-sided p=0.05. Also in the reference paper [14] one-sided p values 
were presented. With one-sided p=0.05, assuming an additive genetic model and MAF 
of 20%, we had approximately 90% and 40% power to detect an OR of 0.8 and 0.9, 
respectively, in the ESRD case-control analysis, and 47% and 18% power to detect a 
HR of 0.8 and 0.9, respectively, in the longitudinal analysis of graft survival. 
As in 164 (14%) cases transplantation was performed from living blood-related donors, 
the PLINK DFAM algorithm was used to account for relatedness in the case-control 
analysis.  
We performed a fixed effects inverse variance meta-analysis to combine the results of 
our case-control study and the previously published one [14]. 
The effect of genotype on graft survival was investigated with Cox regression analysis 
including as covariates known predictors of GF (donor and recipient age and sex, donor 
type, ischemia times, delayed graft function and acute rejection episodes history, 
immunosuppression regimen). 
To study association between genotype and uromodulin urinary levels after 
transplantation, due to small number of individuals homozygote for the minor allele, 
genotypes were combined into two groups: minor allele carriers (heterozygotes and 
homozygotes for the minor allele) and non-carriers (homozygotes for the ancestral 
allele). Statistical significance of differences between the groups was tested with a 
Mann-Whitney U test. 
  




Patient characteristics are presented in Table 1.  
There was no deviation from Hardy-Weinberg equilibrium in controls (p=0.49). The 
rs12917707 minor allele frequency (MAF) in the overall sample was 17.3%, comparable 
to HapMap data and previous publications [7, 8, 14]. The MAF was 18.2% and 16.5% in 
kidney donors and ESRD patients, respectively. In the additive genetic model, adjusted 
for age, sex and case-control relatedness, OR [95% CI] for ESRD was 0.89 [0.76-1.03] 
per copy of the minor allele, one-sided p=0.04, which is direction-consistent with the 
previously published association results [14]. A meta-analysis of our results and those of 
the abovementioned study [14] showed a significant association of rs12917707 with 
ESRD: OR [95% CI] 0.91 [0.85-0.98], p=0.008 (Figure 2).  
Figure 2. Meta-analysis forest plot. 
 
There was no interaction between rs12917707 and age or sex (p=0.92 and p=0.97, 
respectively). We did not observe association between rs12917707 genotype and any of 
the underlying etiology of ESRD (Table S1).  
  
Chapter 4  
74 
Table 1. Patient characteristics. 
ESRD patients, n=1142  
Age, years 47.7±13.5 
Sex: male, n (%) 662 (58.0) 
Primary disease:  
- glomerulonephritis, n (%) 242 (21.2) 
- autosomal dominant polycystic kidney disease, n (%) 155 (13.6) 
- pyelonephritis, n (%) 128 (11.2) 
- renal vascular disease, n (%) 110 (9.6) 
- IgA nephropathy, n (%) 89 (7.8) 
- diabetes types I and II, n (%) 47 (4.1) 
- other/uncertain etiology, n (%) 371 (32.5) 
Kidney donors, n=1184  
Age, years 44.5±14.3 
Sex: male, n (%) 602 (50.8) 
Living donors, n (%) 282 (23.8) 
- from which related donors, n (%) 164 (58.2) 
Matched donor-recipient pairs, n=1066  
Recipient age, years 48.1±13.5 
Recipient sex: male, n (%) 620 (58.2) 
Donor age, years 44.6±14.3 
Donor sex: male, n (%) 540 (50.7) 
Living donors, n (%) 261 (24.5) 
Cold ischemia time, hours 17.4 [9.0-23.0] 
Total warm ischemia time, minutes 40.0 [34.0-51.0] 
Delayed graft function, n (%) 332 (31.1) 
Post-transplant follow-up duration, years 5.5 [3.0-8.7] 
Acute organ rejection episodes history, n (%) 368 (34.5) 
Death-censored graft failure, n (%) 172 (16.1) 
Death with a functioning graft, n (%) 182 (17.1) 
Renal transplant recipients with urine available, n=282  
Age, years 52.1±12.3 
Sex: male, n (%) 152 (53.9) 
Urine collection time point, years after transplantation 4.2 [2.2-6.1] 
Continuous normally distributed variables are presented as means±SD, non-normally distributed – as medians 
[IQR].  
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During a median [IQR] 5.5 [2.9-8.8] years of follow-up, 172 (16.1%) cases of death-
censored GF occurred and 183 (17.1%) patients died with a functioning graft. Donor 
kidney rs12917707 MAF was higher in subjects with a functioning graft as compared to 
cases that suffered death-censored GF (18.7% vs 17.2%, respectively). There was no 
significant association between donor rs12917707 and GF as in a univariate Cox 
regression analysis hazard ratio (HR) [95% CI] for GF was 0.92 [0.69-1.23], p=0.57. 
A multivariate Cox regression model adjusted for known predictors of graft survival 
(Table S2) showed a HR [95% CI] 0.96 [0.72-1.28], p=0.76. Exclusion of cases with ≤1 
year graft survival use did not change the results. Recipient rs12917707 also was not 
associated with GF (HR [95% CI] 1.04 [0.78-1.38], p=0.788). 
In a subset of renal transplant recipients (n=282), in which 24-h urine collected at 
median [IQR] 4.2 [2.2-6.1] years post-transplant was available for uromodulin 
measurements, donor rs12917707 genotypes distribution was 4 / 94 / 184, 
correspondingly, MAF was 18.0%. Uromodulin concentrations ranged from 0.3 to 42.6 
µg/ml, median [IQR] 8.6 [5.8-13.3] µg/ml, and were significantly lower in carriers of the 
rs12917707 minor allele in the donor genotype as compared to non-carriers: 7.3 [5.4-
10.8] and 9.4 [6.4-15-6] µg/ml, respectively (p=0.007) [Figure S1]. Recipient rs12917707 
was not associated with uromodulin urinary levels (p=0.43). 
 
Discussion 
Thus, we have independently confirmed the association between UMOD rs12917707 
and ESRD in a large case-control study. It was of similar direction and magnitude as 
previously reported [14], and in a meta-analysis of our results and the cited data 
convincing statistical significance was reached. 
We did not find an association between rs12917707 genotype and etiology of ESRD. 
This suggests a universal, non-specific effect of the SNP on renal function decline 
irrespectively of underlying primary disease. A previous study described interaction 
between UMOD variant rs4293393 (in perfect LD with rs12917707) and age [12]. We, 
however, did not observe interaction with age or sex in our population.  
Importantly, the observed relationship of the UMOD variant with ESRD in native kidneys 
did not translate into association with renal function loss in the transplanted kidney as we 
did not find an association between the donor rs12917707 and GF. Although the SNP 
effect on GF was direction-consistent with the case-control analysis and suggestive of a 
protective trend, the results were not statistically significant. It might indicate true 
absence of an association and differential involvement of UMOD in the pathophysiology 
of native and transplanted kidneys, or point to the fact that our longitudinal study was 
underpowered to detect the genetic effect due to the moderate sample size. 
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Remarkably, uromodulin urinary levels in patients after renal transplantation were 
associated with donor UMOD rs12917707 genotype. The subset of transplant recipients, 
in which urinary uromodulin was studied, was representative of the whole sample in 
terms of MAF and genotypes distribution. Uromodulin concentrations were significantly 
lower in recipients-carriers of the donor rs12917707 minor allele as compared to non-
carriers. Thus, the genetic effect on uromodulin urinary level that was previously found in 
the native kidneys was reproduced in the transplanted kidneys, with similar direction of 
effect. This implies that it is indeed the UMOD genotype of the kidney that associates 
with uromodulin production. 
Several arguments support the genetic analysis of a kidney transplant cohort. First, a 
case-control study with kidney donors, instead of the general population, as controls 
may have augmented statistical power to reveal the subtle genetic effects expected from 
common variants. Second, a transplant population provides the opportunity to study 
renal function loss in both native and transplanted kidneys through investigation of 
ESRD before and GF after transplantation. Finally, uniqueness and elegance of a 
transplantation setting is that it enables to test effects of both recipient and donor 
genotype on phenotype and thus discriminate between local (intra-renal) and systemic 
(extra-renal) processes. 
The strengths of our study include the cohort’s size, its wide spectrum of underlying 
primary kidney disease and the specific design. However, some limitations deserve to be 
mentioned. Our longitudinal study may have been underpowered to detect significant 
SNP effect on GF. Power limitations also exist for the analysis of specific ESRD 
etiologies. Further, the analysis of the risk for ESRD is cross-sectional and needs to be 
confirmed by longitudinal studies studying incident ESRD. Unfortunately, the design and 
performance of such studies in CKD patients is challenging, and thus these are only 
emerging [22-24]. We did not have information on patients ethnicity, however, a reliable 
estimate for an average patient population in our region is that over 90% of the 
individuals are of European ancestry. Subsequently, our results are not generalizable to 
other ethnicities. Urinary uromodulin in renal transplant recipients was measured at 
different time points ranging from 1 to 9 years after transplantation. For those patients 
with presence of residual native kidney function, we cannot exclude a possible 
confounding effect of recipient rs12917707 genotype on urinary uromodulin 
concentration. However, this would have biased results to a null effect, while we have 
detected a significant association. 
In summary, we have independently confirmed the association between genetic variation 
at the UMOD locus and ESRD. Also, donor kidney genotype was significantly associated 
with urinary uromodulin concentration in renal transplant recipients providing evidence 
that genetic make-up of the kidney determines this intermediate phenotype. Further 
research, including targeted sequencing of the region, bioinformatic analyses and 
functional experiments, is required to unravel the mechanisms by which common genetic 
variation at UMOD cause kidney disease.  
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0 1 2 
N 799 310 33  
Glomerulonephritis, n (%) 168 (21.0) 69 (22.3) 5 (15.2) 0.623 
Polycystic kidney disease, autosomal 
dominant (adult) form, n (%) 111 (13.9) 37 (11.9) 7 (21.2) 0.298 
Pyelonephritis, n (%) 91 (11.4) 35 (11.3) 4 (12.1) 0.990 
Renal vascular disease, n (%) 81 (10.1) 26 (8.4) 3 (9.1) 0.671 
IgA nephropathy, n (%) 61 (7.6) 26 (8.4) 2 (6.1) 0.853 
Diabetes type I and II, n (%) 33 (4.1) 14 (4.5) 0 (0.0) 0.462 
Digits 0-2 designate number of the rs12917707 minor allele copies per genotype 
Table S2. Predictors of GF (univariate Cox regression analysis) in 1066 renal transplant 
recipients followed up for a median [IQR] 5.5 [2.9-8.8] years after transplantation 
  HR  95% CI P value 
Recipient age at transplantation 0.99 0.98-1.00 0.037 
Recipient sex: male 1.11 0.82-1.51 0.495 
Donor age 1.02 1.01-1.03 0.002 
Donor sex: male 0.98 0.73-1.33 0.907 
Donor type: living vs deceased 0.54 0.35-0.84 0.006 
Cold ischemia time 1.03 1.01-1.04 0.001 
Total warm ischemia time 1.02 1.01-1.03 0.001 
Delayed graft function 3.83 2.83-5.19 <0.001 
Acute rejection episodes history 1.87 1.38-2.52 <0.001 
HR, hazard ratio; CI, confidence intervals.  
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Figure S1. Uromodulin urinary concentration in 282 renal transplant recipients at 4.2 [2.2-6.1] 
yrs post-transplant by donor and recipient genotype stratified by presence (carriers) or 
absence (non-carriers) of UMOD rs12917707 minor allele.  
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Abstract 
Chronic kidney disease (CKD) is a complex disorder. As genome-wide association 
studies identified cubilin gene CUBN as a locus for albuminuria, and urinary protein loss 
is a risk factor for progressive CKD, we tested the hypothesis that common genetic 
variants in CUBN are associated with end-stage renal disease (ESRD) and proteinuria.  
First, a total of 1142 patients with ESRD, admitted for renal transplantation, and 1186 
donors were genotyped for SNPs rs7918972 and rs1801239 (case-control study). The 
rs7918972 minor allele frequency (MAF) was higher in ESRD patients comparing to 
kidney donors, implicating an increased risk for ESRD (OR 1.39, p=0.0004) in native 
kidneys.  
Second, after transplantation recipients were followed for 5.8 [3.8-9.2] years (longitudinal 
study) documenting ESRD in transplanted kidneys − graft failure (GF). During post-
transplant follow-up 92 (9.6%) cases of death-censored GF occurred. Donor rs7918972 
MAF, representing genotype of the transplanted kidney, was 16.3% in GF vs 10.7% in 
cases with functioning graft. Consistently, a multivariate Cox regression analysis showed 
that donor rs7918972 is a predictor of GF, although statistical significance was not 
reached (HR 1.53, p=0.055). There was no association of recipient rs7918972 with GF. 
Rs1801239 was not associated with ESRD or GF.  
In line with an association with the outcome, donor rs7918972 was associated with 
elevated proteinuria levels cross-sectionally at 1 year after transplantation.  
Thus, we identified CUBN rs7918972 as a novel risk variant for renal function loss in two 
independent settings: ESRD in native kidneys and GF in transplanted kidneys. 
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Introduction 
Chronic kidney disease (CKD) is a complex multifactorial disorder with an important 
genetic component [1-3]. A recent genome-wide association study (GWAS) identified the 
cubilin gene CUBN as a locus for albuminuria: a missense single-nucleotide 
polymorphism (SNP) rs1801239 (Ile2984Val) in this gene was associated with elevated 
urinary albumine-to-creatinine ratio and microalbuminuria in both the general population 
and in diabetic patients [4].  
As albuminuria is a risk factor for progression of CKD up to end stage renal disease 
(ESRD) [5], we hypothesized that genetic variation in CUBN is associated with 
development of ESRD. To test this hypothesis we genotyped patients with ESRD, 
admitted for renal transplantation, with their donors as a control population, for SNPs in 
the CUBN locus and followed the recipients after transplantation documenting clinical 
parameters and occurrence of graft failure (GF). 
Two CUBN SNPs were genotyped in our study: the previously published rs1801239 and 
a tagSNP rs7918972. The latter was selected based on its linkage disequilibrium with 9 
other SNPs thus covering more variability in the locus and taking into account that one of 
the linked polymorphisms is a coding missense variant which might potentially be 
functional. Another selection criterion was the minor allele frequency (MAF); we targeted 
a lower part of the common variability range, with MAFs between 10 and 15%. 
Within this cohort we performed essentially two independent analyses: 1) ESRD patients 
admitted for renal transplantation versus kidney donors (extreme case-control study) – to 
test for association with ESRD in native kidneys; and 2) long-term post-transplant follow-
up for GF in the recipients (longitudinal study) – for association with ESRD in the 
transplanted kidney.  
We also tested association of the CUBN SNPs with 24-h total urinary protein excretion 
as an intermediate phenotype.  
 
Methods & Materials 
Study population 
From all renal transplantations carried out in our center between 1993 and 2008 we 
retrospectively selected 1142 first graft recipients and 1186 donors for the present 
genetic study. The exclusion criteria were: cases of re-transplantation, combined 
kidney/pancreas or kidney/liver transplantation, technical problems, absence of DNA and 
loss of follow-up. A flowchart of the study participants selection is shown in the Figure 1. 
After transplantation the recipients were followed up and immunosuppression regimen, 
clinical and laboratory parameters, and time to GF were documented. GF was defined 
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as return to dialysis or re-transplantation and was censored for death with a functioning 
graft. Cases with post-transplant graft survival <1 year were excluded from the analyses, 
to decrease heterogeneity in the sample, as graft loss < 1 year is to an important extent 
due to acute complications, such as technical surgical problems, delayed graft function 
and/or acute rejection episodes, whereas we wanted to focus on the process of chronic 
transplant dysfunction. Donor and recipient characteristics, transplantation-related 
parameters and clinical data (24h urinary protein excretion, blood pressure, renal 
function) were retrieved from medical records. The Institutional Review Board of the 
University Medical Center Groningen approved the study protocol. Written informed 
consent was given by all recipients and living donors. For deceased donors, with 
research carried out after the organ removal and implantation, no consent was required. 
According to Dutch law general consent for organ donation and transplantation includes 
consent for research projects. The study was conducted according to the principles of 
the Declaration of Helsinki. All the genetic and clinical data were anonymized prior to 
analyses. 
 
Figure 1. A flowchart of the study participants selection 
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DNA isolation, tagSNP selection and genotyping 
DNA was extracted from peripheral whole blood (in recipients and living donors) or 
lymph nodes/spleen lymphocytes (in deceased donors) using a commercial kit following 
the manufacturer’s instructions, transferred into 2 ml Eppendorf tubes and stored at -
20°C. Absorbance at 260nm was measured with NanoDrop spectrophotometer (ND-
1000, NanoDrop Technologies) and DNA concentration was calculated by the NanoDrop 
nucleic acid application module. As a measure of DNA purity 260/280 and 260/230 
absorbance ratios were assessed. Where samples failed to meet the minimum DNA 
concentration and purity recommended for Illumina genotyping, repeated isolation 
attempts were made. 
Two SNPs in the CUBN locus were genotyped: missense (Ile2984Val) rs1801239 and 
rs7918972. The latter is a tagSNP in the CUBN intron, which was selected using 
Genome Variation Server v5.11 (Seattle SNPs Program for Genomic Applications). This 
program utilizes the LDSelect algorithm [6]. All the SNPs within the CUBN gene 
including 500 bases at the gene flanking regions were submitted to the selection 
procedure. The following parameter settings were used: HapMap-CEU population 
(unrelated only, no HapMap 3), monomorphic sites excluded, r2 threshold 0.8, minimal 
genotype coverage for tagSNPs 85%. Further, for our study we considered SNPs with 
MAFs 10-15%, tagging as many other variants as possible including the missense ones. 
Rationale for the arbitrary MAF cut-off was based on the general expectation that rarer 
variants have a slightly higher likelihood to be causal and may confer stronger effects. At 
the same time, as power to detect such effects depends on sample size, we were 
constrained by the moderate sample size of our study. That is why we set the cut-off in 
the range of 10-15%. Using these settings, the SNP rs7918972 was the best tagSNP 
meeting all our criteria (minimal MAF – 10%, maximal number of the tagged SNPs – 9, 
tagging a missense variant) and therefore was ultimately chosen for this study. This SNP 
is in strong linkage disequilibrium with intronic SNPs rs4088454, rs7897625, rs7897716, 
rs7898076, rs11254232, rs11254238, rs7897442, rs7897705 and missense 
(Asn3552Lys) rs1801232, all of which map to the CUBN locus. The LD structure of the 
studied CUBN SNPs is shown in the Supplemental Figure S1. 
Genotyping of the selected SNPs was performed using the Illumina VeraCode 
GoldenGate assay kit (Illumina, San Diego, CA, USA), according to the manufacturer's 
instructions. Genotype clustering and calling were performed using BeadStudio Software 
(Illumina). In five individuals genotyping was unsuccessful. 
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Statistical analysis 
Analyses were performed with PASW Statistics 18.0 (SPSS Inc., Chicago, IL) and 
PLINK v1.07 (S. Purcell, http://pngu.mgh.harvard.edu/purcell/plink/) [7]. QUANTO v1.2.4 
(http://hydra.usc.edu/gxe/) and PASS v11 were used for power estimation. PolyPhen2 
[8] was used to predict functional consequences of the missense SNP. The studied 
CUBN SNPs LD structure plot was generated with SNAP v2.2 [9]. 
As a routine data quality control, alleles frequencies, Hardy-Weinberg equilibrium and 
case/control differential missingness were tested for. Subsequent statistical analyses 
were performed on a final sample of 2323 subjects in a case-control design (1141 
recipients vs 1182 donors) and 962 renal transplant recipients in a longitudinal design. 
With two-sided p=0.05, assuming an additive genetic model and MAF of 10-15%, we 
had 57% and 99% power to detect an OR of 1.2 and 1.4, respectively, in the ESRD 
case-control analysis, and 43% and 87% power to detect a HR of 1.5 and 2.0, 
respectively, in the Cox regression analysis of graft survival. 
Genotype-phenotype associations were tested under an additive genetic model and 
results (regression coefficients and p-values) are reported per copy of the minor allele. 
In the case-control analysis, the PLINK DFAM algorithm was used to account for donor-
recipient relatedness within living-donor transplantation cases. Interaction between the 
SNPs was tested with the PLINK --epistasis function which includes the interaction term 
and the marginal effects of the SNPs into the interaction model. Subsequently, stratified 
logistic regression analyses were performed for each of the three groups of minor allele 
carriers of both SNPs using the group of non-carriers as the reference. 
For the longitudinal study we included cases with post-transplant graft survival ≥1 year. 
The effect of SNPs on graft survival was investigated with Kaplan-Meier and Cox 
regression analyses including known predictors of GF (donor and recipient age and sex, 
donor type, cold and warm ischemia times, immunosuppressive therapy). 
Association between genotypes and 24h urinary protein excretion was studied cross-
sectionally at 1 year after transplantation assuming stable graft function at this time-
point. As proteinuria was considered a left-censored phenotype with 0 values in 24.4% 
of patients (due to the diagnostic assay detection limit and rounding of routinely reported 
values), it was analyzed with Tobit regression [10, 11], both univariately and including 
relevant covariates (age, sex, systolic and diastolic blood pressure). 
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Results 
Main patients characteristics are presented in Table 1. 
The overall minor allele frequency was 13.1% for rs7918972 and 12.5% for rs1801239. 
There was no deviation from Hardy-Weinberg equilibrium in controls (p=0.2908 for 
rs7918972; p=0.4126 for rs1801239). The missing genotypic data fraction was not 
different between cases and controls (p=1.000 and p=0.625 for rs7918972 and 
rs1801239, respectively). There was no linkage disequilibrium between rs7918972 and 
rs1801239 (r2=0.002, D'=0.059). The missense rs1801232 (Asn3552Lys), tagged by 
rs7918972, was predicted to be benign by PolyPhen2: score 0.011; sensitivity 0.96; 
specificity 0.72. 
Table 1. Patient characteristics. 
ESRD patients, n=1141  
Age, years 48.2±13.5 
Sex: male, n (%) 662 (58.0) 
Primary disease:  
- glomerulopathies, n (%) 292 (25.6) 
- kidney cysts, n (%) 188 (16.5) 
- tubulo-interstitial lesions, n (%) 135 (11.8) 
- diabetes types I and II, n (%) 47 (4.1) 
- renal hypoplasia, n (%) 23 (2.0) 
- drug-induced nephritis, n (%) 15 (1.3) 
- other/uncertain etiology, n (%) 488 (43) 
Kidney donors, n=1182  
Age, years 44.5±14.3 
Sex: male, n (%) 603 (51.0) 
Living donors, n (%) 282 (23.9) 
- from which related donors, n (%) 164 (58.2) 
Transplantation, n=962 renal transplant recipients  
Cold ischemia time, minutes 1140 [ 869-1428] 
Total warm ischemia time, minutes 40 [ 34-50] 
Follow-up duration, years  5.8 [ 3.8-9.5] 
Measured GFR at 1 year post-transplant, ml/min 54.8±19.2 
Total proteinuria at 1 year post-transplant, g/24h 0.20 [0.05-0.40] 
Acute rejection episodes history, n (%) 324 (33.7) 
Graft failure, n (%) 92 (9.6) 
Death with a functioning graft, n (%) 152 (15.8) 
Continuous normally distributed variables are presented as means±SD, non-normally distributed – as 
medians [IQR].  
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Case-control study: ESRD patients vs kidney donors 
The minor allele frequency (MAF) for rs7918972 was significantly higher in ESRD 
patients as compared to kidney donors, implicating an increased risk of ESRD: OR [95% 
CI] 1.39 [1.16-1.65], p=0.0004, in an additive model adjusted for age, sex and case-
control relatedness (Table 2); additional adjustment for diabetes status did not change 
the results. There was no association between rs7918972 genotype and any of the 
primary diseases (etiology of ESRD). The MAF for rs7918972 was not different between 
living and deceased donors and in the latter it was not significantly associated with the 
cause of death (mortality due to cerebro- or cardiovascular accident vs other reasons). 
Genotype of rs1801239 was not associated with case/control status or any of the other 
traits studied. 
The effects of the two SNPs were not independent as a case-control test for epistasis 
revealed an interaction between them (p=5×10-10). A finer analysis showed that the 
rs7918972 minor allele requires a copy of the rs1801239 minor allele to express its risk 
phenotype (OR 3.15 [2.21-4.48], p=1.8×10-10), whereas the minor allele of rs1801239 
displays protective effect in the absence of rs7918972 minor allele (OR 0.65 [0.52-0.81], 
p=1.7×10-4) [Table 3]. 
 
Longitudinal study: post-transplant follow-up 
A total of 92 (9.6%) cases of death-censored GF occurred and 151 (15.8%) patients died 
with a functioning graft during a median [IQR] of 5.8 [3.8-9.5] years of follow-up. 
Donor MAF, representing genotype of the transplanted kidney, was higher in subjects 
that suffered death-censored GF as compared to cases with a functioning graft (16.3% 
vs 10.7%, respectively). Kaplan-Meier survival analysis revealed worse graft survival 
(p=0.067) for the carriers of the minor allele (Figure 2). Consistently, a multivariate Cox 
regression analysis showed that donor kidney rs7918972 is a predictor of GF yielding a 
HR of 1.53 [0.99-2.37], p=0.055, per copy of the minor allele, in a model adjusted for 
donor and recipient age and sex, donor type (living vs deceased), ischemia times, 
immunosuppressive drug use and acute rejection episodes (Table 4). In contrast, 
recipient rs7918972 was not associated with development of GF (HR 1.00, p=0.992). 
Neither donor nor recipient rs1801239 was significantly associated with GF. There was 
no statistically significant interaction between the two SNPs in the longitudinal analysis 
of GF. Neither donor nor recipient genotypes were significantly associated with 
cardiovascular or all-cause mortality during post-transplant follow-up. 
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OR [95% CI] per 
copy of the 





count 21 / 301 / 819 12 / 246 / 924    
MAF, % 15.0% 11.4% 1.39 [1.16-1.65] 0.0004 
rs1801239 
Genotypes, 
count 8 / 276 / 857 14 / 266 / 902   
MAF, % 12.8% 12.4% 1.04 [0.87-1.24] 0.6686 
OR, odds ratio; CI, confidence interval. aLogistic regression model adjusted for age and sex, with 




Table 3. Interaction between the SNPs in the CUBN locus in the case-control study of 








N of the minor 
allele copies 0 1 or 2 
 Reference OR 0.93 [0.75-1.15] 
0 OR 1.00 p=0.484 
 
n=1352 n=407 
 OR 0.65 [0.52-0.81] OR 3.15 [2.21-4.48] 
1 or 2 p=1.7×10-4 p=1.8×10-10 
 n=391 n=173 
Logistic regression model adjusted for age and sex. Odds ratios (OR) [95% confidence intervals] for risk of 
ESRD, p-values and patients number (n) are presented in relation to simultaneous presence of both minor 
alleles in genotype. 
 
  







Figure 2. Curves of long-
term renal graft survival by 
donor rs7918972 genotype.  
Numbers 0 to 2 designate 
corresponding number of the minor 
allele copies per genotype. The 
logrank test showed borderline 
statistical significance of the 





Table 4. CUBN SNPs in the longitudinal study with follow-up for graft failure. 
HR, hazard ratio; CI, confidence interval. 
a
 univariate Cox regression 
b
 multivariate Cox regression model adjusted for donor and recipient age and sex, donor type (living or deceased), 



























count 2/26/64 8/171/691 1.50 [0.99-2.26] 0.056 
1.53 
[0.99-2.37] 0.055 
 MAF, % 16.3% 10.7% 
rs1801239 Genotypes, 
count 2/15/75 11/201/658 0.80 [0.49-1.30] 0.363 
0.75 
[0.43-1.31] 0.311 








count 3/22/67 15/234/621 0.94 [0.62-1.43] 0.773 
1.00 
[0.64-1.56] 0.992 
 MAF, % 15.2% 15.2% 
rs1801239 Genotypes, 
count 0/20/72 6/212/651 0.78 [0.48-1.26] 0.308 
0.70 
[0.40-1.25] 0.229 
 MAF, % 10.9% 12.9% 
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We found donor rs7918972 to be associated with proteinuria levels cross-sectionally at 1 
year of post-transplant follow-up (beta 0.201, p=0.015) [Table 5]. No association 
between the SNPs and renal function by measured GFR or creatinine clearance was 
observed at the same time-point; however, donor rs7918972 showed a directionally 
consistent, although not statistically significant, trend for association with an increased 
rate of GFR decline (data not shown). 
Table 5. CUBN SNPs association with urinary total protein excretion cross-sectionally 
at 1 year after transplantation. 
Genotype SNP Univariate Tobit regression Multivariate Tobit regressiona 
  Coefficient SE p 
value Coefficient SE 
p 
value 
Donor rs7918972 0.223 0.083 0.007 0.201 0.082 0.015 
 rs1801239 -0.039 0.078 0.617 -0.021 0.077 0.784 
Recipient rs7918972 -0.072 0.071 0.313 -0.049 0.070 0.488 
 rs1801239 -0.028 0.081 0.726 -0.023 0.080 0.779 
aModel adjusted for donor and recipient age and sex, donor type (living or deceased), systolic and diastolic 
blood pressure. Coefficients are given per copy of the minor allele. 
 
Discussion 
In the present study we followed up the results of a recent GWAS, which identified the 
cubilin gene CUBN as a locus for albuminuria [4]. As albuminuria is an established risk 
factor for progressive renal function loss, the GWAS findings raised the hypothesis that 
genetic variation in the CUBN locus could be associated with progressive renal function 
loss and finally end stage renal disease. To test this hypothesis we studied the cited top 
SNP as well as a tagSNP in CUBN in relation to final renal clinical outcomes, namely 
ESRD in native kidneys and GF in the transplanted kidney.  
In a case-control design we studied rs7918972 and rs1801239 genotypes in ESRD 
patients versus kidney donors. The MAF for rs7918972 was significantly higher in ESRD 
patients as compared to kidney donors, imposing a 39% increased risk for ESRD per 
copy of the minor allele. Follow-up data after transplantation showed direction-consistent 
trend for an association between donor kidney rs7918972 and development of GF in 
recipients. Thus, the SNP in CUBN locus was associated with susceptibility to develop 
ESRD in two settings, namely ESRD in native kidneys and GF in transplanted kidneys. 
Transplantation represents a unique setting, also from genetic point view: an organ with 
its own genotype functions in an organism with another genotype. We tested both donor 
and recipient genotype for association with the renal outcome to investigate whether it is 
the kidney genotype that determines its own fate or it is the recipient genotype that 
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influences function and survival of the transplanted organ. This unique design is useful 
for genetic research in nephrology as it enables discrimination between the renal and 
extra-renal mechanisms [12]. 
In our study, it was donor rather than recipient CUBN genotype that was associated with 
GF, suggesting involvement of local, intra-renal pathways in processes of transplanted 
kidney survival which are independent of systemic influences.  
Albuminuria is known as a predictor of cardiovascular and non-cardiovascular mortality 
[13]. However, in our study CUBN genotypes did not associate with cerebro- or 
cardiovascular accident as a cause of death in donors and cardiovascular and all-cause 
mortality after transplantation in recipients.  
As no albuminuria data were available and urinary albumin levels are known to correlate 
with total protein, we tested association of the CUBN SNPs with 24-h total urinary 
protein excretion as a surrogate phenotype. Interestingly, we found donor rs7918972 to 
be associated with elevated proteinuria levels cross-sectionally at 1 year after 
transplantation. This is consistent with our results of association with the outcome, and 
also in line with the results of a recent study which revealed, using exome sequencing, a 
deleterious mutation in CUBN in a family of proteinuric patients, thus confirming the 
CUBN gene involvement in proteinuria [14].  
In the original GWAS [4] the CUBN SNP rs1801239, associated with elevated urinary 
albumine-to-creatinine ratio and microalbuminuria. However, this SNP was not 
associated with CKD or estimated GFR. In agreement with this, our case-control study 
showed no association between this SNP and ESRD. Also, rs1801239 was not 
associated with GF in our longitudinal study Instead, it was the other CUBN 
polymorphism, the tagSNP rs7918972, that was associated with ESRD in our study. 
The CUBN locus is characterized by a high variability, with both common and rare 
mutations. Mutations in the CUBN locus are known to be the cause of Imerslund-
Gräsbeck syndrome (OMIM #261100, Finnish type) which is a rare (the estimated 
prevalence is <6:1,000,000) autosomal recessive disorder characterized by vitamin B12 
deficiency commonly resulting in megaloblastic anemia, and also neurological damage 
and mild proteinuria [15]. However, we did not aim to address previously clinically-
associated Mendelian mutations in the CUBN in our study. We aimed to investigate 
whether common variation, as opposed to rare mutations in Imerslund-Gräsbeck 
syndrome, in the CUBN associates with kidney disease. In the same time, we targeted a 
lower part of the common variability range, with MAFs between 10 and 15%, aiming to 
reveal allegedly stronger genetic effects. We selected two SNPs in the CUBN locus for 
the present study: first, the one previously published to be associated with albuminuria 
levels in the general population, i.e. the missense variant (Ile2984Val) rs1801239, and 
second the tagSNP in the CUBN intron, rs7918972. The latter is in high linkage 
disequilibrium (r2=0.831) with another missense variant rs1801232 (Asn3552Lys) in 
CUBN, which might be responsible for the biological impact of the polymorphism on the 
 CUBN as a novel locus for ESRD 
 93 
protein level. The minor allele of rs1801232 leads to an asparagine-to-lysine amino acid 
substitution in the C-terminal CUB27 domain of cubilin. Despite the amino acids differ in 
chemical properties (isoelectric points: Asn 5.4, Lys 9.8), the substitution was predicted 
to be benign by bioinformatics algorithms. However, the mutation is close to sites of N-
glycosylation (amino acid 3533) and di-sulfide bond (between amino acids 3564 and 
3586) and therefore might potentially interfere with secondary protein structure and, 
consequently, function. The Imerslund-Gräsbeck syndrome mutations, for which 
functionality was proven, affect the IF-cobalamin-binding region in the CUB8 domain of 
cubilin (rs121434430 Pro1297Leu), CUB6 domain (CUBN IVS6 C-G in-frame insertion) 
or CUB23 domain (CUBN IVS23 G-T transversion at the conserved donor splice site of 
exon 23). The SNPs that we studied were spatially distant from these variants and 
located to the CUB22 domain (rs1801239) and CUB27 domain (rs1801232 tagged by 
rs7918972). 
The rs7918972 CUBN SNP, associated with ESRD and GF in our study, is localized in 
high proximity to the neighboring gene, RSU1. Although the nine SNPs tagged by 
rs7918972 are all located in the CUBN locus, linkage disequilibrium with and 
involvement of the RSU1 is theoretically possible and cannot be entirely ruled out 
(Suppl. Fig S1). The RSU1 gene encodes Ras suppressor protein 1, which participates 
in the Ras signal transduction pathway, growth inhibition and nerve-growth factor 
induced differentiation processes. Its mRNA is expressed in the kidney (according to the 
NCBI GEO profiles), in a low-to-moderate quantity (51 transcripts per million, according 
to the NCBI EST profiles). However, functional proof is beyond the scope of the present 
study, and further research will be needed to discriminate between the effects of these 
neighboring genes. 
Interestingly, we found an interaction between the two SNPs studied. According to our 
data, the rs7918972 minor allele requires a copy of the rs1801239 minor allele to 
express its risk phenotype, whereas the minor allele of rs1801239 displays protective 
effect in the absence of rs7918972 minor allele. This pattern was observed in the case-
control study and warrants further investigation to determine whether found statistical 
interaction has biological implications. 
Our study was conducted in kidney transplant recipients, and thus reflects a population 
that developed ESRD in their native kidneys and was eligible to receive a 
transplantation. As such, renal transplant recipients represent a relatively healthy subset 
of the ESRD population, a selection bias inherent to any study in renal transplantation. 
This should be considered a limitation to our study. In chronic renal disease, both in 
native kidney disease and in transplantation, mortality is high, and for analyses on ESRD 
the competing risks of mortality, in particular cardiovascular, are therefore relevant to 
consider. In the current population, mortality with functioning graft was 15.8 percent, and 
no association with either of the CUBN SNPs was observed. 
Our longitudinal study of graft failure may have been underpowered to detect a 
significant SNP effect. Insufficient power might thus be an explanation of the fact that 
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convincing statistical significance was not reached in the graft survival analysis for 
association with rs7918972. Studies in larger populations are warranted to confirm an 
association between the CUBN SNP and GF. 
Conclusion 
Our study confirms association of the CUBN with renal phenotypes of progressive renal 
function loss and urine protein loss. We first identified CUBN SNP rs7918972 as a novel 
genetic variant of susceptibility for ESRD in a case-control design. In a separate proof-
of-principle longitudinal study, which served as an internal replication, we reproduced the 
association. Thus, rs7918972 was associated with susceptibility to develop progressive 
renal function loss in two settings, namely ESRD in native kidneys and GF in 
transplanted kidneys. It was kidney genotype that associated with increased risk, 
supporting impact of intra-renal pathways on organ damage. Our study set-up – 
analyzing both donor and recipient genotypes – provides a powerful design for 
hypothesis-driven studies on risk loci for renal damage enabling differentiation between 




Figure S1. CUBN regional LD plot. 
The figure was generated using HapMap data (release 22, CEU population). The horizontal blue line represents 
an arbitrarily chosen LD threshold (r2=0.8). SNPs are shown as diamonds. The color gradient between the 
diamonds reflects the pairwise LD between the SNPs, with color intensity of each diamond being directly 
proportional to the r2 value. Boundaries of the gene coding regions are shown as green horizontal lines. The 
largest size diamonds represent the present study SNPs. The shaded area designates a span of the gene region 
tagged by rs7918972.  
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Abstract 
Genome-wide association studies reported SLC22A2 variants to be associated with 
serum creatinine. As SLC22A2 encodes the organic cation transporter 2 (OCT2), the 
association might be due to an effect on tubular creatinine handling. To test this 
hypothesis we studied the association of SLC22A2 polymorphisms with phenotypes of 
net tubular creatinine secretion: fractional creatinine excretion (FEcreat) and bias of 
estimated glomerular filtration rate (eGFR). We also studied the association with end-
stage renal disease (ESRD) and graft failure (GF) in renal transplant recipients. 
SLC22A2 SNPs, rs3127573 and rs316009, were genotyped in 1142 ESRD patients 
receiving renal transplantation and 1186 kidney donors as controls. GFR was measured 
with 125I-iothalamate clearance. Creatinine clearance was also assessed. FEcreat was 
calculated from the simultaneous clearances of creatinine and 125I-iothalamate. 
Donor rs316009 was associated with FEcreat (beta -0.053, p=0.024), and with estimated 
(MDRD and CKD-EPI) but not measured GFR. In line, donor rs316009 was associated 
with bias of the MDRD and CKD-EPI but not the Cockroft-Gault equation. Both SNPs 
were associated with ESRD: odds ratios [95% CI] 1.39 [1.16-1.67], p=0.00065, and 1.23 
[1.02-1.48], p=0.042, for rs3127573 and rs316009, respectively. Neither SNP was 
associated with GF. 
Thus, SLC22A2 is associated with phenotypes of net tubular creatinine secretion and 
ESRD..
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Introduction 
Genome-wide association studies (GWAS) identified a number of loci influencing renal 
function (7, 23, 24) usually using renal function estimates based on serum creatinine as 
a proxy for glomerular filtration rate (GFR).  
Serum creatinine, however, is not only determined by GFR, but also by the rate of 
creatinine generation, extrarenal elimination and by tubular handling (5, 31, 35, 46, 49). 
Dissecting the biological mechanisms underlying genetic associations with serum 
creatinine, therefore, is pivotal for proper interpretation of GWAS findings. In particular, it 
is relevant to assess whether loci associated with serum creatinine reflect susceptibility 
to renal damage (1), or, alternatively, reflect biological variations in creatinine generation 
or in creatinine handling unrelated to the risk for renal damage. 
The SLC22A2 gene is associated with serum creatinine and estimated GFR (eGFR) (7). 
However, SLC22A2 might well be a creatinine secretion locus. First, SLC22A2 SNPs 
were associated with GFR estimated from serum creatinine but not cystatin C (23, 34). 
Second, the SLC22A2 gene encodes the organic cation transporter 2, OCT2, a 
predominant transporter involved in tubular creatinine secretion. It is expressed in the 
basolateral membrane of proximal tubule cells (29), where it mediates creatinine uptake 
from the peritubular capillaries, as an initial step in tubular creatinine secretion (9, 29, 38, 
51, 52, 59).  
Tubular secretion accounts for 10-20% of urinary creatinine excretion (5, 35, 46). 
Presence of tubular secretion as an additional mechanism of creatinine clearance 
translates into an acknowledged systematic error (bias) for creatinine-based GFR 
estimation methods (35, 45, 46, 49).  
In the present study we test the hypothesis that the association between genetic 
variation in the SLC22A2 locus and eGFR is due to association of SLC22A2 with tubular 
secretion of creatinine. To this purpose, we investigated first the association of SLC22A2 
variants with fractional excretion of creatinine (FEcreat) as an intermediate phenotype for 
tubular creatinine secretion. Second, we tested the association of SLC22A2 with the bias 
of eGFR assessed by the Modification of Diet in Renal Disease (MDRD) and the Chronic 
Kidney Disease Epidemiology Collaboration (CKD-EPI) equations. As a “negative 
control” we also tested the association of SLC22A2 with the bias of the creatinine 
clearance estimated by the Cockroft-Gault equation, hypothesizing that SLC22A2 would 
be associated with bias of the MDRD and CKD-EPI equation, but not with that of the 
Cockroft-Gault equation as the latter is calibrated on creatinine clearance. Finally, we 
tested the association of SLC22A2 with end-stage renal damage in native and 
transplanted kidneys.  
The studies were performed in the REGaTTA (REnal GeneTics TrAnsplantation, 
Groningen, the Netherlands) cohort (12, 40), a large single-center renal transplant 
cohort, where we genotyped both donors and recipients. Since the SLC22A2 gene 
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expression is restricted to the kidney with scarce extra-renal sites of expression 
(placenta, brain) [NCBI UniGene database (58)], donor SLC22A2 genotype largely 
represents kidney genotype; accordingly, we tested associations between the recipient 
phenotypes and the donor SLC22A2 polymorphisms. For this study we selected the two 
most prominent among previously characterized SLC22A2 polymorphisms: rs3127573 
and rs316019. The first SNP, rs3127573 in the SLC22A2 5′ region, was the top SNP 
reported for association with serum creatinine and eGFRcreat (7). The other, a missense 
rs316019, is the most frequent coding variant in the SLC22A2 gene and is also the best 
functionally characterized. This polymorphism in the exon 4 results in an Ala270Ser 
amino acid substitution with functional consequences for the protein and was associated 
with impaired transport of OCT2 substrates in vitro (8, 15, 48, 57, 61). Because 
genotyping of rs316019 was technically not possible in this study, we searched for 
another SNP to use as a proxy. Thus, rs316009, a highly correlated tag SNP in perfect 
linkage disequilibrium (LD: r2=1) in the SLC22A2 intron, was genotyped instead, 
assuming that it represents rs316019. Therefore, in the subsequent manuscript sections 
we refer to rs3127573 and rs316009. 
 
Methods & Materials 
Study population 
This study was conducted in the REGaTTA cohort, with assessment of association with 
end-stage renal disease (ESRD) in the total cohort, and assessment of association with 
the intermediate phenotypes in distinct sub-groups where the detailed phenotypes were 
available. The selection flowchart of the study is shown in Figure 1. Patient 
characteristics, transplantation-related parameters, clinical and laboratory data were 
retrieved from medical records.  
1) The total cohort consisted of 1184 kidney donors and 1141 first graft recipients (1066 
matched donor-recipient pairs), assessed post-hoc from all renal transplantations in our 
center between 1993 and 2008, excluding cases of re-transplantation, combined 
kidney/pancreas or kidney/liver transplantation, technical problems, absence of DNA and 
loss of follow-up. After transplantation the recipients were followed up during median 
[IQR] 5.5 [3.0-8.7] years for graft failure (GF) defined as return to dialysis or re-
transplantation, censored for death with a functioning graft. Allele frequency in recipients 
versus donors was analyzed in a case-control approach to test for the association of 
SLC22A2 with ESRD. Follow-up data in the recipients were used for analysis of 
association with GF.  
2) Data on 125I-iothalamate clearance at 1 year after transplantation, serum creatinine 
and creatinine clearance from 24 hour urine, collected the day before 125I-iothalamate 
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clearance measurements, were available for 738 recipients. These data were used to 
assess the association of SLC22A2 with the bias of eGFR. 
3) Simultaneously measured 2-hour clearances of creatinine and 125I-iothalamate were 
available in 348 recipients, studied at median [IQR] 3.5 [1.7-6.9] years after 
transplantation. These data were used to calculate FEcreat and analyze for its association 
with SLC22A2. The overlap between the subgroups of patients with true GFR and 
FEcreat measurements (n=738 and n=348, respectively) was 264 cases. 
The Institutional Review Board of the University Medical Center Groningen approved the 
study protocol. Written informed consent was given by all recipients and living donors. 
For deceased donors, with research carried out after the organ removal and 
implantation, no consent was required by Dutch law. The study was conducted 
according to the principles of the Declaration of Helsinki. All the data were anonymized 
prior to analyses. 
 
Figure 1. A flowchart of the study participants selection. 
All cases of renal transplantation carried out in the University Medical Center Groningen in 1993-2008 were 
considered for inclusion. The exclusion criteria were re-transplantation, combined kidney/other organ 
transplantation, technical problems, absence of DNA and loss of follow-up. A total of 1141 end-stage renal 
disease patients (recipients) and 1184 kidney donors were successfully genotyped and included into the 
subsequent analyses. The grey-shaded areas indicate different studies performed to answer corresponding 
research questions of the present project. 
(e)GFR, (estimated) glomerular filtration rate; FEcreat, fractional excretion of creatinine. 
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Treatment protocols and renal function measurement 
The treatment regimen in our transplant population has been described in more detail 
elsewhere (13). Briefly, standard immunosuppression consisted of cyclosporine micro 
emulsion (Neoral, Novartis, Pharma b.v., Arnhem, the Netherlands; 10 mg/kg; trough-
levels idem) and prednisolone from March 1993 until May 1996, mycophenolate mofetil 
(Cellcept, Roche, Nederland b.v., Woerden, the Netherlands; 2 g/d) was added from 
May 1997 to date.  
The routine follow-up includes measurement of true GFR at regular intervals by 125I-
iothalamate clearance, as described in detail by Visser et al. (55). Creatinine clearance 
was also measured as a routine, from 24-hour urine collected on the day preceding the 
GFR assessment. As of 2006 simultaneous measurement of creatinine clearance was 
included in the protocol, as described in detail by Sinkeler et al. (46). Briefly, serum and 
2-h urine creatinine measurements were obtained during the measurement of 125I-
iothalamate GFR and FEcreat was calculated as (U/P)creat/(U/P)iot from the same samples 
as the 125I-iothalamate clearance, thus avoiding discrepancies due to collection errors 
and diurnal changes in renal function. Creatinine was measured with the Roche 
enzymatic creatinine assay, which is isotope dilution mass spectrometry-traceable. The 
assay was calibrated to the reference standard (Cleveland Clinic Laboratory 
measurements), as proposed by Coresh et al. (11), and described in more detail by Tent 
et al. (50). 
 
DNA isolation and genotyping 
DNA was extracted from peripheral whole blood (in recipients and living donors) or 
lymph nodes/spleen lymphocytes (in deceased donors) using a commercial kit following 
the manufacturer’s instructions, transferred into 2 ml Eppendorf tubes and stored at -
20°C. Absorbance at 260 nm was measured with NanoDrop spectrophotometer (ND-
1000, NanoDrop Technologies) and DNA concentration was calculated by the NanoDrop 
nucleic acid application module. As a measure of DNA purity 260/280 and 260/230 
absorbance ratios were assessed. Where samples failed to meet the minimum DNA 
concentration and purity recommended for Illumina genotyping, repeated isolation 
attempts were made. 
Genotyping of rs316019 was not possible for technical reasons as the polymorphism 
was not supported by the used assay. Instead we genotyped rs316009, an intronic 
SLC22A2 SNP which is in perfect linkage disequilibrium (r2=1.0) with rs316019. 
Genotyping of the selected SNPs, rs3127573 and rs316009, was performed using the 
Illumina VeraCode GoldenGate assay kit (Illumina, San Diego, CA, USA), according to 
the manufacturer's instructions. Genotype clustering and calling were performed using 
BeadStudio Software (Illumina). 
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Statistical analysis 
Analyses were performed with PASW Statistics 18.0 (SPSS Inc., Chicago, IL) and 
PLINK v1.07 (S. Purcell, http://pngu.mgh.harvard.edu/purcell/plink/ (37)). 
Genotype-phenotype associations were tested under an additive genetic model and 
results (regression coefficients and p-values) are reported per copy of the minor allele. 
Association between the SLC22A2 SNPs and FEcreat was studied with linear regression. 
Relevant covariates (age, sex, BMI, drugs use) were included in the multivariate model. 
Drugs use was coded as yes/no co-trimoxazole and cyclosporin A/tacrolimus/no 
calcineurin inhibitor. 
MDRD (25, 26), CKD-EPI (27) and Cockroft-Gault (10) equations were used to calculate 
eGFR. Predictive performance of the equations for GFR estimation was analyzed by 
assessing their precision (the scatter of the observations and expressed as R2), 30 and 
10% accuracy (the percentage of subjects within, respectively, 30 and 10% of true GFR, 
i.e. 125I-iothalamate clearance) and bias (the mean prediction error calculated as 
∑(predicted value - true value)/n) (2). 
Statistical significance of differences in renal function, its estimates and bias of GFR 
estimation between the SLC22A2 SNPs genotypes was tested with Kruskal-Wallis test 
(similarly to the general genotypic 2df-test). 
Association with ESRD was tested in a case-control design by comparing 1141 ESRD 
patients admitted for renal transplantation and 1184 kidney donors. The PLINK DFAM 
algorithm was used to account for case-control relatedness within living-donor 
transplantation cases. 
The effect of the SNPs on graft survival was studied in 1066 renal transplant recipients. 
A Cox regression analysis was performed including known predictors of GF (donor and 
recipient age and sex, donor type, ischemia times, delayed graft function and acute 
rejection episodes history, immunosuppressive drugs) as covariates in a multivariate 
model. Kaplan-Meier survival curves were built for analysis and visualization of graft 
survival in genotypic groups, and the log rank test was used to test for significance of 
differences between the curves.  
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Results 
Main patient characteristics are presented in Table 1 for the total cohort and for the 
subgroups. 
In the total cohort, the minor allele frequencies were 11.6% for rs316009 and 13.2% for 
rs3127573. There was no deviation from Hardy-Weinberg equilibrium in controls − 
donors (p=0.47 and p=1.00 for rs316009 and rs3127573, respectively). There was no 
linkage disequilibrium between the two SNPs (r2=0.002 in our cohort, r2=0.008 in 
HapMap release 22 CEU population). 
 
Table 1. Patients characteristics: 
1A. Baseline parameters at transplantation and outcomes during 5.5 [3.0-8.7] years of follow-
up in the total cohort 
1066 matched donor-recipient pairs 
Recipient age (years), mean±SD 48.1±13.5 
Recipient sex: male, n (%) 621 (58.3) 
Donor age (years), mean±SD 44.6±14.3 
Donor sex: male, n (%) 540 (50.7) 
Living donors, n (%) 260 (24.4) 
- from which related donors, n (%) 149 (14.0) 
Cold ischemia time (hours), mean±SD 16.4±9.7 
Delayed graft function, n (%) 331 (31.1) 
Acute organ rejection episodes history, n (%) 369 (34.6) 
Death-censored graft failure, n (%) 172 (16.1) 
Death with a functioning graft, n (%) 183 (17.2) 
 
 
1B. Subgroups of patients with refined phenotype of renal function 
 
Recipients at 1 
year post-
transplant 
Recipients at 3.5 
years post-
transplant 
N 738 348 
Recipient age (years), mean±SD 48.5±13.7 53.7±13.1 
Recipient sex: male, n (%) 431 (58.4) 182 (52.3) 
Serum creatinine (µmol/l), mean±SD 144.6±49.5 128.1±51.1 
Creatinine clearance (ml/min), mean±SD 63.3±21.9 70.5±23.0 
Measured GFR (ml/min), mean±SD 55.1±19.1 56.2±20.8 
FEcreat, mean±SD - 1.05±0.18 
Recipient BMI (kg/m2), mean±SD 26.4±4.3 26.6±4.7 
Co-trimoxazole use, n (%) - 19 (5.5) 
Calcineurin inhibitor type: cyclosporin A, n (%) 531 (72) 189 (54.3) 
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Association of the SLC22A2 variants with FEcreat, renal function estimates and 
performance of eGFR 
In 348 recipients FEcreat was assessed from simultaneous clearances of creatinine and 
125I-iothalamate. It ranged from 0.71 (min) to 1.39 (max) [Figure 2], with a mean of 1.05, 
indicating a 5% mean contribution of tubular secretion to creatinine clearance. 
Determinants of FEcreat are given in Table 2 displaying univariate effects of donor and 
recipient characteristics and the multivariate linear regression model. The donor kidney 
rs316009 (the proxy SNP for the functional rs316019) was associated with lower FEcreat 
in an allele dose-dependent manner (beta -0.053 per copy of the minor allele, p=0.024) 
in the model which included donor age and sex, recipient age, sex, BMI, use of co-




Figure 2. A histogram of the fractional creatinine 
excretion (FEcreat) values in 348 renal transplant 
recipients at median [IQR] 3.5 [1.7-6.9] years after 
transplantation.  
The distribution of FEcreat values is demonstrated, as well as the 
fact that in a proportion of the recipients FEcreat is below 1. 
 
 
Table 2. Determinants of fractional creatinine excretion in 348 renal transplant recipients at 
median [IQR] 3.5 [1.7-6.9] years after transplantation. 
  
Univariate Multivariate 
Beta SE p value Beta SE p value 
Donor rs316009 -0.038 0.021 0.078 -0.053 0.024 0.024 
Donor rs3127573 0.035 0.023 0.119 0.021 0.027 0.433 
Donor age -0.0004 0.001 0.550 1.6×10-4 0.001 0.725 
Donor sex: male -0.016 0.02 0.426 0.05 0.024 0.039 
Recipient age -0.003 0.001 <0.001 -0.005 0.001 <0.001 
Recipient sex: male 0.175 0.017 <0.001 0.179 0.024 <0.001 
Recipient BMI 0.007 0.003 0.016 0.009 0.003 0.001 
Co-trimoxazole use 0.009 0.043 0.839 0.129 0.156 0.391 
Calcineurin inhibitor 
type -0.004 0.011 0.686 -0.028 0.013 0.035 
Regression coefficients are presented per copy of the minor allele. SE, standard error. 
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Association analyses of renal function, its estimates and performance of eGFR were 
conducted in 738 recipients at 1 year post-transplantation. Precision (R2) of the GFR 
estimation methods was 0.59, 0.60 and 0.48, for MDRD, CKD-EPI and Cockcroft-Gault 
formulas, respectively. 10% and 30% accuracy were 23.8% and 74.3%, 29.8% and 
81.8%, 29.5% and 76.0% for MDRD, CKD-EPI and Cockcroft-Gault equations, 
respectively. 
Data on renal function and renal function estimates are given in Table 3 by a breakup by 
donor kidney genotype. There was no difference in serum creatinine or creatinine 
clearance between the genotypes. Measured GFR was not different between the 
genotypes either. However, MDRD and CKD-EPI eGFR was slightly but significantly 
higher with each copy of the rs316009 minor allele in the kidney genotype (p=0.016 and 
p=0.022 for MDRD and CKD-EPI, respectively). This was paralleled by a decrease in 
GFR estimation bias of MDRD and CKD-EPI equations across the rs316009 genotypes, 
with eGFR closely approximating actual GFR in the minor allele homozygotes. 
Cockcroft-Gault equation performance was not affected by the genotypes. The 
rs3127573 was not significantly associated with renal function estimates. 
 
Association of the SLC22A2 variants with phenotypes of renal function loss – ESRD and 
GF 
The genotypes of the studied SLC22A2 variants were unequally distributed between the 
ESRD patients and kidney donors. There were more carriers of both SNPs minor alleles 
among ESRD patients than among donors. Correspondingly, the MAFs of rs3127573 
and rs316009 were significantly higher in ESRD patients (14.9% and 12.9%, 
respectively) as compared to kidney donors (11.4% and 10.6%, respectively), implicating 
an increased risk of ESRD in association with the minor allele. In the additive genetic 
model adjusted for age, sex and case-control relatedness odds ratios (OR) [95% CI] for 
ESRD were 1.39 [1.16-1.67] per copy of the rs3127573 minor allele, p=0.00065, and 
1.23 [1.02-1.48] per copy of the rs316009 minor allele, p=0.042 (Table 4). 
During follow-up of a median [IQR] 5.5 [3.0-8.7] years 172 (16.1%) cases of GF occurred 
and 183 (17.2%) patients died with a functioning graft. In a multivariate Cox regression 
model adjusted for donor and recipient age and sex, donor type, cold ischemia duration, 
history of delayed graft function and acute rejection episodes, immunosuppressive drugs 
none of the two donor kidney SLC22A2 SNPs was significantly associated with GF 
under an additive genetic model (Table 5). Log rank test showed p=0.530 and p=0.078 
for significance of differences between the graft survival curves by donor rs316009 and 
rs3127573 genotypes, respectively. None of the SNPs was associated with overall or 
cardiovascular mortality in recipients (not shown). 
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Table 3. Renal function and its creatinine-based estimates in 738 renal transplant recipients 






value 0 1 2 
n=594 n=135 n=9 






(ml/min) 61.0 (48.0-76.0) 64.0 (46.5-79.3) 62.0 (48.0-66.0) 0.797 
Measured GFR (ml/min) 54.0 (42.0-68.0) 53.0 (42.0-65.3) 55.0 (40.5-58.0) 0.756 
eGFR MDRD (ml/min) 43.1 (34.7-53.7) 43.9 (36.6-57.4) 51.4 (49.0-53.7) 0.016 
eGFR CKD-EPI (ml/min) 46.6 (36.8-58.0) 49.2 (38.8-64.3) 55.3 (53.1-58.0) 0.022 
eGFR Cockcroft-Gault 
(ml/min) 59.6 (48.2-73.8) 65.4 (49.0-76.2) 64.2 (56.8-71.5) 0.307 
Bias MDRD (ml/min) -10.5 (-17.5- -3.0) -6.8 (-15.0-1.0) -1.9 (-6.1-7.1) 0.001 
Bias CKD-EPI (ml/min) -6.9 (-13.6-0.5) -2.9 (-11.6-5.1) 2.2 (-2.1-9.1) <0.001 
Bias Cockcroft-Gault 







value 0 1 2 
n=579 n=151 n=7 






(ml/min) 60.0 (47.0-76.0) 64.0 (49.0-77.0) 73.5 (69.8-97.5) 0.076 
Measured GFR (ml/min) 54.0 (41.0-67.0) 54.0 (44.0-67.0) 60.0 (56.3-74.3) 0.565 
eGFR by MDRD (ml/min) 43.1 (34.7-54.4) 43.9 (35.2-53.6) 46.9 (35.0-51.2) 0.884 
eGFR CKD-EPI (ml/min) 47.1 (37.0-59.5) 47.6 (37.9-57.1) 48,4 (32,8-52,3) 0.829 
eGFR Cockcroft-Gault 
(ml/min) 60.5 (48.2-74.2) 60.2 (49.6-74.0) 55,4 (47,8-73,5) 0.901 
Bias MDRD (ml/min) -9.0 (-16.6- -1.9) -10.2 (-18.4- -4.1) 
-20.4 (-27.9- -
10.6) 0.104 
Bias CKD-EPI (ml/min) -5.7 (-12.8-1.6) -7.5 (-14.8- -0.4) -9,5 (-23,1- -7,2) 0.058 
Bias Cockcroft-Gault 
(ml/min) -0.2 (-10.3-9.0) 0.3 (-12.1-7.5) -21,0 (-42,4-1,5) 0.110 
Data are presented as medians (IQR). Numbers 0 to 2 designate corresponding number of the minor allele copies 
per genotype. Statistical significance of the differences was tested with Kruskal-Wallis test. 
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Table 4. SLC22A2 SNPs in the case-control study of ESRD patients versus kidney donors: 
genotypes distributions and minor allele frequencies 








OR [95% CI] 
per copy of 
the minor 
allele 
P value a 
rs3127573 Genotypes, 
count 11 / 317 / 813 12 / 245 / 927 
1.39 [1.16-
1.67] 6.54×10-4 
 MAF, % 14.9 11.4 
rs316009 Genotypes, 
count 14 / 260 / 867 13 / 224 / 947 
1.23 [1.02-
1.48] 0.04 
 MAF, % 12.6 10.6 
MAF, minor allele frequency; OR, odds ratio; CI, confidence interval. 
a














HR [95% CI]a 
P valuea 
rs3127573 1.21 [0.88-1.65] 0.244 1.16 [0.85-1.59] 0.343 
rs316009 1.20 [0.87-1.65] 0.269 1.26 [0.90-1.75] 0.175 
HR, hazard ratio; CI, confidence interval. 
Cox regression analyses were run under the additive genetic model, the coefficients are presented per copy of the 
minor allele. 
a
 Adjusted for donor and recipient age and sex, donor type (living vs deceased), cold ischemia duration, history of 
delayed graft function and acute rejection episodes, immunosuppression drugs 
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Discussion 
This study in renal transplant recipients reports a significant association between donor 
SLC22A2 SNP rs316009 and FEcreat, with lower FEcreat in the presence of one or two 
minor alleles. An association was found between rs316009 and eGFR (MDRD and CKD-
EPI), but not with measured GFR. In line, bias of the eGFR equations was significantly 
associated with rs316009. Remarkably, both SLC22A2 SNPs were associated with the 
increased risk for ESRD in native kidneys. Thus, genetic variation in SLC22A2 can 
modulate net tubular creatinine handling, hence affecting the bias of the main renal 
function equations that are calibrated on measured GFR. The association with ESRD is 
in line with a role for tubular functions in progressive renal function loss, and deserves 
further substantiation. 
By the required sample size, GWA studies for renal function usually rely on simple renal 
function estimates, mostly serum creatinine and eGFRcreat (7), sometimes complemented 
by renal function estimates with cystatin C (23, 24), to account for the short-comings of 
serum creatinine and/or eGFR for renal function assessment. Dissociation in outcomes 
for association with creatinine and cystatin C (34) is useful to separate genetic loci that 
are related to true GFR from loci that affect creatinine level by creatinine generation or 
tubular secretion. Thus, the SLC22A2 locus emerges as a locus likely to influence 
creatinine secretion rather than true GFR (24), as supported by the current study. 
Tubular secretion of creatinine has wide inter-individual variability (35, 45). We show that 
genetic variation in the SLC22A2 locus, i.e. the SLC22A2 SNP rs316009, in the donor 
kidney is an independent determinant of FEcreat. The lower FEcreat per copy of the 
rs316009 minor allele is consistent with prior in vitro studies showing that the correlated 
polymorphism, rs316019, which we assumed to be the true causal variant tagged by 
rs316009, resulted in decreased transport of OCT2 substrates (8, 15, 48, 57, 61). 
In line with data in healthy subjects, FEcreat was associated with age, gender and BMI, 
supporting the robustness of this phenotype and its determinants (46). Our current data, 
for the first time, demonstrate that genetic factors are also involved in FEcreat. Age, sex 
and BMI are all related to muscle mass and hence creatinine supply, a possible common 
denominator in the association with tubular creatinine secretion. Of note, these factors 
can influence creatinine transporter expression. In rodents, pronounced sexual 
dimorphism in renal SLC22A2 expression was reported, with higher mRNA levels (47) 
and greater transport of OCT2 substrates in renal slices from male rats (53). In line, 
testosterone up-regulates and estradiol moderately down-regulates rOCT2 renal 
expression in rats (54).  
Drug use, in particular trimethoprim, might affect FEcreat (14, 21, 22, 33). In the 19 
patients on co-trimoxazole in our study, however, we found no effect on FEcreat, possibly 
due to lack of statistical power or the low dose of co-trimoxazole. The type of calcineurin 
inhibitor (cyclosporin A or tacrolimus), however, affected FEcreat, although an older report 
did find no effect of cyclosporine A on tubular transport of creatinine (19).  
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In our patients FEcreat ranged from 0.71 to 1.39. Of note, FEcreat was <1 in 41% of the 
patients, implicating net tubular creatinine reabsorption. Creatinine reabsorption, albeit 
infrequent, has been described previously (30, 31, 35, 45). It is considered physiological 
in newborns and the elderly, and is attributed to tubular characteristics allowing for 
“back-leak” of creatinine, namely an immature tubular structure with increased 
permeability in newborns and tubular atrophy in the elderly, respectively (30, 31). 
Moreover, it has been reported in pathological conditions, such as decompensated heart 
failure or uncontrolled diabetes (35). In renal transplant recipients, a small study (45) 
reported several cases with a ratio creatinine clearance/polyfructosan clearance < 1, 
interpreted by the authors to be due to tubular creatinine reabsorption. Those prior 
studies were small, however, thus precluding a reliable estimation of the frequency of 
FEcreat <1.  
Of note, iothalamate clearance on the average yields values 8 percent higher than 
polyfructosan (inulin) (3, 4, 36), so our values of FEcreat would be correspondingly lower if 
using different tracer. However, assuming an 8% lower true GFR would still have 
resulted in an FEcreat <1 in 30.8% of our patients (data not shown). 
The proportion of patients with FEcreat <1 was substantially higher than we found in 
healthy subjects with the same methodology, where 17% had FEcreat <1 (46). Our study 
was not designed to unravel mechanisms of such differences, but several explanations 
are possible. First, other populations with FEcreat <1 are characterized by impaired 
tubular functional integrity, either by tubular immaturity (newborns) or tubular atrophy 
(elderly). This suggests that tubulo-interstitial damage, as commonly present in 
transplant recipients (41), can contribute to negative FEcreat. Drug use, including co-
trimoxazole, calcineurin inhibitors, fluoroquinolones, cimetidine or other, affecting OCT2 
function could also be involved (14, 21, 22, 33). Finally, the single kidney state of the 
transplanted kidney leads to elevation of single nephron GFR. In general, tubular 
functions adapt in proportion to changes in GFR, in order to maintain glomerulo-tubular 
balance (6, 17, 18, 44). Whether this also applies to the regulation of OCT2, however, 
has not been demonstrated. Lagging behind of OCT2 up-regulation in the single kidney 
state could then account for low FEcreat. Further studies would be needed to support this 
assumption.  
In line with the effect on FEcreat, bias of the MDRD and CKD-EPI equation was 
significantly associated with the rs316009 minor allele, with a net difference in bias of 
approximately 9 ml/min between homozygotes for the ancestral and the minor allele for 
both equations. No such effect on bias was found for the Cockroft-Gault equation, which 
is in line with its calibration on creatinine clearance. Thus, genetic variability in tubular 
creatinine handling can induce a systematic error in assessment of eGFR by creatinine-
based equations that can lead to spurious associations with eGFR.  
Remarkably, and unexpectedly, the SLC22A2 SNPs were associated with prevalent 
ESRD with an increased odds ratio for ESRD for the minor alleles of both SNPs. This is 
in line with the increasing recognition of the role of tubulo-interstitium in the 
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pathophysiology of renal disease, and, accordingly, the notion that an integrative 
measure of both glomerular and tubular function may bear more prognostic relevance 
than a specific measure for GFR only (42). Considering the substrate polyspecificity of 
OCT2 (59), reduced tubular secretion of various candidate substances might potentially 
be involved, including catecholamines, dopamine, prostaglandins, advanced glycation 
end products, and, possibly, uremic toxins, that could affect the kidney either directly or 
by effects on blood pressure and volume status and hence promote progressive renal 
damage (16, 20, 28, 32, 56, 60). Finally, the association with ESRD as indicator for the 
susceptibility to renal damage is corroborated by recent GWAS data reporting a 
suggestive association between rs316019 and diabetic nephropathy (43). 
We did not observe an association between the donor kidney SLC22A2 SNPs and GF. 
Although the SNPs effect was direction-consistent with the case-control analysis of 
ESRD in native kidney, the results were not statistically significant. It might indicate true 
absence of an association or lack of power to detect a genetic effect on GF, and 
warrants further investigation in larger transplant populations.  
The strength of our study lies in its specific design and the detailed renal phenotype. 
However, limitations should be mentioned. Our work was a single-center study in a 
predominantly Caucasian population, which limits generalizability, and we acknowledge 
an inherent selection bias within ESRD cases towards patients eligible for 
transplantation. The results on the detailed renal phenotype were obtained in renal 
transplant recipients only, and hence cannot be generalized to native kidneys. Finally, 
our in vivo clinical approach only allows solid conclusions on net creatinine handling, and 
assumptions on OCT2 rely on inference.  
Significance / Implications: 
Our study represents a hypothesis-driven in vivo follow-up of prior GWAS and in vitro 
studies. It introduces FEcreat as a novel renal phenotype in genetic studies. SLC22A2 
genotype is associated with phenotypes of net tubular creatinine secretion, namely 
FEcreat and bias of eGFR. Thus, genetic variability of tubular creatinine handling should 
be taken into account in GWAS analyses on creatinine-based renal function phenotypes, 
and in this respect profiling the SLC22A2 variants can improve eGFR performance. 
Finally, the association of SLC22A2 SNPs with ESRD is consistent with a role of tubular 
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Introduction 
It is well established that a genetic component plays an important role in the 
multifactorial etiology of renal disease.1-3 Heritability of renal function indices (serum 
creatinine, glomerular filtration rate, and creatinine clearance) was demonstrated by 
several twin and family studies4 and genome-wide association studies (GWAS) identified 
a large number of associated loci.5-7  
Serum urea (also known as blood urea nitrogen, or BUN), along with creatinine, is the 
most frequently requested measurement of renal function in the assessment of patients 
with renal disease. Due to different mechanisms of synthesis and clearance, the two 
markers are not fully equivalent in estimation of renal function, and in some conditions 
serum urea is considered to be superior to creatinine.8-10 Urea is the end product of 
protein catabolism; it is synthesized mainly in the liver and excreted by the kidney. Its 
blood level depend on numerous factors including hydration status, metabolic rate, 
dietary protein intake, medication use, liver, cardiac and renal function. Role of putative 
genetic factors can be also proposed.  
The latter has been substantiated by a recent study which estimated heritability for urea 
to be 0.44 [95% CI 0.35-0.53].11 This implies that approximately 44% of the inter-
individual variation in blood urea could be explained by additive genetic effects, thus 
indicating a relatively high contribution of genetic factors. Furthermore, a recent GWAS 
of serum biochemical traits performed in a sample of about 14,300 Japanese subjects12 
found several loci associated with blood urea nitrogen (BUN). However, no genetic loci 
for this trait have been detected thus far in European populations. 
We thus aimed to identify genetic loci influencing blood urea concentration in European 
subjects. This will help to explain variability in urea levels that exists in the general 
population and ultimately will provide insight into pathways and physiological 
mechanisms involved in regulation of this compound. 
 
 
Methods & Materials 
Study population 
We performed this study in the population of NESDA (Netherlands Study of Depression 
and Anxiety) which is an ongoing longitudinal cohort study to examine the prevalence, 
long-term course and consequences of depressive and anxiety disorders in the adult 
population. A detailed description of the study design can be found elsewhere.13 
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Briefly, a total of 2981 participants, consisting of a healthy control group, people with a 
history of depressive or anxiety disorder and people with current depressive and/or 
anxiety disorder, were recruited from community (19%), primary care (54%) and 
outpatient psychiatric clinics (27%), and included at the baseline assessment in 2004-
2007. Inclusion criteria were a lifetime diagnosis of major depressive disorder  
or anxiety disorder, age between 18 and 65 years and self-reported western European 
ancestry. Persons who were not fluent in Dutch and those with a primary diagnosis of a 
psychotic disorder, obsessive compulsive disorder, bipolar disorder, or severe substance 
use or dependence were excluded. Biological sample collection and biobanking 
procedures, i.e. blood sampling and DNA isolation, took place during the baseline visit 
and has been previously described in detail.14 
Imputed data of the Affymetrix 600K genome-wide genotyping array including 2,473,986 
post-quality control autosomal SNPs were available for 1925 subjects. 
 
Urea measurement 
Urea concentration (mmol/L) was measured in Li-heparin plasma using a kinetic UV 
enzymatic assay for the quantitative determination of urea on a Roche automated 
clinical chemistry analyzer. 
This method is characterized by high analytical sensitivity (lower detection limit is 0.53 




Urea plasma concentration values were obtained for 1901 subjects with genome-wide 
SNP genotyping data. The values which exceeded 4 standard deviations from the mean 
(n=5) were considered to be outliers and were excluded from the subsequent analyses. 
The final sample thus consisted of 1896 individuals (613 males, 1283 females). 
Prior to running genetic association analyses, the phenotype of interest was first 
explored using PASW Statistics 18.0 (SPSS Inc., Chicago, IL) to test the distribution and 
correlations with potential covariates. Subsequently, SNPTEST v2.2.018,19 was used for 
genome-wide association testing. The linear regression on single SNP genotypes was 
run under an additive genetic model, using thresholded genotypes (calling threshold 0.9) 
and non-transformed, non-standardized urea concentration as a dependent variable. As 
covariates, sex, age, age2, body mass index (BMI) and the top ten principal component 
analysis scores (PCA1-10) were incorporated. Also, to adjust for potential confounding 
by renal function, serum creatinine or glomerular filtration rate (eGFRcreat) estimated from 
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it by the Modification of Diet in Renal Disease (MDRD) Study equation15 were included 
as covariates (the values were natural log transformed to approximate normality of the 
distribution). Additionally, to test for plausible gender-specific associations, we divided 
the whole sample into males and females and performed the analysis in the two 
subgroups separately.  
We thus ran 9 models depending on covariates used:  
1) age, age2, sex, BMI, PCA1-10;  
2) age, age2, sex, BMI, PCA1-10, serum creatinine;  
3) age, age2, sex, BMI, PCA1-10, eGFRcreat;  
4-9) models 1-3 in a sex-stratified manner. 
For visualization of the results, WGAViewer v1.26I. 201016 was used to build the 




The Q-Q plot of the total sample consisting of 1896 individuals (Figure 1) showed no 
deviation from the expected distribution, thus, there were no systematic biases causing 
statistics inflation. Accordingly, the genomic control λ (lambda) was 0.9986, confirming 








Figure 1. Quantile-quantile plot of the 
observed vs expected -2 loge p values. 
The lower line indicates the 90th percentile, while 
the upper one denotes the point where the p values 
lift off from the expected distribution. 
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The corresponding Manhattan plot (Figure 2), however, showed that none of the SNPs 
reached the genome-wide significance level of 5×10-8 for association with blood urea. 
The additional adjustment for serum creatinine or eGFR, as well as running the analyses 
in a sex-stratified manner, did not materially change the association results or 
significance magnitude (data not shown). 
The three SNPs, identified in the GWAS of BUN in a Japanese population12, were not 




Figure 2. Manhattan plot of -log10 p values (y axis) for association with plasma urea by 




Table 1. A comparison of the genome-wide association results for blood urea between the 
previous study in a Japanese population and our present report. 
 GWAS in a Japanese population12 Our GWAS * 
SNPs MAF Beta (SE) p MAF Beta (SE) p 
rs9820070 0.31 -0.087 (0.013) 1.24×10-11 0.40 -0.051 (0.036) 0.150 
rs11709625 0.17 0.102 (0.016) 1.46×10-10 0.19 -0.020 (0.045) 0.653 
rs4890568 0.24 -0.087 (0.014) 2.02×10-10 0.06 -0.126 (0.083) 0.132 
* The results of the model with additional adjustment for serum creatinine are presented to allow for comparison 
with the cited study12. MAF, minor allele frequency; SE, standard error of the mean. 
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Discussion 
We present genome-wide association results for plasma urea concentration in European 
subjects. To our knowledge, this was the first GWAS focusing on this trait in a European 
population. However, our analyses identified no significant loci for this phenotype. The 
lack of statistical significance in our study might be explained by the study design issues, 
namely insufficient sample size and crude phenotype.  
We used a relatively small discovery cohort of 1,900 individuals in our GWAS. To gain 
adequate statistical power to be able to detect SNP effects at genome-wide significance 
level (p=5×10-8), we would need a substantially larger sample size. To achieve that, 
GWAS in additional cohorts followed by a meta-GWAS analysis are needed.  
However, a recently reported GWAS of serum metabolite levels,11 although it used a 
relatively large population of 8,300 individuals, identified no significant loci for blood 
urea. This might point to the fact that this phenotype presents an analytical challenge. 
Plasma urea is a complex and composite phenotype. The levels of urea present in blood 
are determined by the interplay of numerous factors including (but not limiting to) 
hydration status, metabolic rate, dietary protein intake, medication use, liver, cardiac and 
renal function, which might obscure subtle genetic effects. In our study we attempted to 
account for an influence of kidney function on blood urea by adjusting the association 
analyses for either serum creatinine or eGFR. Also in the previous GWAS of BUN in a 
Japanese population adjustment for creatinine was used.12 However, we were not able 
to control for potential confounding by other factors. In particular, it would be highly 
relevant to obtain the information on dietary protein intake and/or urea urinary excretion. 
Therefore, further studies in more thoroughly phenotyped populations might be useful to 
dissect the environmental determinants of blood urea and reveal the putative genetic 
ones. 
Given the clear gender dimorphism of many metabolic traits, in particular, blood urea, 
and the recent evidence of gender differences of genetic variants in metabolism-related 
genes,17 we re-analysed the data looking for sex-specific effects, i.e. those restricted to 
males or females only. However, these gender-stratified analyses revealed no 
significantly-associated loci of interest. Again, the lack of statistical significance could be 
attributed to insufficient power due to small sample size. 
The three SNPs, identified to be associated with BUN in a Japanese population,12 were 
not significantly associated with the phenotype of interest in our GWAS of European 
subjects. This might be explained by either low statistical power of our study or existence 
of ethnicity-specific loci for blood urea. The latter is supported by the observation that the 
frequency of one of the top SNPs, rs4890568, appeared to be substantially different 
between the populations. In the future, we intend to expand our study by performing 
GWAS in additional cohorts followed by a meta-GWAS analysis. If this results in 
detection of significant hits, we will approach the Japanese group for replication of our 
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findings, which will enable us to discriminate between plausible population-specific and 
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Genetics of common kidney disease: from GWAS to clinical nephrology  
Since the first successful GWAS in 2005,1 major advances have been made by this 
method to unravel the genetics of common disorders, including kidney disease. Multiple 
genetic loci have been identified in association with kidney function, CKD, albuminuria 
and some other renal traits.  
Some of the genomic loci, detected through GWAS for common variants, contain also 
rare mutations of large effect which were already known to cause monogenic diseases 
of the kidney. For example, the CUBN gene, highlighted in the GWAS of albuminuria 
that identified a common associated polymorphism,2 harbors mutations causing a rare 
autosomal-recessive disorder, Imerslund-Gräsbeck disease. Another example is UMOD, 
deleterious mutations in which result in autosomal-dominant renal disorders, namely 
medullary cystic kidney disease-2 and familial juvenile hyperuricemic nephropathy, while 
GWAS found common variation in this locus to be associated with renal function traits 
and CKD.3-7 
Such a “re-discovery” of Mendelian genes, confirming prior genetic concepts, fuelled 
confidence in the GWAS approach. Perhaps even more important, GWAS identified 
genomic regions previously unsuspected of being involved in kidney (patho)physiology, 
thus providing interesting clues that could lead to discovery of novel pathways of 
disease, or better understanding of alleged pathways of disease. 
However, albeit a powerful approach for gene discovery, GWAS by itself does not 
provide mechanistic insights. In fact, GWAS generate many interesting hypotheses to be 
tested in post-GWAS follow-up research. The studies described in this thesis provide 
such post-GWAS efforts, aimed at carrying the genotype-phenotype associations 
observed in prior GWASs on renal traits towards the realm of clinical nephrology. To this 
purpose we selected three loci identified by GWASs for association with eGFR and 
albuminuria, respectively, based on biological knowledge of their possible role in the 
kidney, and tested these in a hypothesis-driven approach in smaller association studies 
where more detail on the renal phenotypes was available.  
 
Functional follow-up of GWAS 
In the past few years, a number of genetic loci has been robustly associated with kidney 
disease. However, statistical association does not equal causality. Absence of proof that 
the associated gene is also the causal one presents a major bottleneck in the biological 
translation of GWAS findings. 
 General Discussion 
 127
Multiple lines of evidence are needed to constitute proof of a causal genetic variant, 
warranting post-GWAS studies on different levels − including bioinformatics (in silico), in 
vitro and in vivo research.  
 
Bioinformatics prediction of molecular function 
Bioinformatics-based SNP prioritization is often the first step of post-GWAS analysis, 
aimed at predicting the likelihood that variation in a particular SNP has functional 
consequences. Polymorphisms in coding regions, causing amino acid changes, 
especially if localized in a conserved region or functional domain of a protein, are likely 
to have functional consequences. Likewise, SNPs mapped to regulatory regions of a 
gene, e.g., promoters or splice sites, can be expected to bear functional potential.8 For 
example, in chapter 6 we used bioinformatics to predict consequences of a genetic 
polymorphism in the CUBN gene for the coded protein, cubilin. Bioinformatics thus 
provides a useful tool to prioritizing SNPs for possible functionality, but subsequent in 
vitro and in vivo studies are needed to prove a biological impact of the polymorphisms 
on the protein level.  
 
Animal models and in vitro studies: functional proof  
As genetic manipulations are obviously impossible in humans, cross-species modeling 
can be used to recapitulate human phenotypes and, thus, validate the genetic discovery 
in an independent setting. Progress in gene orthology knowledge has made it possible to 
take advantage of distant animal species in the targeted study of genes that have clinical 
relevance for human diseases. In mouse, rat, zebrafish and other model organisms 
genetic engineering can thus be used to mimic the human disease by gene knock out 
(knock in, knock down) and obtain useful insights into gene function.9,10 Additionally, in 
vitro studies help to define the molecular mechanisms by which genetic variants affect 
pathways of cellular or tissue physiology.  
 
In vivo clinical studies 
The final proof that a particular genetic variation bears clinical relevance will by definition 
require clinical studies. Moreover, clinical pathophysiological studies are indispensable 
in elucidating the genotype-phenotype relationships in terms of underlying mechanisms. 
Clinically oriented post-GWAS studies, aimed at elucidating genotype phenotype 
relationships of loci identified in GWAS to be associated with renal traits, constitute the 
backbone of this thesis. For each of these loci we applied a hypothesis-driven approach, 
aiming to integrate previous GWASs results with renal phenotypes.  
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Dissecting renal phenotypes 
UMOD 
UMOD holds a prominent place among renal loci due to the unique feature that the gene 
expression product, uromodulin, is excreted into urine and is thus easily available for 
quantitative assessment.11-13 Prior studies reported that uromodulin level in the urine is 
genetically determined: a region upstream from the UMOD gene contains rs12917707 
and several other SNPs (e.g. rs4293393 and rs13333226) in high linkage disequilibrium 
(LD) which were repeatedly shown to be associated with urinary uromodulin 
concentration.5,14,15 Urinary uromodulin thus constitutes a non-invasive intermediate 
phenotype that is potentially useful to unravel genotype-phenotype relationships. 
Chapters 2 through 4 of this thesis, therefore, were devoted to UMOD and its possible 
role in the susceptibility to renal damage. 
Urinary uromodulin has been reported to have prognostic value for the subsequent 
course of renal function in native kidneys. Genetically elevated urinary uromodulin 
concentration was associated with prevalent and incident CKD.5 A recent study, 
moreover, suggested an association between the UMOD variant genotype and the risk 
for ESRD.7 However, the level of statistical significance was only nominal warranting 
further investigation. In chapter 4 we demonstrated that UMOD is indeed a susceptibility 
gene for ESRD, with the minor rs12917707 allele being associated with a lower risk. 
Such an independent replication of the results, confirming robustness of the previous 
findings, is of importance for genetic association studies, and warrants further studies on 
the role of UMOD in the susceptibility to renal damage. 
Few data are available on uromodulin excretion in renal transplantation, and data on its 
prognostic value in renal transplantation are lacking altogether. In chapter 2, therefore, 
we investigated urinary uromodulin levels in a large cohort of renal transplant recipients 
(RTRs) and found excretion of uromodulin to be associated with renal allograft function, 
morphology and outcome in a peculiar bimodal fashion: both lower and higher 
uromodulin levels were associated with higher creatinine clearance, lower interstitial 
fibrosis/tubular atrophy score and reduced risk of graft failure. The bimodal association 
with renal damage parameters and outcome is at variance with prior data in native 
kidneys and indicates that urinary uromodulin cannot be considered a straightforward 
biomarker for renal damage, at least in the setting of renal transplantation. Interestingly, 
total urinary uromodulin excretion was substantially elevated in RTRs as compared to 
CKD patients and healthy subjects, which is remarkable considering that RTRs have 
only one functioning kidney. These data prompted further exploration of the genetic and 
environmental determinants of urinary uromodulin excretion.  
As UMOD is expressed exclusively in the kidney, we assumed that kidney (i.e donor) 
genotype would be associated with urinary uromodulin rather than recipient genotype. In 
line with our hypothesis, in chapter 4 we found that urinary uromodulin levels in renal 
transplant recipients were indeed associated with donor and not recipient UMOD 
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rs12917707 genotype. Thus, the genotype-phenotype association for this intermediate 
phenotype that was previously reported in the native kidney was now reproduced in the 
transplanted kidney, with a similar direction of effect. This implies that it is indeed the 
UMOD genotype of the kidney that associates with uromodulin production. 
In chapter 3 we investigated factors influencing urinary uromodulin in healthy subjects 
and in renal patients. In part 1 we found that urinary uromodulin concentration exhibits 
no diurnal or infradian rhythms in healthy individuals. Accordingly, fluctuations in 
uromodulin excretion over the day closely followed urinary volume, or urinary flow. This 
finding might be relevant to the high uromodulin excretion in renal transplant recipients, 
where urine flow per kidney is twice as high as in subjects with two functional kidneys, 
but this assumption would require further substantiation. Furthermore, we assessed the 
variability of uromodulin that has useful practical implications for designing subsequent 
studies. In part 2 we observed an effect of dietary sodium intake on urinary uromodulin 
levels in CKD patients, with a trend for decreased uromodulin excretion during low 
sodium as compared to high sodium diet. Such a direction of the effect is in line with the 
previous studies in healthy subjects15,16 and the general population.17 Our data support 
the preservation of the response of urinary uromodulin to sodium load in CKD patients. 
This is of interest, as it might represent a modality to manipulate urinary uromodulin. If 
the association between higher urinary uromodulin levels and worse renal prognosis 
would be based on an adverse pathophysiological effect of higher urinary uromodulin 
levels, such modulation of uromodulin could be of potential benefit. However, our data 
on the bimodal association with renal damage in renal transplant recipients warrant for 
cautious interpretation of the implications of urinary uromodulin. 
Taken together, our studies provide independent confirmation of UMOD as a gene 
associated with ESRD since we found a minor allele of its variant rs1297707 to be 
associated with lower risk of ESRD. Furthermore, we showed that it was indeed the 
kidney UMOD genotype that determines urinary uromodulin levels. Finally, our data 
illustrated that this intermediate phenotype is subject to complex regulation, with not only 
genetic but also environmental factors influencing its levels. These data support the 
relevance of UMOD for CKD, and warrant prioritization of UMOD for further 
pathophysiological studies, as the mechanisms relating UMOD, urinary uromodulin, and 
the pathogenesis of renal damage are still enigmatic. It is noteworthy here, that, among 
the substantial number of loci identified for renal traits, and the even larger number of 
loci for blood pressure, UMOD is among the very few that associates with both blood 
pressure and renal function. Considering the impact of sodium status on urinary 
uromodulin and the dependency of genotype-phenotype associations on sodium 
intake,15 exploration of gene-environment interaction between UMOD and sodium status 
on pathways of renal damage or protection would be a logical target for further study.  
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CUBN 
Prior data on Mendelian disorders, as well as GWAS findings on CUBN suggested a 
potential role for CUBN as a renal damage gene. Mendelian mutations in the CUBN 
gene result in a rare autosomal-recessive disorder, namely Imerslund-Gräsbeck disease 
(OMIM #261100, Finnish type). It typically manifests with megaloblastic B12 vitamin-
deficient anemia and peripheral neuropathy. The renal phenotype is characterized by 
mild to moderate proteinuria, that is due to a molecular defect in the cubilin protein, that 
leads to inefficient reabsorption of low molecular weight proteins in the proximal 
tubule.18-20 Of note, a recent GWAS2 found common variation in the CUBN gene to be 
associated with albuminuria traits in the general population. 
According to its pathogenesis, proteinuria associated with cubilin dysfunction can be 
classified as tubular proteinuria and accordingly has been considered “innocent”, i.e. not 
leading to renal damage. However, albuminuria is a well-known risk factor for 
progressive renal function loss, and it would be important to establish or refute the 
presumed innocence of CUBN-associated urinary protein loss.  
We, therefore, investigated the association between genetic variation in CUBN and the 
renal susceptibility to damage in chapter 5. First, we found that a common variant in the 
CUBN locus was associated with an approximately 40% increased risk for ESRD. 
Furthermore, a direction-consistent trend was observed for an association between the 
donor kidney CUBN SNP and development of graft failure in renal transplant recipients. 
Moreover, in the recipients the donor CUBN SNP was associated with higher proteinuria 
levels. Of note, the CUBN gene is expressed mostly in the kidney and intestine, and to 
smaller extent in some other tissues and organs.21 Our data, demonstrating an 
association of donor rather than recipient CUBN genotype with development of graft 
failure and proteinuria after transplantation, support involvement of local, intra-renal 
pathways in processes of transplanted kidney function and survival, rather than systemic 
influences.  
Thus, CUBN was associated with phenotypes of progressive renal function loss and 
proteinuria, and can be considered a renal susceptibility gene, rather than a locus for 
“innocent” albuminuria. The fact that the CUBN variant was associated with both ESRD 
and GF, with the same direction of the effect, suggests involvement in common 
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SLC22A2 
A substantial number of genetic loci was associated with serum creatinine and/or 
eGFRcreat as markers of renal function in recent GWASs. However, the association with 
creatinine-based estimates might not only relate to kidney function in terms of GFR but 
also to creatinine biosynthesis or its tubular secretion. 
In chapter 6 we followed up a plausible creatinine secretion locus, SLC22A2. It encodes 
the organic cation transporter 2, OCT2 which is a predominant transporter involved in 
the renal secretion of creatinine. In the kidney it is expressed in the basolateral 
membrane of proximal tubular cells, where it mediates tubular uptake of creatinine from 
the peritubular capillaries as an initial step in its vectorial transport to the apical cell 
membrane followed by secretion into the lumen. 
We studied the association of SLC22A2 polymorphisms with two phenotypes of net 
tubular creatinine secretion: namely fractional creatinine excretion (FEcreat) and bias of 
estimated glomerular filtration rate (eGFR) in renal transplant recipients. As the 
SLC22A2 gene expression is known to be restricted to the kidney, with only scarce 
extra-renal expression sites,21 we could avoid unnecessary multiple testing and test only 
donor kidney genotype for association with recipient phenotypes. In line with our 
hypothesis, the SLC22A2 common variant in the donor kidney genotype was associated 
with FEcreat. Accordingly, the variant was associated with eGFR, that is, renal function 
estimated from creatinine by either the MDRD or the CKD-EPI equation, but not with 
GFR measured by iothalamate clearance as a gold standard. Thus, the association with 
eGFR is due to the association with the tubular component of renal creatinine excretion. 
In line, the SLC22A2 variant was associated with bias of eGFR, but not with bias of the 
Cockroft-Gault equation. The latter is modeled on creatinine clearance, and accordingly 
includes the tubular component of renal creatinine excretion as well. 
Remarkably, the SLC22A2 variants were associated with increased risk of ESRD. This 
may seem counterintuitive, as the association with FEcreat points towards a predominant 
tubular effect, rather than an effect on renal glomerular function or renal disease. 
However, the finding is in agreement with the recent recognition of the tubular 
compartment as an important player in pathophysiology of renal disease and the 
emerging evidence that an integrative measure of both glomerular and tubular function 
may bear more prognostic relevance than a specific measure for GFR only. The 
substrate polyspecificity of OCT2 may be relevant here, as OCT2 is not only involved in 
the secretion of creatinine, but also in the tubular excretion of biologically active 
compounds that play a role involved in the pathophysiology of progressive renal 
damage, such as catecholamines, AGEs, and, allegedly, some uremic toxins.  
The observed relationship of the SLC22A2 variants with ESRD did not translate into 
association with renal function loss in the transplantation setting, i.e. GF. It is suggestive 
of differential involvement of this gene in the pathophysiology of native and transplanted 
kidneys. 
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Thus, our results demonstrate that the SLC22A2 gene is not related to glomerular 
filtration rate, but to creatinine tubular secretion. We introduced FEcreat as a novel renal 
phenotype for genetic association studies. Remarkably, the SLC22A2 variants were also 
associated with increased risk of ESRD, thus highlighting the role of tubular function in 
progressive renal function loss.  
 
Blood urea as a novel renal phenotype 
Blood urea, along with creatinine, is the most frequently used measurement of renal 
function in the assessment of patients with renal disease. It provides an index of the 
metabolic impact of reduced renal function, specifically reflecting the renal excretion of 
breakdown products of protein metabolism. As such, it is a phenotype of interest. 
However, it remains a largely underexplored phenotype, with no associated genetic loci 
identified in Caucasians thus far. At the same time, heritability studies showed a 
relatively high contribution of genetic factors to the inter-individual variation in blood 
urea, in spite of its well-acknowledged environmental component. 
We therefore performed a GWAS of this trait in European subjects (chapter 7). 
However, a relatively small size of the discovery cohort so far did not allow for sufficient 
statistical power to reveal significant loci for this phenotype. Although we detected no 
significant hits, our study provided an initial step in exploring this renal trait. Subsequent 
research efforts are warranted to identify specific responsible genetic loci influencing 
blood urea concentration in European individuals. 
 
Clinical utility of nephrogenetic findings 
Prediction of kidney disease risk 
The potential to enable a personalized prediction of disease risk has been suggested as 
one of the translational applications of GWAS.22-25 
In chapters 4 through 6 we tested variants in plausible genes for association with 
prevalent ESRD and incident GF. We found that common variants in the CUBN (chapter 
5) and SLC22A2 (chapter 6) loci were associated with increased risk for ESRD (odds 
ratio (OR) ranging from 1.2 to 1.4), while the UMOD SNP (chapter 4), on the contrary, 
conferred protection against ESRD (OR 0.9). Besides, the CUBN variant predicted 
(hazard ratio 1.5) incidence of graft failure in our longitudinal study of renal transplant 
recipients. 
Such a small magnitude of the effects, in agreement with general observations from 
previous GWAS, is typical for the majority of common variants. As the small ORs are not 
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useful for predicting risk to individuals, this led to the realization that the main yield of 
GWAS will probably not be the prediction of individual risk, but rather discovery of 
biological pathways underlying polygenic diseases and traits.22-26  
 
Test performance 
In chapter 6 we showed that genetic variation in the SLC22A2 locus has consequences 
for the precision and accuracy of creatinine-based GFR estimation methods. In our 
study, bias of the MDRD and CKD-EPI equations, but not the Cockroft-Gault equation, 
was significantly associated with the rs316009 SLC22A2 SNP. This shows that 
genetically determined variability in tubular creatinine handling can induce a systematic 
error in assessment of eGFR by creatinine-based equations. This should be taken into 
account in GWASs of creatinine-based renal function phenotypes. In this respect, 
profiling the SLC22A2 variants and using them as covariates in genome-wide regression 
analyses of creatinine-based estimates can be suggested to adjust for the genetically 
determined differences in tubular secretion of creatinine. Yet, quantitatively the effect 
was small, and of limited clinical relevance. 
 
Future research perspectives 
In the general introduction of this thesis we mentioned that all renal function loci, 
identified thus far by multiple GWASs, collectively account for only 1.4% of the variation 
in eGFRcreat. At the same time, heritability of GFR has been estimated to range from 33 
to 75%, indicating that between approximately 33 and 75% of the inter-individual 
variation in GFR can be explained by additive genetic effects.22,23,27,28 Similarly, although 
heritability estimates of albuminuria range from 16 to 49%, the top hit of the GWAS of 
albuminuria traits (urinary albumin-to-creatinine ratio and microalbuminuria) explained 
only 0.2% of the total variance of this phenotype22,23. Such discrepancy between the 
estimated contribution of genetic factors to disease and the proportion of the phenotypic 
variation explained by GWAS-identified SNPs is called “missing heritability”. 
Some researchers argue that the missing heritability problem is caused by statistical 
issues, resulting, on the one hand, in overestimation of heritability in twin studies, and, 
on the other hand, under-detection of associated variants in GWAS due to inadequate 
sample size and overly stringent significance requirements. The prevailing opinion, 
however, is that sources of missing heritability include unidentified rare and structural 
genetic variants, epigenetic changes such as miRNAs, methylation or histone 
modification, as well as gene × gene and gene × environment interactions.29,30  
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The missing heritability problem thus constitutes a rationale for further research to 
uncover additional genetic loci in order to identify the “remainder” of the total heritable 
contribution to common diseases and traits. 
To identify previously undetected variants with smaller effect sizes through GWAS, 
enlarging the sample size of the initial discovery stage is a strategy that is helpful, by 
increasing the statistical power. In fact, genetic discovery is nowadays usually conducted 
as a meta-analysis of results from many individual GWASs, with total sample sizes 
reaching 100,000 individuals and higher. Therefore, collective efforts by consortia of 
investigators, efficiently joining resources of the international research community, are 
needed to make the most of the GWAS method. However, while power issues are 
becoming less of a concern in the current era of the “mega consortium”, the 
progressively smaller effects sizes in follow-up studies indicate that simply enlarging 
power will not provide the final solution here.  
In some of the studies described in this thesis we faced power issues as well. For 
example, graft failure analyses were probably underpowered to reveal statistically 
significant genetic effects (chapters 4 and 6) or reach convincing statistical significance 
level (chapter 5). Studies in larger renal transplant populations are warranted to reliably 
demonstrate the presence or absence of an association between the SNPs and 
incidence of graft failure. Also in our GWAS of blood urea (chapter 7) insufficient sample 
size was a likely cause for the lack of statistical significance. To achieve adequate 
statistical power for this study, we intend to perform GWASs in additional cohorts 
followed by a meta-GWAS analysis. 
To reveal the putative “hidden” genetic variants still uncaptured by GWASs, fine-
mapping and targeted deep resequencing of the previously associated candidate 
regions provide useful strategies. Contemporary DNA-sequencing technologies using 
massively parallel pyrosequencing platforms, known as next-generation (NextGen) 
sequencing, make possible whole exome or even whole genome high-resolution 
coverage.31-34 Besides, they enable detection of some structural variants (copy number 
variants, CNVs),35,36 thus expanding the range of captured polymorphisms. Such 
sequencing efforts are expected to result in discovery of a large number of novel, 
potentially causal, variants. 
Another strategy that might aid in discovery of new susceptibility loci is improvement and 
refinement of phenotyping, by expanding to additional or more accurate measures of 
renal function that more closely relate to renal (patho-) physiology than simple 
integrative measures such as eGFR and albuminuria. In this thesis we showed that this 
strategy can be informative, as illustrated by the novel renal phenotype that we 
introduced, namely fractional excretion of creatinine (chapter 6). Albeit informative, it is 
not a routinely available measure, so the sample size remained rather limited. Therefore, 
subsequent genetic association testing in larger appropriately phenotyped cohorts is 
required to explore this trait further. Furthermore, investigating gene × gene and gene × 
environment interactions might provide additional novel insights into genetic architecture 
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of complex, polygenic diseases such as CKD. For instance, in our case-control study of 
ESRD we found an interaction between two genetic variants in the CUBN locus (chapter 
5). According to our data, the rs7918972 minor allele requires a copy of the rs1801239 
minor allele to express its risk phenotype, whereas the minor allele of rs1801239 
displays a protective effect in the absence of the rs7918972 minor allele. However, this 
warrants further experimental functional investigation to determine whether the observed 
statistical interaction implies also biological interaction. 
Furthermore, gene × environment interaction is highly relevant to explore, all the more 
so because environmental factors are in principle accessible to intervention. Our group 
previously reported gene × environment interaction for the ACE (I/D) genotype and 
sodium status37 and the current data suggest that sodium status interacts with genotype-
phenotype associations for UMOD as well. Effect of genetic variation in the UMOD locus 
on urinary uromodulin level was reported previously,5 and independently replicated in 
our study in renal transplant recipients (chapter 4). Dietary sodium affected urinary 
uromodulin excretion in both healthy individuals15,16 and CKD patients (chapter 3). 
Whether the genetic effect of UMOD on the susceptibility to renal damage also 
modulated by exposure to a sodium load is unknown, and interventional studies 
involving an environmental challenge of high/low sodium diet are needed to elucidate the 
putative gene × environment (more precisely, gene × diet) interaction here.  
Another type of gene × environment interaction with potential clinical relevance can be 
gene × drug interaction. Pharmacogenetics is an emerging discipline, addressing genetic 
variation in pharmacokinetics as well as pharmacodynamics, that holds the promise of 
pharmacotherapy that is better suited to the individual physiological needs than a one-
size-fits-all approach.38-41 Our studies did not specifically address pharmacogenetic 
questions. However, it is interesting to note that several drugs are known to affect 
tubular secretion of creatinine.42-45 In our study we found also the SLC22A2 genetic 
variant to be one of the determinants of creatinine secretion (chapter 6). It would be 
highly interesting to investigate whether there is an interaction between the drug and 
gene effects and what the modality of such interaction is. Moreover, the association of 
SLC22A2 and risk for ESRD prompts to investigate the long term renal risks of drugs 
affecting creatinine secretion, such as co-trimoxazole. 
A recently proposed promising approach is to integrate gene association analyses with 
the functional biological knowledge on gene expression (transcriptomics, proteomics, 
metabolomics) and its regulation (regulomics, epigenetics, microRNA profiling) to reveal 
molecular mechanisms underlying the genetically determined phenotypic variance.46  
As a high degree of cellular heterogeneity of the kidney and concomitant complexity of 
its physiology pose a challenge for understanding and interpreting straightforward 
genotype-phenotype associations, integration of all the biological data at a systems level 
seems only appropriate to gain an insight into complex renal traits47-51 (Figure 1). We 
believe that integrating data on DNA variation, transcription and phenotype has the 
potential to enhance identification of the associations between DNA variation and 
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complex diseases like CKD, as well as characterize those parts of the molecular 
networks that drive the disease. As contemporary research goes beyond a single-gene 
focus, integrative approaches, aimed at analyzing high-dimensional biological data by 
merging data from multiple sources, will significantly enhance the identification of key 
drivers of complex disease beyond what could be achieved by genetic association 
studies alone. 
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Conclusions 
In the contemporary era of intensive genetic research and rapid generation of large 
scale data on genotype-phenotype associations, our results illustrate the relevance of 
dedicated clinical studies for the translation of genotype-phenotype associations from 
GWAS to the setting of clinical nephrology. Our data illustrate that refinement and 
dissection of the renal phenotype, as with FEcreat and true GFR instead of eGFR, allow 
better insight into the functional and clinical consequences of the genetic variant. Also, 
they show the potential of genetics as a dissection tool: our data on the association of 
SLC22A2 with ESRD strongly suggest that functional tubular changes may contribute to 
further renal function loss. This would have been notoriously difficult to show in a merely 
phenotypic study, where it is almost impossible to dissect cause and consequence in the 
association between tubular functional changes and subsequent ESRD.  
Our data also illustrate that the translation of GWAS data on renal traits to clinical 
nephrology is neither simple not straightforward. Yet, by integrating the newly generated 
data with knowledge from clinical pathophysiology, new insights are obtained that 
eventually contribute to elucidation of the genetic basis of susceptibility and progression 
of CKD. This may ultimately support the development of novel tools for diagnosis, 
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In de Westerse wereld heeft ongeveer 10% van de volwassen bevolking een vorm van 
chronische nierschade, en dit aandeel zal naar verwachting verder toenemen, ten 
gevolge van de toenemende levensverwachting en de toename van 
overgewicht/obesitas en type 2 diabetes mellitus. Doordat nierziekten gepaard gaan met 
een sterk verhoogd risico op hart- en vaatziekten is de morbiditeit en mortaliteit onder 
nierpatiënten hoog. Tevens is de kwaliteit van leven van de nierpatiënt duidelijk 
verminderd, met name indien nierfunctievervangende therapie in de vorm van dialyse 
(nierspoelen) nodig is. Een chronische nierziekte kan vele oorzaken hebben waardoor 
het ziektebeeld als entiteit een uitgesproken heterogeen karakter heeft. Genetische 
factoren spelen een belangrijke rol in het ontstaan en ernst van het ziektebeeld en 
identificatie van deze genetische factoren is belangrijk om kennis over nierziekten te 
vergroten, maar ook om het diagnosticeren en het behandelen ervan te verbeteren. 
In de afgelopen decennia heeft genetisch onderzoek ons veel geleerd over de 
zogenaamde “Mendeliaanse” nierziekten, een groep nierziekten die het directe gevolg 
zijn van één enkele DNA-mutatie. Tot deze groep nierziekten behoren bijvoorbeeld de 
aandoeningen: “autosomaal dominante polycysteuze nierziekten” en “syndroom van 
Alport”. Bij andere nieraandoeningen, de zogenaamde complexe ziekten, is er niet een 
overwegende rol van één mutatie, maar zijn er effecten van meerdere genetische 
varianten, die elk op zichzelf een relatief kleine bijdrage leveren. Daarnaast zijn er ook 
bijdragende omgevingsvarianten. 
Door middel van Genome Wide Association Studies, dat wil zeggen het genotyperen 
van het gehele genoom, en koppeling van de variatie daarin aan klinische gegevens, is 
de laatste jaren een snel toenemende hoeveelheid gegevens verkregen over de 
associatie van bepaalde ziektekarakteristieken, zoals bloeddruk of mate van nierfunctie, 
met bepaalde variaties in het DNA, ook wel single-nucleotide polymorfismen (SNPs) 
genoemd. Door middel van GWAS worden nu veel SNP’s ontdekt die mogelijk betrokken 
zijn bij het ontstaan en progressie van nierziekten. De eerste studie die gebruikmaakte 
van de GWAS-methode in grote humane cohorten werd in 2005 gepubliceerd. waarna 
een toenemend aantal ziektekarakteristieken met behulp van deze methode zijn 
onderzocht. Het aantal neemt inmiddels zeer snel toe, en daarmee ook het aantal met 
klinische kenmerken geassocieerde SNPs. Een nadeel van de GWAS-methode is dat 
het alleen associaties blootlegt, maar geen specifieke informatie oplevert over het 
mechanisme waarop een bepaalde genetische verandering tot een bepaalde 
ziektekarakteristiek leidt. Daarvoor is dus vervolgonderzoek nodig. Voor SNPs die 
geassocieerd zijn met variaties in nierfunctie, is het niet alleen belangrijk om 
onderliggende mechanismen te onderzoeken, maar ook, of de betreffende SNPs ook 
geassocieerd zijn met een verhoogde kans op klinisch relevante nierschade, in het 
bijzonder eindstadium nierfalen. In dit proefschrift onderzoeken we voor een aantal 
SNPs die recent werden geassocieerd met nierfunctie, de relatie met het risico op 
eindstadium nierfalen, en mogelijke onderliggende mechanismen. Daarmee proberen 
we de resultaten van GWAS-onderzoek te vertalen naar de klinische praktijk. 
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Voor dit proefschrift onderzochten we SNPs in een drietal genen waarvan recent met 
GWAS een verband met nierfunctie is gevonden. Dit zijn: (1) UMOD, dat codeert voor 
het eiwit uromoduline, het meest voorkomende eiwit in urine; (2) CUBN, dat codeert voor 
het eiwit cubilin dat een rol speelt bij de terugresorptie van eiwit in de nier; en (3) 
SLC22A2, dat codeert voor een eiwit dat een rol speelt bij de uitscheiding van 
afvalstoffen door de nier. 
Hoofdstuk 2 t/m 4 richt zich op het eiwit uromoduline, dat wordt uitgescheiden in de urine 
en daardoor eenvoudig meetbaar is. Eerder werd al aangetoond dat de uitscheiding van 
uromoduline in de urine het beloop van de nierziekte kan voorspellen, en bovendien dat 
genetische variatie in het UMOD gen mede de uitscheiding van uromoduline in de urine 
bepaalt. Daarmee zou het effect van genetische variatie in het UMOD gen op simpele 
wijze in de urine meetbaar zijn. Wij onderzochten dit in een aantal studies in patiënten 
met nierziekte, in patiënten na niertransplantatie, en in gezonde vrijwilligers. In 
hoofdstuk 2 onderzochten we of de uitscheiding van uromoduline in de urine het falen 
van het niertransplantaat kan voorspellen. We vonden dat de uitscheiding van 
uromoduline bifasisch geassocieerd is met de functie van het niertransplantaat. Zowel 
een lagere als hogere excretie van uromoduline in de urine was geassocieerd met een 
betere nierfunctie, minder littekenvorming in de nier en minder verlies van niercellen, 
waardoor het transplantaat minder schade oploopt. Deze bifasische associatie is niet in 
overeenstemming met eerder onderzoek in nierpatiënten zonder niertransplantaat (dus 
in de eigen nieren). Dit lijkt te suggereren dat meten van uromoduline in de urine weinig 
toegevoegde waarde heeft in niertransplantatiepatiënten; ook geeft het aan dat de 
relatie tussen uromoduline in urine en nierschade blijkbaar complexer is dan verwacht. 
In hoofdstuk 3 onderzochten daarom in meer detail de rol van niet-genetische factoren 
bij de concentratie uromoduline in de urine, bij gezonde vrijwilligers en nierpatiënten. In 
het eerste gedeelte van de studie onderzochten we de 24-uursvariatie in de uitscheiding 
van uromoduline, alsmede de dag-tot-dag variatie bij vrijwilligers. De uitscheiding van 
uromoduline had bij hen geen duidelijk dag-nacht ritme, en er was ook weinig intra-
individuele variatie van dag tot dag. Uromoduline heeft echter wel een duidelijke inter-
individuele variatie, hetgeen implicaties kan hebben voor verdere vervolgstudies. In het 
tweede gedeelte van de studie onderzochten we de effecten van zoutbeperking en 
farmacologische interventie op de uitscheiding van uromoduline bij nierpatiënten. We 
vonden dat de uitscheiding van uromoduline in de urine lager is tijdens zoutbeperking 
wat in overeenstemming is met resultaten in gezonde vrijwilligers. In hoofdstuk 4 
vonden we dat UMOD een duidelijke relatie heeft met de concentratie uromoduline in de 
urine van patiënten na niertransplantatie. Bovendien was UMOD geassocieerd met het 
risico op eindstadium nierfalen. Samenvattend ondersteunen onze studies een rol van 
het UMOD gen bij het ontstaan en beloop van nierziekten. De uitingsvorm van dit gen – 
namelijk de concentratie uromoduline in de urine – wordt op complexe wijze wordt 
gereguleerd, met een belangrijke bijdrage van niet-genetische factoren. Het 
mechanisme van de relatie tussen variatie in het UMOD gen en nierschade blijft 
vooralsnog onduidelijk: wel is opmerkelijk dat variatie in het UMOD gen ook betrokken is 
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bij bloeddrukregulatie. Dit zou potentieel van belang kunnen zijn voor de rol bij 
nierschade.  
Het tweede onderzochte gen betreft het CUBN gen. Dit codeert voor het eiwit cubiline. 
Het CUBN gen is betrokken is bij de nierziekte “Imerslund-Gräsbeck”, een zeer 
zeldzame nierziekte die veroorzaakt wordt door mutaties in het CUBN gen. Deze ziekte 
gaat gepaard met eiwitverlies in de urine (proteïnurie) ten gevolge van een inefficiënt 
verlopende reabsorptie van bepaalde eiwitten in de nier ten gevolge van een niet goed 
werkend cubiline. Hernieuwde aandacht voor cubiline is ontstaan doordat GWAS-
onderzoek aantoonde dat andere, frequenter voorkomende variaties in het CUBN gen 
samenhangen met proteïnurie in de algemene bevolking en bij patiënten met 
nierschade. Proteïnurie is een bekende risicofactor voor nierfunctieachteruitgang, 
waarbij meer verlies van eiwit in de urine samenhangt met meer nierschade en een 
slechtere prognose. In hoeverre deze variaties in het CUBN gen daardoor geassocieerd 
zouden kunnen zijn met het risico op nierschade, was echter niet bekend. Wij testten 
daarom de hypothese dat variatie in het CUBN gen geassocieerd is met het risico op 
eindstadium nierfalen. In hoofdstuk 5 hebben we daartoe, in ontvangers van een 
niertransplantaat, onderzocht of genetische variatie in het CUBN gen een relatie heeft 
met nierschade (in de vorm van proteïnurie) en met progressieve 
nierfunctieachteruitgang (gedefinieerd als terugkeer naar dialyse of anderszins falen van 
het niertransplantaat). Ten eerste vonden we dat een veelvoorkomende CUBN SNP 
samenhing met een ongeveer 40% hoger risico op falen van het niertransplantaat. 
Bovendien was het CUBN SNP van de donornier geassocieerd met meer proteïnurie in 
de niertransplantatiepatiënt. Deze SNP is dus geassocieerd met zowel proteïnurie, als 
met een verhoogde kans op progressief nierfunctieverlies.  
In hoofdstuk 6 onderzochten we de manifestaties van genetische variatie in het gen 
voor SLC22A2. Eerder werd, in GWAS studies, gevonden dat deze SNP een relatie 
heeft met de nierfunctie, gemeten met behulp van creatinine. Werd de nierfunctie 
gemeten met behulp van Cystatine-C, dan was er geen relatie. Dit leidde tot de 
hypothese dat genetische variatie in SLC22A2 leidt tot een effect op serum creatinine 
door een effect op tubulaire secretie, temeer daar SLC22A2 in de niertubulus een 
transport functie heeft. We onderzochten daarom de relatie tussen tubulaire uitscheiding 
van creatinine en variatie in het gen voor SLC22A2: hiertussen bestond inderdaad een 
verband, terwijl er met glomerulaire filtratiesnelheid juist geen verband aanwezig was. 
Opmerkelijk was, dat er ook een verband werd gevonden tussen genetische variatie in 
SLC22A en het risico op eindstadium nierfalen. Blijkbaar is een goede tubulaire 
transportfunctie beschermend tegen progressief verlies van nierfunctie. 
Tot slot hebben we in hoofdstuk 7 zelf de GWAS-methode gebruikt om SNP’s te 
ontdekken die verband houden met de regulatie van ureum in het bloed. Doordat onze 
patiëntengroep relatief klein was hadden we echter onvoldoende statistische kracht om 
deze SNP’s te ontdekken. Aanvullend onderzoek is dus nodig om deze SNP’s te kunnen 
lokaliseren. 
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Samenvattend illustreert dit proefschrift het belang van nauwkeurig uitgevoerde 
klinische studies voor de vertaling van de resultaten van GWAS-onderzoek naar 
de klinische praktijk. Onze data laat zien dat het analyseren van specifieke 
ziektekarakteristieken ons betere inzichten kan geven in de invloeden van 
verschillende genetische varianten op de ontwikkeling van nierschade. Deze 
nieuwe inzichten kunnen op termijn bijdragen aan het ontrafelen van de 
genetische basis van nierziekten, en daarmee op termijn mogelijk leiden tot betere 
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